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1. INTRODUCTION 
 
1.1. Background  
The delivery of drug molecules to the human body for treatment purpose is an 
important fact in the medical sciences1.Since the ancient era, progresses in the 
pharmaceutical field have also been made in the research and development of diverse 
types of effective drug delivery dosage forms. During past few decades, there has 
been an enhanced demand in the pharmaceutical field still for more patient-friendly 
and compliant effective drug delivery dosage forms2. The drug properties such as 
drug solubility, drug absorption, bioavailability and carrier properties (e.g., residence 
time at the particular target-site) are the chief constraints for effective drug delivery 
by any dosage forms. The novel drug delivery dosage forms able to manage the 
drawbacks of the conventional dosage forms through delivering the drug molecules 
over longer period, enhancing drug solubility, maintaining drug activity, availing 
target-specificity, reducing chances of side-effects,etc3. The goals of any ideal novel 
drug delivery systems include delivering of the drug molecules to desired target sites 
to limit side-effects, supplying drug molecules through the specific areas of the body 
without any chances of drug degradations, maintaining therapeutic plasma-drug level 
for prolonged time periods, predicting controlled drug releasing profiles, reducing 
dosing intervals and thereby, increasing patient compliances4. Globally, several 
researches are performing on for the development of effective targeted drug delivery 
dosage forms.   
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1.2. Targeted drug delivery 
In 1909, Paul Ehrlich first initiated the era of the development for targeted 
delivery of molecules, when he predicted the drug delivery mechanism that would 
target to diseased cells, directly 3, 5, 6. Paul Ehrlich proposed drug delivery to be a 
‘magic bullet’. According to him, targeted drug delivery as an event, where a drug 
releasing carrier conjugate/complex delivers drug molecules exclusively to the 
preidentified target cells in a specific manner.  Gregoriadis described drug targeting 
using novel drug delivery systems as ‘old design in new cloths’ 6.  
 
The ‘drug targeting’ can be defined as the capability to direct the 
drugmolecules, specifically to the desired site of action with little or absence ofany 
interaction with the non-target tissues6, 7.The perception of the ‘targeted drug 
delivery’ is intendedfor endeavoring to concentrate the desired drug molecules in the 
tissues ofinterest at the desired site,while dropping the relative drug concentrations in 
the other tissues of the body, and thus, the targeted drug molecules are localizedatthe 
desired targeted site8. Therefore, the remaining tissues are notaffected by the targeted 
drug molecules due to the maintenance lower concentrations of the free drug 
molecules in the blood stream9. Additionally, the loss of drugs doesnothappen due to 
localization of drug molecules, leading to achieve utmost effectiveness of the 
medication5, 6.Unwanted side-effects can be diminished by delivering the maximal 
portion of the applied dose accomplishment of the desired site through the targeted 
drug delivery systems, which can be partially attempted by the use of novel carriers10, 
11
.Various important pharmacokinetic issues like tissue distributions, plasma 
clearance kinetics, drug metabolisms as well as cellular interactions of drugs can be 
controlled through the site-specific delivery systems5-7. The drug targeting to the 
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diseased organs or sites in the body can be attained by linking particulate systems or 
to cell specific ligands (e.g.,glycoproteins, or immunoglobulins), or macromolecular 
carriers to monoclonal antibodies, or by modifications in the surface characteristics, 
so that these are not identified by the reticulo endothelial systems (RES) 7.The 
targeted drug deliveries to the desired site of the diseased organs are the most 
challenging research fields in the drug delivery and medical sciences12.The target 
specific drug delivery may be occurred at cellular, molecular or sub-molecular levels2. 
The high concentration at the target site is a result of relative cellular uptake of the 
drug carrier, release of drug molecules at the target site of desired area of the body13. 
Drug targeting is signified if the target part is distinguished from other parts, where 
toxicity may arise, and also if the active drug molecules could be placed 
predominantly in the proximity of the target site. The restricted distribution of the 
parent drug molecules to the non-targeting sites with effective accessibility to the 
target sites could maximize the advantages of the targeted drug therapy3. It isvery 
difficult and multifaceted for any drug molecule to reach at the target site in the 
complex cellular network of the diseased area2. Researches and investigations 
associated to the development of targeted drug delivery system is currently aday is 
highly preferred and facilitating the field of drug delivery and medicine world3. The 
current research on the targeted drug delivery systems is burgeoning with the newer 
ways to expand the effective drug delivery technologies and methodologies. 
Currently, a numbers of drug delivery carriers were investigated to deliver drug 
molecules at the target organs/tissues of the diseased body, which include synthetic 
polymers, proteins, serum, immunoglobulins, microspheres, erythrocytes, liposomes, 
niosomes, etc3, 7. The targeted drug deliveryis especially important in cancer 
chemotherapy and enzyme replacement treatment13, 14. 
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1.3. Targeted drug delivery carriers 
Carriers are the important entities, which is required for the successful 
deliveries of the loaded drugs to the target organs or sites. These elute or deliver the 
drugs within or in vicinity of the target. Drug loaded carriers can perform these either 
through an inherent properties or acquired (by structural modifications), to interact 
specifically with the biological targets, or otherwise, these are engineered to deliver 
the loaded drug molecules in the proximity of preidentified target cell lines 
demanding the optimal therapeutics. An ideal drug delivery carrier as a selective 
targetable device should have the following characteristics3:  
1. The targeted drug deliverycarrier should be biodegradable, non-toxic and 
non-immunogenic.  
2. It should be capable of optimal drug loading and drug releasing properties, 
according to the therapeutic need. 
3. After recognition and internalization, the targeted drug deliverycarrier 
system should release the drug molecules at proximity of preidentified 
target organs, tissues or cells, demanding the optimal therapeutics. 
4.  The targeted drug delivery carrier system should be recognized 
specifically by the target organs, tissues or cells and must maintain the 
activity.  
5. The carrier system should be able to cross the anatomical barriers and in 
case of tumor chemotherapy tumor vasculature.   
6. The biomodules utilized for the carrier investigation and site recognition 
must not be ubiquitous, otherwise it can cross over the sites, defeating the 
targeting concept.   
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Some examples of targeted drug delivery carrier systems appended as pilot 
molecules to deliver the drug molecules selectively to the intended organs, tissues or 
cells have been presented below 32 
1. Colloidal carrier systems 
a) Vesicular systems: Liposomes, Immunoliposomes, Niosomes, Virosomes, 
Pharmacosomes, etc. 
b) Particulate systems: Microparticles, Nanoparticles, Nanocapsules, Solid 
lipid nanoparticles, Magnetic microparticles, etc.  
 
2. Cellular carrier systems  
Resealed erythrocytes, Antibodies, Leukocytes, Platelets, Serum albumin, etc.  
 
3. Polymer-based carrier systems 
Mucoadhesive, Signal sensitive, etc. 
 
4. Supramolecular carrier systems 
Micelles, Mixed micelles, Reverse micelles, Polymeric micelles, Lipoproteins 
(Low density lipoproteins, High density lipoproteins,    Chylomicron), Synthetic 
LDL mimicking particles (supramolecule biovector system) 
 
5. Macromolecular carrier systems 
a) Proteins, Glycoproteins, Neoglycoproteins, Artificial viral envelops (AVE), etc. 
b) Lectins and Polysaccharides 
c) Glycosylated water soluble polymers 
d) Monoclonal antibodies (Mabs), Immunological Fab fragments, Bispecific Abs, 
Antibody enzyme complex 
e) Toxins, Immunotoxins, rCD4 toxin conjugates  
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Based on the nature of the origin of these above mentioned targeted drug 
delivery carrier systems, these are also classified as3: (a) Endogenous: e.g., Resealed 
erythrocytes, Serum albumin, Low density lipoproteins, High density lipoproteins, 
Chylomicron, etc., and (b) Exogenous: e.g., Microparticles, Nanocapsules, etc.Recent 
years, a wide variety of effective site-specific as well as targeted drug delivery carrier 
systems have been investigated and developed by the drug delivery and medical 
researchers.   Amongst the various site-specific and targeted drug delivery carriers, 
fewer are at the stage of clinical trials, where colloidal vesicular carrier systems prove 
their strong potential for the effective drug delivery to the target-site of the diseased 
organs, tissues or cells of the body. 
 
Recent research directed that the colloidal vesicular carrier systems appear to 
resolve the troubles of oral bioavailability of drugs31. Among various colloidal 
vesicular drug carriers, lipid-based vesicular systems like liposomes and niosomes are 
gaining remarkable status due to their biocompatibility as these aredevoid of any 
antigenic, allergic or pyrogenic reactions33. These carrier systems can perform as drug 
reservoirs as well as provide controlled release of the loaded drug molecules. 
Additionally, modifications of their compositions or surfaces can allow the targeting 
of the diseased organs, tissues or cells of the body. Even, these are widely 
investigated for the effective use in cancer targeting therapeutics, recently14.  
 
1.4.Cancer and cancer targeting  
Currently, cancer is a most leading reason of death worldwide. In 2012, about 
55 million people died worldwide, out of which more than 8 million people died from 
various kinds of cancers15. Cancer is a complex fatal disease, which is associated to 
genetics, age, gender, life-style, geographical region, etc16. Cancer is occurring as a 
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result of progressive accumulation of genetic or epigenetic alterations 17. The 
important attribute of cancer is the rapid progressive uncontrolledgrowth of abnormal 
cells and the abnormal growth can invade the adjacent parts of the body (invasion) 
and spreads to the other organsin the body via lymph or blood (metastasis)33. During 
the development of cancers, the transformation of normal somatic cells into malignant 
tumor cellshappens via a complex multi-stage course of actions involving various 
biochemical changes as well as genetic changes16.The entire process of cancerous 
development comprises 3 distinct steps.In the first step, the normal cells get converted 
into neoplastic cells (i.e., initiation)followed by transformation into overt neoplasm 
(i.e., promotion) thatfinally lead to the final progression stage17. 
 
Currently, the major challenges in cancer chemotherapy are associated to 
toxicity on healthy proliferating cells and multi-drug resistance against anticancer 
drugs18. The life-threatening side-effects caused by non-specific tissue distribution of 
anticancer drugs have constrained the systemic high dose approach 19. The resistance 
instigated by anticancer agents extends the cross-resistance to variety of anticancer 
drugs having diverse chemical structures and cellular targets 20,21. Once the drug 
resistance develops, the systemic administration of anticancer drugs becomes 
ineffective and the drug resistance is further stimulated. Accordingly, there is an 
emergency in cancer therapy. The success of cancer therapy is understood by its 
ability to reduce and eliminate tumors without damaging healthy tissues in the 
infected organs. These facts put the accent on the requirement for new generation, 
more effective and safe therapies for the treatment of cancers21. A diverse species of 
cancerous cells have specific characteristics that are trying to exploit through the 
applications of nanotechnology to target cancerous cells and treat cancers 22. 
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Recently, the progress of nanotechnology offers wonderful promise in cancer 
therapy, prevention and diagnosis 23. The combination of two disciplines- 
‘nanotechnology’ and ‘oncology (cancer science)’ has given rise the new field, “nano-
oncology” providing the cancer researchers and scientists with various innovative 
ways to diagnose and treat various types of cancers 18, 24. The anticancer agents used 
in the cancer therapy mainly can kill target cells, but also normal cells in the body 
resulting undesired side-effects25. For achieving better therapeutic application, 
nanocarriers are considered for the target-specific drug delivery to various cancer-
infected sites in the body in order to improve the therapeutic efficiency, while 
minimizing undesirable side-effects26, 27. Improvements in target to non-target 
concentration ratios, increased drug residence at the target site, are some of the major 
reasons for greater emphasis on the use of nanoparticulate anticancer drug delivery 
systems26. Nanotechnology also presents the capacity diseases in initial stages, like 
finding hidden colonies often observed in patients diagnosed with lungs, breast, colon, 
prostate and ovarian cancers 28. It is apparent that almost all types of cancers, which 
can be treated by cytotoxic drugs not only demand for controlled drug releasing but 
also target specific drug releasing patterns at the quantitative levels 14. The rationale 
of using nanotechnological applications for cancer targeting is based on these 
following issues2, 26: 
 
[1] For cancer targeting applications, nanoparticles should be able to deliver 
concentrate dosing of drugs in the surrounding area of thetumor targets via the 
improved permeability and retention effects or active targeting through 
theligands on the surface of nanoparticles;  
[2] Nanoparticles should decrease the drug exposure ofhealth tissues through 
limiting the drug distribution to the target organs, tissues or cells. 
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Efforts in the field of medicinal chemistry, combinatorial chemistry, drug 
delivery and nanotechnology continue to give rise to wider range of discovery and 
effective delivery of various kinds of anticancer drugs with enormous therapeutic 
prospective29. However, many of the anticancer drugsencompasswith some of the 
important physicochemical issues such as solubility and stability or biological issues 
like toxicity,which arise as barrier for their developmentinto viable treatment 
strategies in the cancer therapy through the incorporation of these within the 
nanoparticulate devices. In numerous cases, the formulation technologies of 
nanoparticulate devicesfor the effective delivery of anticancer drugs areinvestigated 
as a means to take benefits of the therapeutic potential of these anticancer drugs. 
Since the clinical applications of various nanoparticulate carriers as drug 
deliverysystems began in cancer therapeutics, a series of chemotherapeutic strategies 
have been developed as well asmodified to improve the therapeutic efficacy of 
anticancer drugs incorporated within the nanoparticulate carrier systems14.The 
conception of incorporating the anticancer drugs into different types of 
nanoparticulate carrier systems for abetter targeting of the anticancer drugs at 
appropriate preidentified cancerous organs, tissues or sellsas destination is extensively 
acceptedby the medical researchers and academicians26. Moreover,nanoparticulate 
carrier systems represent promising drug delivery modules and hence, these can 
represent alternative vesicular systems with respectto other delivery systems because 
of their capability to encapsulate different type of anticancer drugs within their 
multienvironmental structure27.A wide variety of nanoparticle-based systems for drug 
delivery in cancer treatment like biodegradable polymeric nanoparticles, polymeric 
micelles, solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), 
nanoliposomes, niosomes, inorganic nanoparticles, magnetic nanoparticles, 
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dendrimers, etc are available 26, 27, 29,30. Among these nanoparticulate carrier systems, 
colloidal vesicular carrier systems mainly lipid-based systems like liposomes and 
niosomes are gaining remarkable status for the effective use in cancer targeted drug 
delivery therapeutics31.  
 
1.5. Niosomes as nanocarriers 
Niosomes are the lipid-based carriers for the use as promising vehicles for 
drug delivery applications34. In 1975, first niosomal formulations were formulated and 
patented by L’Oreal35.These are mainly non-ionic surfactant vesicles having 
microscopic bilayer lamellar structure obtained on the proper mixtures of non-ionic 
surfactantslike spans or tweens and cholesterol with the subsequent hydration in the 
aqueous media36.In the bilayer lamellar structure, the hydrophobic parts are oriented 
away from the aqueous solvents, whereas the hydrophilic heads stay behind in contact 
with the aqueous solvents. The common structure of niosome is presented in Fig. 1.1. 
However, these may also be prepared with various ionic amphiphiles like 
dicetylphosphate, stearylamine, etc., in order to attain a stable suspension. Similar to 
liposomes, niosomes are formed on the hydration on non-ionic surfactant films, which 
hydrate imbibing or encapsulating the hydrating aqueous solutions 36. Basically, 
niosomal vesicles do not form spontaneously37. Thermodynamically stable niosomal 
vesicles form only in the presence of proper mixtures of non-ionic surfactants as well 
as charge inducing agents36.The size of the niosomes lies in nanometric scale usually 
in the range of 100 – 300 nm37. The characteristics of the niosomes can be altered 
through varying the composition, surface charge, lamellarity, tapped volume, etc38. A 
variety of forces work inside the vesicular structure of niosomes and are accountable 
for maintaining the vesicular structure of these, e.g., the van der Waals forces 
amongstthe surfactant molecules, the entropic repulsive forces of head groups of the 
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surfactant molecules, the repulsive forces rising from electrostatic interactions 
between charged species of surfactant molecules, the shortacting repulsive forces, etc. 
However, the stability of niosomes are influenced by types of the surfactants, 
characteristics of the encapsulated drug molecules, storage temperature, the use of 
membrane-spanning lipids, the inclusion of charged molecules, the interfacial 
polymerization of the surfactant monomers in situ,etc38. 
 
Fig. 1.1: Structure of niosome 
 
Niosomes present a structural similarity to liposome and hence, these are able 
to represent as alternative kinds of vesicular systems with respect to liposomes. These 
are believed to be better carriers for drug delivery as compared to liposomes due to 
various issues like cost, stability at pH variations, sterilization,etc39. The drug 
encapsulation efficiency of these systems increases with increment in the 
concentration as well as lipophilicity of surfactant40. Niosomes canperform as drug 
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depots and these are able to release the drugs in a controlled manner3. These also 
behave like liposomesin vivo and to prolong the circulation of encapsulated 
drugs,varying the organ distribution of the carrier system as well as the metabolic 
stability36. Niosomes are able to modify the plasma clearance kinetics, tissue 
distribution, drug metabolism and cellular interaction of the drug molecules41, 42.These 
may be employed as vehicles for poorly absorbable drug molecules to develop the 
novel drug delivery system4.Delivery of various kinds of drug molecules can be 
possible using niosomal systems like oral, topical, parentral, ophthalmic, targeting, 
etc39. Niosomes are able to improve the bioavailability of the encapsulated drug 
molecules through crossing the barrier of gastrointestinal tract (GIT) by transcytosis 
of ‘M cells’ of Peyer's patches in the intestinal lymphatic tissues43.Several drugs also 
encapsulated within the niosomes for the delivery through the transdermal route to 
enhance the drug permeation and the therapeutic efficacy 44.The niosomes are also 
taken up by the reticulo endothelial system (RES). Such kind of localized drug 
accumulation strategy is employed in treatment of various diseases like cancer, 
leishmania, etc 36, 45. Also, some non-RES like immunoglobulins recognize the lipid 
surfaces of niosomal delivery systems 38. The encapsulation of various kinds of 
anticancer agents with in niosomal carriers has reduced the drug induced toxic 
adverse effects while improving cancer targeting and the anticancer efficacies 46. 
Since niosomes are non–ionic in nature, these are less toxic and increasethe 
therapeutic index of drug moleculesthrough restricting their action to the target 
cells45.The drug targeting through the use of linkages to niosome via antibody is 
presented in Fig. 1.2. 
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Fig. 1.2: Drug targeting through the use of linkages to niosome via antibody 
1.6. Classes of niosomes: 
On the basis of vesicle sizes, niosomes can be classified into three categories3:  
a) Small Unilamellar Vesicles (SUV, vesicle size: 0.025-0.05 μm)  
b) Multi-lamellar Vesicles (MLV, vesicle size: > 0.05 μm) 
c) Large Unilamellar Vesicles (LUV, vesicle size: >0.10 μm). 
1.7. Advantages of niosomes 
The potential advantages of niosomes are presented below37,3,39:  
[1] Simple methods are required for the formulation of niosomes. Even large–scale 
production can be possible.  
[2] The excipients,apparatus and equipments used for the formulation of niosomes 
are economical.Therefore, niosome formulation process is not expensive. 
[3] Since the niosomal structure presents position to accommodate hydrophilic, 
lipophilic and amphiphilic drug moieties, these can be employed for a variety of 
drug molecules. 
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[4] Niosomes displays the flexibility in their structural features (i.e., composition, 
size and fluidity) and can be intended in relation to the preferred situation. 
[5] Niosomesenhance the therapeutic potential of the drug molecules by protecting 
from the biological environment as well as restricting influences to the target 
cells, thuslowering the clearance of the drugs. 
[6] Niosomes perform as a depot for releasing the drug molecules slowly and 
present controlled release of drug molecules. 
[7] Niosomes enhance the stability of the encapsulated drugs at various pH. 
[8] Niosomes enhance the oral bioavailability of various drugs. 
[9] Niosomes are osmotically active as well as stable at various pH environments. 
[10] Niosomes can improve the skin penetration of drug molecules through topical 
administration. 
[11] Niosomes are able to reach the site of action through oral, parenteral and topical 
routes. 
[12] Niosomal carriers are biocompatible, biodegradable and non-immunogenic in 
nature. 
[13] Niosomal dispersions in an aqueous phase can be emulsified easily in a non-
aqueous phase. This is helpful to manage the release rate of the drugs and 
administer normal vesicles in the external non-aqueous phase. 
[14] The niosomal vesicle dispersions offer better patient compliances. 
[15] Niosomal formulations possess longer shelf-lives.  
[16] Contrasting liposomes, niosomes are stable even at room temperature and less 
susceptible to light. 
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1.8. Compositionof Niosomes 
The composition of niosomes includes surfactants (mainly non-ionic), 
cholesterol and charge inducing substances3, 39,47. 
 
 Surfactants: 
A wide variety of surfactants and their blends in different molar ratios have 
been employed to encapsulate many kinds of drugs in the niosomes 48.In the 
preparation of niosomes, non-ionic surfactants are the commonly employed 
surfactants. The non-ionic surfactants are employed for this purpose because of some 
potential advantages associated with the stability and compatibility compared with 
other types of surfactants 49. Non-ionic surfactants contains both polar (hydrophilic) 
and non-polar (hydrophobic) parts and possess high interfacial activity. The non-polar 
tail contains one or two alkyl or perfluoro alkyl groups or a single steroidal group 50. 
The non-ionic surfactants aregenerally non-toxic, less irritating and less haemolytic to 
the biological cellular surfaces. These are also helpful to maintain their surface active 
property near the physiological pH in formulations. These also exert several important 
functions including acting as stabilizer, solubilizer, emulsifier, wetting agents, 
permeability enhancers, etc49. The non-ionic surfactant types which are mostly 
employed in the preparation of niosomes are ether linked surfactants, ester linked 
surfactants, sorbitan esters, alkyl amides, fatty acids and amino acid compounds50, 47.    
 
 Ether-linked surfactants: 
Ether-linked surfactantsare mainly polyoxyethylene alkyl ethers, which 
encompass hydrophilic as well as hydrophobic moieties, and both are linked with the 
ether linkage47. The common formula of thesetypes of surfactant surfactants is 
CnEOm, where n should be 12-18 and m should be 3-7. Ether-linked surfactants with 
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polyhydroxyl headand ethylene oxide parts are also reported to be employed in the 
niosomepreparation47. The single alkyl chain surfactants, C-16 monoalkyl glycerol 
ethers with average of three glycerol parts is one of the examples of theether linked 
surfactants employed for the niosome preparation. Polyoxyethylene 4-lauryl ether 
(Brij30) has a‘Hydrophilic Lipophilic Balance’ (HLB) value of 9.7 and phase-
transitiontemperature of more than 10°C47. Contrasting with other alkyl ether 
derivatives, these reduce the vesicle formation in the presence of cholesterol; Brij 30 
forms LUV, when combined with 30 mM/Literof cholesterol. It cannot be employed 
to formulate some drugs, iodides, salicylates, sulfonamides, phenolic substances, 
mercury salts, tannins, etc., as it cause oxidation leading to the discoloration of the 
product. Polyoxyethylene stearyl ethers (Brij72and76) and Polyoxy ethylene cetyl 
ethers (Brij 58) are also employed in preparation of niosomes 36, 49. 
 
 Ester-linked surfactants: 
Ester-linked surfactants have ester linkage between hydrophilic and 
hydrophobic groups47. These surfactants have been investigated for their use inthe 
preparation and delivery of sodium stibogluconate to experimental marine visceral 
leishmaniasis46. 
 Sorbitan esters: 
Sorbitan esters orpolyoxy ethylene esters are the most extensivelyemployed 
ester-linked surfactants in the food industry in particular 47. These esters are often 
used in the cosmetic industry to make soluble the essential oils in water based 
products 49.Commercially available sorbitan esters are the mixtures of the partial 
esters of sorbital and its mono as well as di-anhydrides with the oleic acid. Sorbitan 
esters have been employed to encapsulate a wide range of drugs including anticancer 
drugs (e.g., doxorubicin)51. 
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 Alkyl amides: 
Alkyl amides are the alkyl galactosides and glucosides, which have ability to 
incorporateamino acid spacers47. The alkyl groups are fully and/or partially saturated 
C-12 to C-22 hydrocarbons as well as some novel amide compounds have 
fluorocarbon chains. 
 
 Fatty acids and amino acid compounds: 
These are amino acids, which are prepared amphiphilic through the addition of 
hydrophobic alkyl side-chains and long-chain fattyacids47.These form “Ufasomes” 
vesicles.Ufasomes are formed from fatty acid bilayers47. 
 
 Cholesterol: 
Cholesterol, a waxy steroid-based metabolite material is an important 
component to manufacture vesicular systems, which lead tothe changes in the fluidity 
as well as permeability of the bilayer structures47. It is generally added to the non-
ionic surfactants to afford thefluidity, rigidity, permeability andorientational order to 
the bilayer structures of the vesicular systems.Cholesterol does not able form the 
bilayer itself. It can be incorporated in a larger molar ratio like 1: 1 in most of the 
vesicular formulations to prevent the vesicle aggregation through the inclusion of 
molecules, which stabilize the vesicular systems against the formation of aggregates 
by the repulsive steric/electrostatic influences52.This directs to the transition from the 
gel-state toliquid phase in the niosomal systems. As a result, niosomal systems 
become less leaky in nature.Being anamphiphilic molecule, cholesterol adjusts its 
hydroxyl group towards the aqueous phase and aliphatic chain, also towards the 
hydrocarbon chain of the surfactant used in the preparation of vesicular structures 
including niosomes47. The rigidization of the prepared vesicles is offeredthrough the 
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alternative positioning of rigid steroidal skeleton with the surfactantmolecules in the 
bilayer structures by restricting the movement of the carbons of hydrocarbon47. 
Cholesterol is also recognizedfor preventing the leakage through abolishing gel to the 
liquid-phase transition 52. Cholesterol imparts the rigidity to the niosomal vesicles, 
which is very vital under in severe stress conditions 53. The interaction of cholesterol 
with Span 60 in bilayer of niosomes is because of hydrogen bonding 49 (Fig. 1.3). 
 
 
Fig. 1.3: Structural interaction between Span 60 and cholesterol 
 Charge inducers: 
Charge inducers enhance the stability of the vesicular structures including 
niosomesthrough the induction of charge on the vesicular surface47. These 
performthrough the preventing fusion of vesicles because of the repulsive forces of 
the same charge, which offers higher values of zetapotential to the vesicular structure. 
The frequentlyemployed negative charge inducers are dihexadecyl phosphate, dicetyl 
phosphate, lipoamineacid.The frequently employed positive charge inducers are 
sterylamine, cetyl pyridinium chloride, etc54,55. 
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 Hydration medium: 
Hydration medium is considered as an important excipient issue in the 
preparation of niosomes. Phosphate buffers of various pHs are among the commonly 
used hydration medium for preparation of niosomes. The pH of the hydration medium 
is the important factor in this case. The pH of the hydration medium depends on the 
solubility of the drugs being encapsulated within the niosomes 50. Accordingly, pH 
5.5 phosphate buffer was employed in the preparation of ketoconazole niosomes56; 
whereas pH 7.4 phosphate buffer was employed in the preparation of meloxicam 
niosomes57. 
 
1.9. Preparation methods of niosomes 
Niosomes are prepared using non-ionic surfactants through different 
methodologies.The desired vesicle sizes, number of double layers in their structure, 
their distributions, drug encapsulation efficiency of the aqueous phase used and 
permeability of vesicles are potentially influenced the way of niosome preparation 3. 
All these constraints should be taken into consideration while making selecting the 
optimum methodology for the formulation of niosomes of desired property37. For the 
preparation of various types of niosomes, various preparation methodologies are 
adopted. Most of the niosome preparation methodologies comprise the hydration of a 
mixture of surfactants or lipids at the elevated temperature subsequently optional size 
reduction to achievedesired qualities of colloidal dispersions containing niosomes. 
Afterward, the un-entrapped drugs are separated from the niosomes containing 
entrapped drug through the centrifugation, dialysis or gel filtration50. Preparation 
methods of various types of niosomes are described below 3, 37, 39. 
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1.9.1. Preparation of small unilamellar vesicles (SUV) 
 
 Sonication:  
These SUV type niosomes (diameter: >100 nm) are larger than the SUV type 
liposomes (diameter: <100 nm)3. Basically in the sonication method, the aqueous 
phase containing drugs to be encapsulated is added to the mixture of surfactants and 
cholesterol in the scintillation vials 36. Then, the mixture is homogenized using a 
sonication probe for 3 minutes at 60°Cto produce uniform sized SUVtypes of 
niosomes. It is also possible to get SUV types of niosomes through the sonication of 
MLV types of niosomes. For the preparation of SUV types of niosomes, probe type 
sonicator is employed 36.  
 
 Microfluidization:  
Among different preparation techniques of niosomes, microfluidization is a 
recently adopted technique to prepare the SUV types of niosomes36.The SUV 
niosomes prepared from microfluidization technique of defined size distribution50. 
This microfluidization techniquefor the preparation of the SUV types of niosomes is 
based on submerged jet principle,where two fluidized streams interrelateat ultra-high 
velocities in precisely defined micro channels within the interaction chambers.The 
impingement of the thin liquid sheet along a common front is assembled in away that 
the energy is supplied to the system stays within the niosomal formation area. As a 
result,SUV types of niosomes are formed with a greater uniformity, smaller 
vesicularsized and better reproducibility 34. 
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1.9.2.Preparation of multi-lamellarvesicles (MUV) 
 Hand shaking method:  
The hand shaking method is also called as ‘Thin film hydration technique’, 
which is used to prepareMUV types of niosomes 36. In this methodology, surfactants 
and cholesterol are dissolved in the suitable volatile organic solvents (such as, 
chloroform,diethyl ether, or methanol) in round bottom flasks to prepare a mixture of 
surfactants and cholesterol. At room temperature (24°C), the volatile organic solvent 
is removed using a rotary evaporator, which leaves a thin layer of solid mixture 
deposition on the wall of the round bottom flasks used in the preparation. Then, the 
dried surfactant film is required to be hydrated with the aqueous phase containing 
drugs with the application of gentle agitation at 50-60°C. This process forms typical 
MUV niosomes36. 
 Trans-membrane pH gradient (inside acidic) drug uptake process (remote 
loading):  
In the method of trans-membrane pH gradient (inside acidic) drug uptake 
process (remote loading), MUV types of niosomes can be produced 36. Required 
surfactants and cholesterol are dissolved in chloroform to prepare surfactants-
cholesterol mixture solution and it is then evaporated under the application of reduced 
pressure to obtain a thin-film on the wall of the round-bottom flasks used in the 
preparation. The developed thin-film is hydrated using 300 mM of citric acid (pH 4.0) 
solutions through vortex mixing. The multi-lamellar vesicles are then frozen and 
thawed for three times.The thawed multi-lamellar vesicles later sonicated using a bath 
type sonicator to prepare a niosomal suspension.To these niosomal suspensions, 
aqueous solutions containing drugsare added and then, vortexed. The pH of these 
niosomal dispersions is then increased up to 7.0-7.2 with 1M disodium phosphate. 
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These dispersion mixtures arethen heated for 10 minutes at 60°C to manufacture the 
desired MUV types of niosomes. 
 
1.9.3. Preparation of large unilamellarvesicles (LUV) 
 Reverse phase evaporation technique:  
Reverse phase evaporation technique is being employed to formulate different 
vesicular carrier systems like liposomes, nanoliposomes, niosomes, archaeosomes, 
etc31. In the reverse phase evaporation technique, surfactants and cholesterol are 
dissolved in mixtures of ether and chloroform36, 58. An aqueous phase containing 
drugs is added to these mixtures. The resulting mixtures containing two phases are 
sonicated at 4-5°C to form a clear gel.Then, clear gel is hydrated by the 0.25 volume 
of the phosphate buffer saline. Alternatively, hydrogenated or non-hydragenated egg 
phosphatidyl choline is dissolved in chloroform and phosphate buffer saline. The 
formed clear gel is further sonicated after the addition of a small amount of phosphate 
buffersaline, pH. Under low pressure, the organic phase is removed at 40°C. The 
resulting viscous niosomal suspensionsarethen diluted with phosphate buffer saline, 
pH and then, heated in a water-bath at 60°C for 10 minutes to manufacturelarge 
unilamellar niosomes.Free drugsto be encapsulated (unentrapped drugs) areusually 
removed through the dialysis and/or centrifugation36. Protamine is added prior to the 
centrifugation procedure to attainthe phase separation50. 
 
 Ether injection technique:  
The ether injection technique is basically based on the slow injection of the 
niosomal ingredients in diethyl ether by a 14gauge needle at approximately 0.25 
ml/minutes rate into a pre-heated aqueous phase, which should be maintained at 
60°C36, 59.The possiblecause behind the development of LUV is that the slow 
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vaporization of the solvents results in an ether gradient, which extends towards the 
non-aqueous interfaces. The former may be accountable for the development of the 
bilayer structures. Depending upon the parameters employed the diameter of the 
niosomal vesicles range from 50 to 1000 nm.The drawbacks of the ether injection 
technique are that a small quantity of ether is recurrently present in the niosomal 
suspensions and it is very difficult to remove. 
 
1.9.4.Miscellaneous 
 
 Multiple membrane extrusion technique:  
In this technique, a mixture of surfactants, cholesterol and diacetyl phosphate 
in chloroform is prepared into thin film through the evaporation36,50. The formed thin 
film is hydrated with aqueous solution of drugs to be encapsulated.The resultant 
vesicular suspensions extruded through the polycarbonate membranes, which are 
placed in a sequence for up to 8 channels. This technique is recognized as 
anexcellenttechnique for controlling the niosomal vesicle size34.  
 
 Emulsion method:  
In the emulsion method, the oil-in-water (o/w) emulsionsareformed from the 
organic solutions of surfactants, cholesterol and aqueous solution of drugs to be 
encapsulated 50, 60.Then, the organic solvent phase is evaporated from the mixture 
dispersion, forming niosomes dispersed in the aqueous phase of the system. 
 
 Lipid injection technique:  
Lipid injection technique does not need any expensive organic phase for the 
preparation of niosomes36. In this technique, the mixture of lipids and surfactants is 
first melted.Then,the melted mixture is injected into heated and a highly agitated 
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aqueous phase containing the dissolved drugs. A homogenous lamellar film is formed 
by shaking. The mixture is ultra-centrifuged and agitated at a controlled temperature.  
 
 
 Bubble method:  
The bubble method is a novel technique for the one-step preparation of 
liposomes as well as niosomes without utilizingthe organic solvents 36. The bubbling-
unit comprises roundbottom flask with the three necks positioned in a water-bath to 
control the temperature of the system. The watercooled reflux and the thermometer 
are positioned in the first neck and second neck, respectively. The nitrogen supply 
was performed through the third neck of the round bottom flask. Surfactants and 
cholesterol are dispersed together in the phosphate buffer at 70°C.The dispersion 
mixture is mixed for 20 seconds with the use of high shear homogenizer and 
afterwards, immediately bubbled at 70°C using nitrogen gas61. As the organic solvents 
are not required, this technique is recognized as one of the economical technique of 
niosome preparation 36.  
 
 Heating method  
 
Heating method is a scalable, non-toxic and one-step preparation of 
niosomes35. The mixtures of non-ionic surfactants, cholesterol and/or charge inducing 
molecules are introduced to the aqueous medium (e.g., buffer, distilled H2O, etc.) in 
the presence of a polyols, such as glycerol. The mixture is then heated with stirring at 
low shear forces until the niosomal vesicles are formed 35. 
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1.9.5. Niosome preparation using polyoxyethylene alkyl ether 
 
The sizes and number of bilayer in vesicles comprising of cholesterol and 
polyoxyethylene alkyl ether can be altered using an alternative method62. The 
temperature increase above 60°C temperature transforms SUV to LUV (less than 1 
μm), while the vigorous shaking at the room temperature demonstrates the opposite 
effect (i.e., transformation of multilamellar vesicles into unilamellar ones). The 
transformation from the unilamellar vesicles into unilamellar ones at the higher 
temperaturesmay be the typicalattribute for polyoxyethylene alkyl ether surfactant, 
since it is recognized that polyethylene glycols (PEGs) and water remix at higher 
temperaturesbecause ofthe breakdown of hydrogen bonds between the water and the 
PEG moieties50. Usually, the free drugs are removed from the encapsulated 
drugsthrough the gel permeation chromatography method, dialysis method or 
centrifugation method or ultracentrifugation method 3.Often, the density differences 
between the niosomes and the external phase are much smaller than that of the 
liposomes.This makesthe separation through centrifugation very difficult. The 
addition of protamine to the vesicle suspension facilitates phase separation during the 
centrifugation50. 
 
1.9.6. Niosome preparation using Micelles 
Niosomes can also be prepared from mixed micellar solutionsthrough the use 
of enzymes. Mixed micellar solution of C-16 G2, dicalcium hydrogen phosphate and 
polyoxyethylene cholesteryl sebacetate diester converts to niosomal dispersions when 
incubated with the enzyme, esterases. Polyoxy ethylene cholesteryl sebacetate diester 
is cleaved through the esterases to yield polyoxyethylene, sebacic acid and 
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cholesterol. Then, cholesterol in combination with C-16 G2 and dicalcium hydrogen 
phosphate yields the C-16 G2 niosomes. 
1.9.7. Formation of niosomes from proniosomes 
Another alternative method of preparing niosomes is to coat a water-soluble 
carrier like sorbitol with surfactants63, 64. The result of the coating process is dry 
formulations, in which each water-soluble particle is covered with a thin-film of dry 
surfactants. These dry preparations are termed as “Proniosomes”.Hu and Rhodes have 
reported that proniosomes are dry formulations of surfactant-coated carriers, which 
can be rehydrated by brief agitation in hot water63. The schematic presentation of 
preparation of niosomes from proniosomes is shown in Fig. 1.4.  
 
Fig.1.4: The schematic presentation of preparation of niosomes from 
proniosomes 
 
Proniosomes are found as dry powder and thus, can be dispensed in capsule 
form 64. These proniosomal carriers possess the capability to diminish the problems 
associated with niosome such as (i) physical instability; (ii) aggregation; (iii) fusion; 
(iv) leaking of the encapsulated drugs; and (v) hydrolysis of the encapsulated drugs, 
which also limits the shelf life of the dispersion 64. Niosomes, which are derived from 
proniosomes are much better than the conventional niosomes, which provide optimal 
flexibility, easy processing, unit-dosing facility and packaging 3. In the stability 
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viewpoint, the dry proniosomes is supposed to be more stable than the pre-
manufactured niosomal formulations. Size distributions and the release performance 
of niosomes derived from proniosomes is also the superior to conventional niosomes 
61, 65
. Blazek-Walsh et al 61 have reported the formulation of niosomes from 
maltodextrin-based proniosomes. This affords a rapid reconstitution of niosomes with 
the minimal residual carrier. The slurry of maltodextrin and surfactants was dried to 
form a free-flowing dry powder, which could be rehydrated through the addition of 
warm water 61. 
 
1.10. Separation of unencapsulated drugs 
 
As in most cases 100 % of the drugs to be encapsulated cannot be 
encapsulated within the niosomal vesicles 66. The unencapsulated drugs should be 
separated from the entrapped ones. The separation of unencapsulatedsolute from 
theformulated vesicular dispersion can be carried outthrough various techniques, 
which includes3: 
 
 Dialysis:  
The prepared aqueous niosomal dispersionsare dialyzed to separate the 
unencapsulateddrugsusing dialysis tubing against phosphate buffers or normal saline 
or glucose solution66. 
 
 Gel filtration:  
The unencapsulateddrugs is separated from the prepared aqueous niosomal 
dispersions through the gel filtration using a Sephadex-G-50 column and elution with 
phosphate buffered saline or normal saline61,67. 
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 Centrifugationor ultracentrifugation: 
The prepared niosomal suspensions are centrifuged (7000 × g for 30 minutes 
for the niosomal suspensions prepared through handshaking method and ether 
injection method) and ultracentrifuged (150000 × g for 1.5 hours).Then, the 
supernatants areseparated. The pellets are washed and then resuspended to attain 
niosomal suspensions free from unencapsulateddrugs 63, 68. 
 
1.11. Postpreparation processes in the manufacturing of niosomes 
The most important postpreparation processes in the manufacture of niosomes 
are downsizing the prepared niosomes as well as separation of unencapsulateddrugs. 
After preparation, the size reduction of niosomes is attained using one of 
thesetechniques given below: 
i. For downsizing of the niosomes, the probe sonication is preferred over the 
bath sonicator. The use of probe sonication results in the manufacturing of the 
niosomes of 100–140 nm size range. For the preparation of SUV types of 
niosomes, probe type sonicator is employed 36.  
ii. Extrusion of the prepared niosomal dispersions through the filters of defined 
pore sizes.  
iii. The combination of sonication and filtration has also been employed to attain 
niosomes of 200-250 nm diameter size ranges (e.g., doxorubicin niosomes)3.  
iv. The microfluidization technique can be employed to yield niosomes of less 
than 50 nm in diameter sizes36, 50. 
v. High-pressure homogenisation technique also can be employed to yield 
niosomes of below 100 nm in diameter sizes.  
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1.12.Factors affecting physico-chemical properties of niosomes 
 
Various factors that affect the physico-chemical properties of the niosomes are 
discussed below:  
 
1.12.1. Nature of Surfactants 
Surfactantsemployed for preparation of niosomal formulationshould have a 
hydrophilic head and hydrophobic tail3. The hydrophobic tail consists of one or two 
alkyl or perfluoroalkyl groups.In some cases, a single steroidal group is present within 
these50. The ether-type surfactant groups with a single-chain alkyl as hydrophobic tail 
is considered as much more toxic than the corresponding dialkyl ether-chains46. The 
ester-type surfactants are generally chemically less stable than the ether-type 
surfactants. Also, the former is comparatively less toxic than the latter one due to the 
chances of degradation of ester-linked surfactants by the enzymes like esterases to 
triglycerides as well as fatty acids,in vivo46.The surfactants with alkyl chain length 
from C-12 to C-18 are considered as suitable for the formulation of niosomal 
vesicles69, 70. Non-ionic surfactants like C-16EO5 (polyoxyethylene cetyl ether) 
and/or C-18EO5 (polyoxyethylene steryl ether) are usually employed for preparation 
of polyhedral niosomal vesicles71. Non-ionic surfactants of Span series having the 
HLB number between, 4 and 8 are able to form vesicles72.Examples of various types 
of non-ionic surfactants used in the manufacturing of niosomes are summarized in 
Table 1.1 
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Table 1.1: Varioustypes of non-ionic surfactants used in the manufacturing of 
niosomes 
Non-ionic surfactants types Examples 
Fatty alcohol 
Steryl alcohol,  
Cetyl alcohol,  
Cetosteryl alcohol,  
Oleyl alcohol, etc. 
Ethers 
Brij,  
Decyl glucoside,  
Lauryl glucoside,  
Octyl glucoside,  
Nonoxynol-9, 
Triton X-100,  
Esters 
Spans,  
Polysorbates (Tweens),  
Glyceryl laurate, etc. 
Block copolymers Poloxamers 
 
1.12.2. Structure of surfactants 
The structural geometry of the vesicular formulations to be prepared from 
surfactants is basically affected by the structure of surfactants used in the 
manufacturing procedure3.The structure of surfactants is recognized to be related to 
the critical packing parameters, which is able to influence the structural geometry of 
the vesicles. Based on the critical packing parameters of surfactants used in the 
manufacturing procedure of niosomes, structural geometry of the formed niosomes 
can be predicted. 
The critical packing parameters of surfactantsused in the manufacturing 
procedure of niosomes can be calculated using following equation3: 
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Critical Packing Parameters (CPP) = v/lc ×a0 
            v = non-polar group volume,  
lc = critical non-polar group length,  
a0= area of polar head group. 
From the critical packing parameter value of surfactants used in the 
manufacturing procedure of niosomes,the types of micelle structure formed can be 
determined as given below3: 
1) The critical packing parameters are less than ½ (½ < CPP) means the indication 
of the formation of spherical micelles. 
2) The critical packing parameters are more than ½ and less than 1 (½ < CPP < 1) 
means the indication of the formation of bilayer micelles. 
3) The critical packing parameters are more than 1(CPP > 1) means the indication 
of the formation of inverted micelles. 
 
1.12.3. Amounts and types of surfactants 
The mean vesicle size of the niosomes enhances proportionally with the 
incrementof the HLB values of non-ionic surfactants such as Span 85 (HLB value, 
1.8) to Span 20 (HLB value, 8.6) since the surface free energy reduces with an 
increase in the hydrophobicity of surfactants used72.The bilayers of theseniosomal 
vesicles are either in the so-called liquid-state or in the gel-state depending on 
temperature of the formulation systems, the types of lipidsand/or surfactantsas well 
asalso the presence of other components like cholesterol. In the gel-state, the alkyl 
chains are present in a well-ordered structureas well asin the liquid-state72. The lipids 
andsurfactants are also characterized by the gel-liquid phase transition temperature73. 
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Phase-transition temperature of surfactant also influences the encapsulation efficiency 
of the niosomes,i.e., Span 60 having the higher transition temperature, which supplies 
better encapsulation to the niosomal vesicles. 
 
1.12.4. Membrane composition 
The stable niosomal vesicles can be formulated with the addition of different 
chemical additives along with the surfactants as well as drugs. The formulated 
niosomes encompassseveral morphologies, their permeability and stability 
characteristics.These can be changedthroughthe manipulation of membrane 
characteristics by the different additives. In case of polyhedral niosomes formed from 
C-16G2, the shape and morphology of these niosomal vesicles remains 
unchangedthrough the addition of low amount of solulan C-24 (cholesteryl poly-24-
oxyethylene ether), which checks the aggregation because of the development of 
steric hindrance74. The average vesicle sizes of the niosomes is affected by the 
membrane compositions,likepolyhedral niosomes formed by C-16G2: solulan C-24 in 
ratio of 91:9, having a comparatively bigger sizes than the spherical or tubular 
niosomes formed by C-16G2: cholesterol: solulan C-24 in ratio of 49:49:274. The 
addition of cholesterol to the niosomal system also offers the rigidity to the membrane 
and decreases the leakage of the drugs from niosome75. The inclusion of cholesterol in 
the niosomal system enhances the hydrodynamic diameter and also the encapsulation 
efficiency72. Generally, the action of cholesterol is of two folds:on one hand, 
cholesterol enhances the chain order of liquid-state bilayers of the niosomal system 
and on the other hand, cholesterol reduces the chain order of gel-state bilayers of the 
niosomal system. At a high concentration of cholesterol, the gel-state is usually 
transformed to the liquid-ordered phase of the system68.An increment in the 
cholesterol content of the bilayers of the niosomal system resulted in a reduction in 
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the release-rate of encapsulated drug material and therefore, an incrementof the 
rigidity of the bilayers of the niosomal system obtained68,76.The presence of the 
charge in the niosomal system tends to amplify the inter-lamellar distance between the 
successive bilayers in the MLV structures and also leads to the greater overall 
encapsulated volume. 
A. Nature of the encapsulated drugs 
The physico-chemical properties of the encapsulated drugs influence both the 
charge and the rigidity of the niosome bilayer. The drugmolecules interact with the 
surfactant-head groups and produce the charge so as to generatea mutualrepulsion 
between the surfactant bilayers and hence, thisenhances the vesiclesizes of the 
niosomal system77.The aggregation of the vesicles is prevented because of the 
chargedevelopment on the bilayers of the system. In case of polyoxyethylene glycol 
(PEG) coated vesicles, some drugsare encapsulated in the long PEG-chains, and thus, 
this reduces the tendency to improve the vesicle sizes of the niosomes63. The HLB 
value of the drugs affects the degree of encapsulation of the drugs within the niosomal 
system. Effect of the nature of drugs on the formation of niosomes is summarized in 
Table 1.2. 
Table 1.2: Effect of the nature of drugs on the formation of niosomes 
Nature of the 
drugs 
Leakage 
from the 
vesicles 
Stability Other properties 
Hydrophobic drugs Reduced Improved Improved transdermal delivery 
of drugs 
Hydrophiliic  
Drugs Improved  Reduced  - 
Amphiphilic  
drugs Reduced - 
Increased drug encapsulation,  
Altered elecrophoretic 
mobility 
Macromolecules Reduced Improved - 
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B. Temperature of hydration 
The hydration temperature of the manufacturing system influences the size 
and shape geometry of the niosomal vesicles. For ideal condition, this should be 
above the gel to liquid-phase transition temperature of the manufacturing system. The 
temperature alteration of the niosomal system affects the assembly of surfactants into 
vesicles and also, induces vesicle-shape transformation 50, 74. Arunothayanunet al.74 
have reported that a polyhedral vesicle formed by C-16G2 : solulan C-24 in a ratio of 
91 : 9 at 25°C 74. On heating, this transformed into the spherical vesicles at 48°C, but 
on cooling from 55°C, the spherical vesicles fabricated a cluster of smaller sized 
spherical niosomes at 49°C before varying to the polyhedral structures at 35°C.In 
contrast, the vesicles formed by C-16G2 : cholesterol : solulan C-24 in a ratio of 49 : 
49 : 2 showed no shape-transformation on cooling or heating (temperature change) 78. 
Along with the above mentioned issues, the volume of hydration medium and the time 
of hydration of niosomes are also critical issues. Inappropriate selection of these 
issues can result in the formation of fragile niosomes or the formation of the drug 
leakage problems. 
 
C. Effect of pH of the hydration medium  
The encapsulation efficiency of niosomes is significantly influenced by the pH 
of the hydration medium employed  for the formulation of niosomes79. At pH 5.5, the 
high encapsulation of flurbiprofen was reported with a maximum encapsulation 
efficiency of 94.60 %. The fraction of flurbiprofen encapsulated within niosomes 
enhanced to about 1.5 times as the pH reduced from 8 to 5.5 and decreased 
considerably at pH less than 6.8. At pH 7.4 and 8, the lowest encapsulation of 
flurbiprofen occurred with the absence of significant differences between them. The 
enhancement in the encapsulation efficiency of flurbiprofen at the lower pH was most 
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probably because of its ionizable carboxylic acid-group.Atthe lower pH, 
proportionsofunionizedflurbiprofenfound enhancedand the partitions 
morereadilyintothelipid-bilayerthantheionized species79. At the lowerpH, the niosomal 
formulations were examined by the opticalmicroscopy method forthepresenceofdrug 
precipitates bothbeforeandaftercentrifugationandwashing. This facilitatesto measure 
theconcentrationof the drugs inthe hydration medium employed giving the 
optimumencapsulationinniosomes. 
 
D. Preparation methodology 
The hand shaking method formulates the vesicles with greater diameter of 
0.35-13 nm compared to the vesicles formulated by the ether injection method (50-
1000 nm)34. Small-sized niosomes can be formulated by the reverse-phase 
evaporation method58, 80. Microfluidization method provides a greater uniformity and 
small-size vesicles34. Niosomes formulated throughthe trans-membrane pH gradient 
(inside acidic) drugs uptake process demonstrated greater drug encapsulation 
efficiency as well as better retention of drugs80. 
 
E. Resistance to osmotic stress 
The addition of hypertonic salt solutions to a niosomal suspension transports 
about the reduction in diameter. In the hypotonic salt solutions, there is apreliminary 
slow release with a slight swelling of the vesicles possiblybecause ofthe inhibition of 
eluting fluid from the vesicles, followed by the faster release, which can be because of 
mechanical loosening of the vesicles structure under the osmotic stress34; 37. 
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1.13. Stability of niosomes 
Niosome vesicles are stabilized on the basis of formation of 4 different forces35: 
 Van der Waals forces among the surfactant molecules used in the preparation 
of niosomes. 
 Repulsive forces emerging from the electrostatic-interactions among the 
chargedgroups of the surfactant molecules used in the preparation of 
niosomes. 
 Entropic repulsive forces of the head groups of surfactants used in the 
preparation of niosomes. 
 Short-acting repulsive forces. 
 
The electrostatic repulsive forces are generated among the vesicles upon 
addition of the chargedsurfactants to the double-layer, increasing the stability of the 
niosomal vesicle systems35. The biological stability of the niosomes formulated with 
alkyl glycosides was exploredby Kiwada et al80, 81. In these reports, Kiwada et al.81, 
82have reported that the formulated niosomes by them were not stableenough in the 
plasma, whichcan be because ofthe single–chain alkyl surfactants used in the 
preparation of these niosomes. In these researches, the formulated SUVs werefound 
more stable enough.Niosomes in the form of liquid crystals and gelsareremaining 
stable enough at both the roomtemperature (25°C) and 4°C for 2 months. Any 
significant dissimilarity hasnot been examinedbetween the stability of these 2 types of 
niosomes regarding leakage. Although, any correlation between the storage 
temperature and the stability has not been observed,it is advocated that niosomes 
should be stored at 4°C. Preferably, these niosomal vesicular systems required to be 
stored as dry for the reconstitution by the nursing staffs or by the patients and also, 
whenrehydrated niosomal systems should displaythe dispersion characteristics that are 
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analogous to the originaldispersion.The simulation studies performed to investigate 
the physical stability of these niosomesfor the duration of transportation to the 
purchaser revealed that the mechanical forces didn’t have anyeffect on the physical 
stability of the niosomal systems. It is believed that the causefor the stability 
ofniosomes can be due to the aggregation prevention of vesicles caused by the steric-
interactionsamong the large polar head groups of surfactants used for the 
preparation.The issues which may affect the stability of niosomes are35: 
a. Types of surfactants used in the preparation of niosomes; 
b. Nature of encapsulated drugs within niosomes; 
c. Storage temperatures; 
d. Detergents; 
e. The use of membrane spanning lipid materials; 
f. The interfacial polymerization of surfactant monomers in situ; 
g. Inclusion of charged molecules. 
1.14. Characterization of niosomes: 
 Determination of drug encapsulation efficiency: 
After the preparation of niosomal dispersion, unencapsulated drugs are 
separated by dialysis 66, 82, centrifugation82, or gel-filtration 72,83.The drugs remained 
ncapsulated within niosomes is determined throughthe complete vesicle disruption 
using 50% n-propanol or 0.1% Triton X-100 and analyzing the resultant 
solutionsthrough appropriate assay method for the drugs 40. 
 
Drug encapsulation efficiency (%) =   Amount of drug entrapped      X 100 
                                                            Total amount of drug 
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 Determination of vesicle size and vesicle size distribution analysis: 
The drug permeability is dependent on the vesicle sizes of niosomes. 
Therefore, the vesicle sizes and vesicle size distribution ofniosomes are essential.To 
determine the mean vesicle sizes and vesicle size distribution, instrumental 
methodsemployed mainly are as follows34,37 
a. Malveran Mastersizer  
b. Optical microscopy  
c. Laser diffraction particle size analyzer  
d. Coulter submicron size analyzer  
e. Photon correlation microscopy 
f. Molecular sieve chromatography, and  
g. Freeze fracture electron microscopy 
 
Recent years, freeze fracture electron microscopy is widely employed in the 
determination of vesicle size and vesicle size distribution analysis. The freeze thawing 
condition of niosomes (keeping the niosomal vesicular suspensions at - 20°C for 24 
hours and then, heating to an ambient temperature) increases the vesicle sizes that 
may be attributed to the fusion of vesicles during the cycle 34. 
 
 Determination of vesicle shape and vesiclesurface characterization: 
To determine vesicle shape and vesicle surface characterization, important 
instrumental methods employed are as follows 34,37 
a. Optical microscopy  
b. Transmission electron microscopy (TEM)  
c. Scanning electron microscopy (SEM) 
d. Field emission scanning electron microscopy (FESEM)  
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 Determination of Zeta potential: 
To determine the colloidal properties of niosomalformulations, zeta potential 
value is essential.Zeta potential can be determined using Malveran Zetasizer. 
 
 Determination of vesicular surface charge: 
Niosomes are usually prepared through the inclusion of charged molecules in 
the lipid bilayers to avoid the aggregation ofvesicles. A decrease in the aggregate 
formation was seen, when the charged molecules like dicetyl phosphate 
wasincorporated within the vesicles. The surface charge on the vesicles is expressed 
in terms of zeta potential and it is calculated using the Henry’s equation, shown 
below84 
£ =μEπη/Σ 
where,£ = Zeta potential; μE = Electrophoretic mobility; η = Viscosity of the 
medium; and Σ = Dielectric constant 
 
 
 Determination of number of lamellae: 
The number of lamellaeis determined by using these following instrumental 
methods85 
a. Nuclear magnetic resonance (NMR) spectroscopy,  
b. Small angle X-ray scattering and  
c. Electron microscopy 
 
 Measurement of membrane rigidity: 
 
The membrane rigidity can be measured through mobility of fluorescence 
probe as the function of temperature 79. 
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 Measurement of bilayer formation: 
The assembly of non-ionic surfactants to form the bilayer vesicles is 
characterized through X-cross formation under the lightpolarization microscopy 85. 
 In vitro drug release study: 
A method of in vitrodrug release rate study methodology with the help of 
dialysis tubing was reported by Yoshioka et al. 72.According to this methodology 
reported, a dialysis sac is washed and then, is soaked in distilled water. The vesicle 
suspensionsare pipetted into a bag made of the tubing and sealed. The dialysis bag 
containing the niosomal vesicles is then positioned in the 200 ml of buffer solution in 
a 250 ml beaker with application of constant shaking at 37 ± 0.5°C. At various 
predetermined time intervals, the buffer solutions are collected. The collected buffer 
solutions are analyzed for the estimation of drug contentsthrough an appropriate assay 
method. 
A different type of in vitro drug release rate study methodology of niosomes is 
reported by Karki et al.86. According to Karki et al.861 ml of prepared niosome 
suspensionsare placed first on the top of the column and the elution isperformed using 
normal saline as in vitro drug release medium. Niosomes are filled within dialysis 
tubing to which a dialysis sac is attached to the one end. The dialysis tube is 
suspended in the phosphate buffer (pH, 7.4) at 37 ± 0.5°C with continuous stirring 
using a mechanical stirrer. At various predetermined time intervals, the buffer 
samples are withdrawn. The collected buffer samples are analyzed for the estimation 
of drug contents through an appropriate assay method using high-performance liquid 
chromatography (HPLC).  
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 In vivo studies: 
For in vivo studies of the niosomal formulations rats and rabbits are used as 
experimental animal. These experimental animals are subdivided with groups as 
control and test. Niosomal formulations to be tested in vivo are administered to the 
experimental animals through appropriate route. At various predetermined time 
intervals, appropriate samples as well as changes in physical condition are recorded 
for pharmacokinetic and pharmacodynamic responses, respectively. 
 
 Stability study: 
The stability study is performed to ensure that the absence ofany degradation 
of active ingredients or drugs encapsulated in the niosomes and the niosome 
formulations does not exhibit any physical or chemical interactions between active 
ingredients or drugs and excipients. The stability study test is also conducted to ensure 
that the activity of the preparation is not lost. Therefore, the formulated niosomes are 
subjected for stability studies for a period of three months. The formulated niosomes 
are divided into 3 portions. First portion is kept at refrigeration temperature (4°C 
±1°C). Second portion at room temperature and third portion is kept at 40°C± 2°C. 
 
 
1.15. Drug delivery applications of niosomes 
 
Niosomes are potentially applicable to encapsulate many pharmacological 
agents and their delivery for their action against various diseases35,47. The 
administration of niosomes through various routes has been also reported49. Some of 
their drug delivery applications are discussed below35,49,47. 
 
 Oral drug delivery: 
The oral route is usually chosen as a leading popular route of drug 
administration. An enhanced oral bioavailability of griseofulvin through the oral 
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administration of griseofulvin loaded niosomes was also observed43. An in vitro–in 
vivo correlation demonstrated that niosomes were the efficient way to enhance the 
oral bioavailability as well as sustained delivery of griseofulvin through the oral 
administration. Span60-based niosomal formulations containing fluconazole (an 
antifungal drug) for oral use withanencapsulation efficiencyof greater than 91% 
demonstrated sustaine drug release pattern by zero-order followed by first-
orderkinetics87. In a report, orally administered niosomes loaded with rifampicin and 
gatifloxacin were found effective against thetuberculosis causing bacteria, 
Mycobacterium tuberculii for a prolonged period and also, were observed better 
results than the conventional dosage formsdue to the reduced dosingas well as greater 
patient compliances88. Yet,the major difficulties to oral delivery of niosomal 
formulations are the hepaticfirst-passmetabolismandgastrointestinal irritation.These 
limitations can be conquered via other routes of drug administration.For the 
oralimmunization,a type of mannosylatednon-ionic surfactant-basedniosomal vesicles 
have been formulated for efficient delivery of plasmid DNA encoding small lsub-unit 
proteins of hepatitisBvirus49. 
 
 Parenteral drug delivery: 
Niosomes of sub-micron sized vesicles are usually employed for the parenteral 
administrations of several drugs. Usually, niosomalvesicles up to 10 μm vesicle-size 
are administered via intraperitoneal or intramuscular route.[R]-59Fe-deferroxamine 
trioxyethylene cholesterol niosomal vesicles were developed for intravenous 
administration89. It was observed that the distribution of such niosomal vesicles 
depended upon the vesicle size as apparentfrom the result indicating the greater 
distribution in liver as well as spleen.The results indicated that the encapsulation of 
doxorubicin within the niosomes decreases the cardiactoxicity upon intravenous 
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administration.Uchegbu et al.51, 90have investigated the influence of the dose on the 
plasma-drugconcentration through theintraperitoneal administration of doxorubicin-
containing niosomes inmouse. 
 
 
 Pulmonary drug delivery: 
Niosomal vesicles are employed in the treatment of asthmatic patients also.  
Terzanoet al. 91 havedevelopedpolysorbate 20-based niosomes containing 
beclomethasone dipropionate for the pulmonary delivery to the patients suffering 
from chronic obstructive pulmonary disease (COPD). They have reported that 
theseniosomes containing beclomethasone dipropionatepresented targeted and 
sustained delivery of encapsulated beclomethasone dipropionate. Along with this, 
these niosomes exhibitedenhanced mucus permeation and improved therapeutic 
effect. Theseniosomal vesicles exhibit an increased permeation rate of 
beclomethasone dipropionate through the model mucosal-barrier and therefore, 
presenting anenhanced targeting of beclomethasone dipropionate in the treatment of 
COPD. In another investigation, Moazeni et al.,92 have also investigated the 
formulation and in vitro analysis of niosomes containing ciprofloxacin for pulmonary 
delivery.  
 
 Drug targeting: 
a) Drug targeting to reticulo-endothelial system (RES): The cells of RES 
preferentially uptake the vesicles47. The uptake of niosomesby the cells of RES is 
also through the circulating serum factors known as opsonins, which is 
recognized to mark them for the clearance. However, such types of localized 
drug accumulation have been developed in the treatment of tumors commonly 
known to metastasize to both the spleen and liver. 
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b) Drug targeting to organs other than reticulo-endothelial system (RES): The drug 
targeting to the organs other than RES is also employed by the various 
researchers. This has been advocated that the carrier systems can be directed to 
the specific-sites in the body through use of antibodies. Various kinds of 
immunoglobulins areinvestigated to bind quite readily to the lipid-surface of the 
vesicles.This offers a convenient and effective meansfor the targeting of drug 
carriers. Numerous cells have the intrinsic capability to identify and also to bind 
particular carbohydrate-determinants.This can be developed to direct the carriers 
system to target any particular cells 93.  
 
 Transdermal drug delivery: 
 
The slow penetration of drug molecules through the skin barrier is the main 
disadvantage of transdermal drug delivery. An enhancement in penetration rate for the 
drug molecules has been attained through the transdermal delivery of drugs 
incorporated in the niosomal formulations. Jayraman et al.94 has researched the 
transdermal delivery of erythromycin from various types of formulations including 
niosomes on the hairless mouse. From results of these studies, it was observed that 
these non-ionic niosomal vesicles are found effective to target the 
pilosebaceousglands. 
 
 Ocular drug delivery: 
Bioadhesivecoated niosomal formulationscontaining acetazolamide was 
formulated usingSpan 60, dicetyl phosphate or cholesterol stearylamine showed more 
affinity for the reduction of intra-ocular pressure as compared to the marketed 
formulation of acetazolamide, Dorzolamide95. The chitosancoated niosomal 
formulation containing timolol maleate (0.25%) displayed more effectivenessfor the 
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reduction of intra-ocular pressure as compared to the marketed formulation of timolol 
maleate (0.25 %) with lesser chances of cardiovascular side-effects96. 
 
 Delivery of peptide drugs: 
In an investigation, Yoshidaet al.72 have investigated the oral delivery of 9-
desglycinamide and 8-arginine vasopressin encapsulated in the niosomes in the in 
vitro intestinal-loop model. They have reported that the stability of these encapsulated 
peptides found increased significantly. 
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2. AIMS AND OBJECTIVES 
 
2.1. AIM 
Niosomes are used to prolong the circulation of the drugs, to alter the 
distribution of drugs and they also have many advantages. Niosomes favor selective 
drug delivery and enhances the therapeutic efficacy and decreases the severity of side 
effects. The need for present study is to encapsulate the drug in the niosomes vesicles 
for effective colon drug delivery for a prolonged period of time. 5-Fluorouracil is one 
of the most effective drugs in the treatment of colon cancer. Our objective of this 
study is to treat colon cancer by formulating niosomes containing 5-fluorouracil and 
leucovorin. Leucovorin is used in the formulation to increase the activity of the drug 
fluorouracil. Since, niosomes prolong the circulation of many drugs and alters the 
distribution of drugs, we aimed at formulating 5-Fluorouracil and leucovorin 
niosomal drug delivery, thereby dose can be minimized and also to achieve sustained 
release for a prolonged period of time and to compare the anticancer activity of 5-
Fluorouracil and leucovorin niosomes with a marketed formulation at different 
concentrations of the drug. The reason for selecting niosomal drug delivery is that 
niosomes can entrap both hydrophilic and lipophilic drugs and also have better 
stability than liposomes. 
 
2.2. OBJECTIVES  
2.2.1. Reason for selecting 5–fluorouracil and leucovorin 
5–Fluorouracil is the most continuously used drug in treating colon cancer 97, 
98
. It belongs to the category anti-metabolites 99. It inhibits with the production of 
proteins which is required for cell growth and reproduction 100. It is used in 
combination with many other drugs now-a-days. Leucovorin is not actually 
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chemotherapeutic agent, but it potentiates the activity of the drug 5-Fluorouracil to a 
great extent 101. Also, it does not possess any serious side effects. Leucovorin is a 
vitamin–B derivative. Conventional dosage forms are available with 5-fluorouracil 
and leucovorin is given in the adjuvant therapy. So both these drugs were selected in 
combination to be formulated as niosomes to treat colon cancer effectively. 
 
2.2.2. Reason for choosing niosomes 
Though many carriers are available under targeted drug delivery systems, 
niosomes was selected in this study because these host many advantages over other 
carriers especially over liposomes, which are structurally similar to niosomes 85. 
Niosomes are osmotically active and more stable compared to liposomes 102. Since 
these can encapsulate both hydrophilic and lipophilic drugs, a wide range of solubility 
of drugs can be accommodated 84. The non-ionic surfactants employed in the 
formulation are biodegradable, bio compatible and non–immunogenic 49, 47. It is 
known that most of the anti-cancer drugs possess severe side effects. But, niosomes 
have the ability to alter the metabolism of a drug34; these can also prolong the 
circulation and half–life of a drug so that the side effects of the drug can be 
decreased37. 
2.3. Plan of Work 
The following experimental protocol was envisaged for a systemic approach to 
the study. 
• Purchase of drugs 5- Fluorouracil, Leucovorin and other excipients used in the 
study. 
• Literature review of the drugs and niosomes. 
• Preformulation studies: 
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a. Identification of drugs, excipients and its mixture using: 
 Infrared spectroscopy ( FTIR Technique) 
 Melting point determination 
 Differential scanning colorimetry 
b. Preparation of calibration curve of drugs in DMSO and buffer 
c. Formulation of niosomes containing 5 –Fluorouracil and combination of 5- 
Fluorouracil and leucovorin niosomes with different surfactants by Lipid  
Hydration technique using Rotary Flash Evaporator. 
d. Selection of best formulation for characterization 
e. Characterization of formulated niosomes: 
 Particle size distribution 
 Vesicle shape and surface characterization by Scanning Electron Microscopy( 
SEM) and Transmission Electron Microscopy (TEM) 
 Percentage yield 
 Drug Entrapment Efficiency 
 In –vitro release study 
 Sterility test of niosomes 
 Stability studies using ICH guidelines 
 Comparison of anti –cancer effect of the prepared niosomal formulations with 
the marketed formulation. 
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3. REVIEW OF LITERATURES 
Recent years, various colloidal vesicular carrier systems are gaining 
remarkable status for the effective use in various kinds of drug delivery therapeutics 
31
. Among these various colloidal vesicular carrier systems, niosomes are the lipid-
based vesicular systems for the use as promising vehicles for drug delivery 
applications 34. In 1975, L’Orealformulated and patented the first niosomal 
formulations 35. Niosomes are the microscopic bilayer lamellar vesicles formed on the 
hydration on non-ionic surfactant films, which hydrate imbibing or encapsulating the 
hydrating aqueous solutions 36. The size of the niosomes lies in nanometric scale 
usually in the range of 100 – 300 nm 37. During last few decades’ considerable 
research efforts have been directed towards the research and development of various 
niosomal formulations for the use in potential drug delivery applications through 
different routes 47,49, 51, 84, 102. 
 
Wang et al.99 have prepared and characterized 5-fluorouracil loaded pH-
sensitive niosomes made of a non-ionic surfactant mixed with cholesteryl 
hemisuccinate (a derivative of cholesterol as a pH-sensitive agent) and succinic acid. 
These 5-fluorouracil loaded pH-sensitive niosomes were prepared through the film 
hydration-probe ultrasound technique. Both the normal and pH-sensitive niosomes 
exhibited spherical morphology structure under the transmission electron microscopy 
(TEM) with average vesicle sizes of 172.00 ± 6.20  nm and 153.00 ± 4.70  nm, 
respectively. The thermotropic status, structure changes and interaction of                            
5-fluorouracil with other excipients were also characterized by the differential 
scanning calorimetry (DSC) and the disappearance of the melting peak of 5-
fluorouracil revealed that the fact of 5-fluorouracil encapsulation within these 
niosomes. The structure of 5-fluorouracil loaded pH-sensitive niosomes was analyzed 
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by the mass spectrometry and proton nuclear magnetic resonance (1H NMR) 
spectrum. The pattern of 5-fluorouracilreleases from normal niosomes and pH-
sensitive niosomes was tested using bulk equilibrium reverse dialysis method. The 5-
fluorouracil releases from normal niosomes and pH-sensitive niosomes in different 
pH medium exhibited a pH-sensitive behavior from the niosomes made of cholesteryl 
hemisuccinate. The in vivo tumor targeting efficacy of these 5-fluorouracil loaded pH-
sensitive niosomes demonstrated a remarkable high concentration of 5-fluorouracil in 
the tumor-site of the mice transplanted with the tumor cell. 
Namdeo and Jain, (1999)100 have formulated niosomes containing                            
5-fluorouracil using a series of Spans, i.e. Span 20, 40, 60 and 80. They have prepared 
these Span-based niosomes containing 5-fluorouracil through the hand shaking 
method, reverse phase evaporation method and ether injection method. The niosomes 
containing 5-fluorouracil prepared by hand shaking method were found less 
permeable, when niosomal vesicles were studied for the effect of various process 
variables such as types of Spans, composition of the lipid and total lipid concentration 
on drug entrapment efficiency  and also the drug release rate. The niosomes 
containing 5-fluorouracil prepared using Span 40 and 60 were found to release                     
5-fluorouracil of 40.90 % and 37.10 % within 6 hours; while niosomes prepared using 
Span 20 and 80 exhibited 52.20 % and 57.10 % of 5-fluorouracil releases, 
respectively within the same time period. Niosomes prepared using Span 40 showed a 
mean vesicle size of 8.1 μm, drug entrapment efficiency of 15.30 ± 1.30 % and 
released 78.60 % of 5-fluorouracil within 6 hours. The incorporation of cholesterol 
within the niosomal formulations found to be reduced the vesicle size to 4.8 μm, drug 
entrapment efficiency to 12.30 ± 0.90 % and released 50.50 % of 5-fluorouracil 
within 6 hours; while the incorporation of dicetyl phosphate within the niosomal 
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formulations further decreased the vesicle size to 3.87 μm, drug entrapment efficiency 
to 10.90 ± 1.10 % and reduced of 5-fluorouracil to 40.90 % within 6 hours. The 
increment in the amounts of lipids used for the niosomes containing 5-fluorouracil 
was found to be translated into an almost linear enhancement in the drug entrapment 
efficiency. The bio-distribution of 5-fluorouracil in the rats was found modified on the 
encapsulation within the nisomal formulations. The concentrations of niosomal  
5-fluorouracil in the liver, lung and kidney were found increased; while it was found 
to be decreased in the intestine as compared to the free drug solution following 
intravenous administration of niosomes containing 5-fluorouracil. These niosomes 
also exhibited a higher and sustained plasma-drug level shape as compared to the free 
drug solution. The pharmacokinetic parameters revealed an improvement in the half-
life, area under the curve and a decrease in the volume of distribution of  
5-fluorouracil on encapsulation within the niosomes.  
 
Cosco et al., (2009)103 have formulated niosomes composed of α, ω-
hexadecyl-bis- (1-aza-18-crown-6) (bola), Span 80 and cholesterol in a molar ratio of 
2:5:2. They have encapsulated 5-fluorouracil (an anti-tumoral drug, which is mostly 
used in the breast cancer treatment) within these bola-niosomes. After the sonication 
procedure these 5-fluorouracil loaded bola-niosomes demonstrated mean vesicle sizes 
of ~ 200 nm and a drug loading capacity of ~ 40 %. Similar results were also attained 
in case of polyethylene glycol (PEG)-coated bola-niosomes (bola, Span 80, 
cholesterol, and DSPE-mPEG2000, in a molar ratio of 2:5:2:0.1, respectively).  
5-fluorouracil loaded PEG-coated and uncoated bola-niosomes were evaluated for 
their activity on MCF-7 and T47D cells. Both the types of 5-fluorouracil loaded bola-
niosome formulations (PEG-coated and uncoated) presented an enhancement in the 
cytotoxic effects on MCF-7 and T47D cells with respect to the free 5-fluorouracil. 
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The confocal-laser scanning microscopy analyses were performed to evaluate both the 
extent as well as the time-dependent bola-niosome/cell interactions. In vivo analysis 
on MCF-7 xeno-graft tumor SCID-mice models demonstrated a more effective anti-
tumoral activity of the PEG-coated 5-fluorouracil loaded bola-niosomes at a 
concentration, which was 10 times lower than that of the free drug solution of  
5-fluorouracil after a treatment of 30 days period. 
The same research group, in another study has investigated the same niosomal 
formulation [composed of α, ω-hexadecyl-bis- (1-aza-18-crown-6) (bola), Span 80 
and cholesterol in a molar ratio of 2:5:2] for the use in the topical delivery of  
5-fluorouracil for the treatment of skin cancer104. These 5-fluorouracil loaded bola-
niosomes demonstrated a mean vesicle size of approximately 400 nm. These niosomal 
vesicles were found to be decreased to around 200 nm through a sonication method of 
niosomepreparation with 0.1 of polydispersion index value. These niosomes exhibited 
5-fluorouracil loading of about 40 % regarding the amount of 5-fluorouracil added the 
preparation systems. These 5-fluorouracil-loaded bola-niosomes were evaluated on 
HaCaT (non-melanoma skin cancer with specific mutations in the p53 tumor 
suppressor gene) and SKMEL-28 (human melanoma) to evaluate the cytotoxic action 
regarding the free 5-fluorouracil. These 5-fluorouracil-loaded bola-niosomes 
illustrated an enhancement of the cytotoxic action regarding the free 5-fluorouracil. 
The confocal-laser scanning microscopy analyses were performed to evaluate both the 
extent as well as the time-dependent bola-niosome/cell interactions. The percutaneous 
permeation of 5-fluorouracil-loaded bola-niosomes was assessed by the using of 
human stratum corneum as well as epidermis membranes. These 5-fluorouracil-loaded 
bola-niosomes presented an enhancement of the drug penetration through the human 
stratum corneum and the epidermis membranes of 8- and 4- folds, respectively, 
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regarding an aqueous solution of 5-fluorouracil and a mixture of empty bola-niosomes 
with an aqueous solution of 5-fluorouracil. 
Parikh et al., (1998)97 have reported the formulation and in vitro evaluation of 
niosomes containing 5-fluorouracil using a non-ionic surfactant series of Spans 
through thin-film hydration method. They have prepared niosomes using Span 40, 60, 
80 and 85. The higher drug entrapment efficiencies of 5-fluorouracil within these 
niosomes made of Span 40 and 60 were seen as compared to the niosomes made of 
Span 80 and 85. It was also seen that incorporation of increased amounts of 
cholesterol increased the entrapment of 5-fluorouracil into these niosomal 
formulations. The leakage of 5-fluorouracil in these niosomes was found reduced on 
the freeze drying.  
 
Hao et al., (2002)60 have prepared niosomes of high encapsulation efficiency 
for a soluble drug. They have employed Span 60 as non-ionic surfactant and 
cholesterol to prepare these niosome through the evaporation-sonication technique. 
These niosomes exhibited good stability for at least 40 days. In these niosomes, 
colchicine was encapsulated as a model drug. To get higher colchicine encapsulation 
efficiency, several processing factors such as the structure of the non-ionic surfactant 
used, level of lipid, colchicine content and cholesterol amount were analyzed and 
optimized. From the obtained results, it was clearly evident that the Span 60 was the 
most ideal surfactant among four kinds of Spans used for the preparation of these 
niosomes containing colchicine. Moreover, colchicines release in the in vitro analysis 
from these niosomes displayed prolonged colchicine release profile over 24 hours. 
The results of this investigation suggested that these optimized niosomes containing 
colchicines not only contained high encapsulation efficiency, but also expected less 
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chance of side-effects. These types of niosomes can be prepared for the encapsulation 
of other soluble drugs.   
 
Desai and Finlay (2002)105 have investigated the potential of the encapsulation 
of all-trans-retinoic acid through the niosomal formulations and delivering it as an 
inhaled aerosol. Various types of non-ionic surfactants like Span and Tweens of 
various grades were employed to achieve the optimal encapsulation and nebulization 
efficiencies. The optimal formulations were obtained with combinations of Span 20-
Tween 80 blend and Span 60-Tween 80 blend using an all-trans-retinoic acid 
concentration of 1 mg/ml.  
 
Balasubramaniam et al., (2002) 106 developed niosomes for the encapsulation 
of daunorubicin hydrochloride through the reverse evaporation process. These 
developed niosomes containing daunorubicin hydrochloride exhibited entrapment 
efficiency of 20 %, which were the higher than the theoretically possible by the 
reverse evaporation process. These niosomes containing daunorubicin hydrochloride 
were found very stable at a storage temperature of 4°C for 3 months period. Even, the 
drug leakage from these formulations was found to be restricted to just only 10 %. 
The in vivo drug release advocated a prolonged daunorubicin hydrochloride release 
over a period of 20 hours. The niosomes containing daunorubicin hydrochloride 
displayed an improved anti-tumor efficiency, when compared to free daunorubicin 
hydrochloride. The niosomes containing daunorubicin hydrochloride was found 
capable to damage the Dalton's ascitic lymphoma cells in the peritoneum within the 
3rd day of treatment; while free daunorubicin hydrochloride took around 6 days and 
the process was found incomplete. The haematological analysis also confirmed that 
the treatment using niosomes containing daunorubicin hydrochloride were superior as 
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compared to the treatment using free daunorubicin hydrochloride. An improved mean 
survival-time was attained by the developed niosomes containing daunorubicin 
hydrochloride, which finally confirmed the overall effectiveness of these niosomal 
formulations. The results of this study recommended that these multilamellar 
developed niosomes containing daunorubicin hydrochloride resisted the immediate 
lysis in the Kupffer cells, whereby a prolonged daunorubicin hydrochloride 
concentration was attained, which improved the cell-lysis. However, the key issue 
accountable for the rapid onset of action could be the improved permeability of these 
niosomes into cell membranes and cytoplasm of the Dalton's ascitic lymphoma cells. 
 
Uchegbu et al., (1995)107 have investigated that PK1 was an N- (2-
hydroxypropyl) methacrylamide (HPMA) copolymer-doxorubicin conjugate. The 
niosome encapsulation was planned a means to enhance the PK1 blood residence-
time, which could potentially promote the tumour uptake and produce a slower-
sustained release of the niosome encapsulated drug. The factors effecting the drug 
encapsulation efficiency and vesicle size of PK1-niosomal formulations were 
evaluated. 5 non-ionic surfactants were employed to formulate the PK1-niosomes, 
namely, hexadecyl poly-5-oxyethylene ether (C16EO5), octadecyl poly-5-
oxyethylene ether (C18EO5), hexadecyl diglycerol ether (C16G2), sorbitan 
monostearate (Span 60) and sorbitan monopalmitate (Span 40). Each surfactants were 
mixed in the equimolar ratio with cholesterol with varying amounts (9–39 mol %) of 
Solulan C24 (a cholesteryl poly-24-oxy ethylene ether). Dicetylphosphate (2 mol %) 
was also added to each mixtures. The passive association of PK1 with the preformed 
C16G2 and Span 60 niosomal vesicles was found low (only 3–4 %), while the 
subsequent dehydration (i.e., freeze drying) afterward rehydration of the niosomal 
formulation enhanced the drug entrapment up to 61 % in the C16G2 niosomal 
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formulation. Transmission electron microscopy (TEM) observation revealed that 
these formulated niosomes possessed an electron dense core, which was an evidence 
of intravesicular concentration of the encapsulated PK1. The increment of Solulan 
C24 content within these niosomal formulations resulted in reduced PK1 entrapment 
within niosomes after the freeze drying and the vesicle sizes were found to be 
decreased. The incorporation of SolulanC24 (39 mol %) caused the marked vesicle 
aggregation on the freeze drying, while at the lower levels (9 mol %), PK1 emerged to 
work as a cryoprotectant. The mean vesicle size of C16G2 niosomes was found 235 
nm. The C16G2 niosomes were unable to induce the lysis of red blood cells at the 
planned dose for the in vivo application. The preliminary in vivo bio-distribution 
analyses demonstrated PK1-C16G2 niosomes were mainly taken up by the spleen and 
liver.  
 
Chandraprakash et al., (1990)40 have prepared unilamellar niosomes for the 
encapsulation of an anti-cancer drug, methotrexate. The drug entrapment efficacy 
within these niosomes was found to be enhanced with the increment in lipophilicity of 
the non-ionic surfactants used for the preparations. The niosomes were prepared using 
span 60 as non-ionic surfactant demonstrated maximum drug entrapment and its 
pharmacokinetic profile in the mice transplanted with S-180 tumor was noticeably 
different as compared with the unentrapped free methotrexate. 
 
The same research group (Chandraprakash et al., 1993)108 has evaluated the 
effect of niosome encapsulation of methotrexate (prepared by the reverse phase 
evaporation technique using Span 60 as non-ionic surfactant), macrophage activation 
on the tissue distribution of methotrexate and tumor size after the administration of 
intravenous infusion into the mice. After the intravenous infusion of the prepared 
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niosomes containing methotrexate into the mice, the methotrexate concentration was 
measured as higher in all tissues of the treated mice except the kidney as compared 
with the free methotrexate solution treatment. The niosomal encapsulation of 
methotrexate and macrophage activation improved the methotrexate delivery to the 
tumor and also found to increase the anti-tumor activity. 
 
Udupa et al., (1993)109 have formulated niosomes using various grades of 
Tweens and Spans as non-ionic surfactants. They have planned to encapsulate the 
anti-cancer agent, methotrexate. The influences of vesicle size distribution, 
methotrexate encapsulation efficiency, and pharmacokinetic parameters on the tumour 
remission of the mice transplanted with S-180 Sarcoma cells were evaluated. 
Niosomes containing methotrexate prepared with Span 60 have shown the promising 
results. 
 
In an investigation, Parthasarathi et al., (1994)80 have formulated niosomes for 
the encapsulation of anticancer drug, vincristine sulfate to evaluate the effectiveness 
of these formulated niosomes as promising drug carrier. These niosomes encapsulated 
vincristine sulfate were prepared through the trans-membrane pH-gradient drug 
uptake process (i.e., the so-called remote loading method). These formulated 
niosomes containing vincristine sulfate were evaluated for the toxicity and anti-
tumour activity after administration of these niosomes to the tumour bearing mice. 
The toxicity of vincristine sulfate was found decreased after the administration of 
niosome containing vincristine sulfate. The in vivo evaluation in the tumour bearing 
mice indicated an enhanced anticancer activity with the reduced toxicity in mice. 
These niosomes can be employed to attain a better delivery of vincristine sulfate at the 
tumour site. 
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Ruckmani et al., (2000)110 developed niosomes containing cytarabine 
hydrochloride and evaluated their effectiveness for the treatment of leukemias. These 
niosomes containing cytarabine hydrochloride were prepared through a lipid 
hydration technique which excluded dicetyl phosphate. The vesicle sizes of these 
niosomes measured were ranged, 600 to 1000 nm. The release of cytarabine 
hydrochloride from these formulated niosomes displayed prolonged cytarabine 
hydrochloride release pattern over 16 hours of period. The drug entrapment efficiency 
of these niosomes containing cytarabine hydrochloride was measured about 80 % for 
the niosomes prepared using Tween 80, Span 60 and Tween 20 as non-ionic 
surfactant. For the niosomes prepared using Span 80, the drug entrapment efficiency 
was measured as 67.50 %. The physical stability of these niosomes containing 
cytarabine hydrochloride was found good over 4 weeks of stability period. 
 
Mokhtaret al., (2008)79 have investigated the formulation of niosomes 
containing a non-steroidal anti-inflammatory drug, flurbiprofen. They have found that 
the flurbiprofen encapsulation efficiency of niosomes was found significantly 
influenced by the pH of the hydration medium employed the formulation of niosomes. 
At pH 5.5, the high encapsulation of flurbiprofen was reported with a maximum 
encapsulation efficiency of 94.60 %. The fraction of flurbiprofen encapsulated within 
niosomes enhanced to about 1.5 times as the pH reduced from 8 to 5.5 and decreased 
considerably at pH less than 6.8. At pH 7.4 and 8, the lowest encapsulation of 
flurbiprofen occurred with the absence of significant differences between them. The 
enhancement in the encapsulation efficiency of flurbiprofen at the lower pH was most 
probably because of its ionizable carboxylic acid-group. At the lower pH, proportions 
of unionized flurbiprofen enhanced and the partitions more readily into the lipid-
bilayer than the ionized species. At the lower pH, the niosomal formulations were 
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examined by the optical microscopy method for the presence of drug precipitates both 
before and after centrifugation and washing.  
 
Bhaskaran and Panigrahi, (2002)111have formulated niosomes loaded with 
salbutamol sulphate using various types of non-ionic surfactants like Tweens (20, 40, 
60 and 80) Spans (20, 40, 60 and 80) and Brij 35 through the transmembrane pH-
gradient technique. The salbutamol sulphate encapsulation efficiencies in these 
niosomes were found varied from 28 % to 79 %. These niosomal vesicles were 
characterized by infrared (IR) spectroscopy. In vitro salbutamol sulphate release 
evaluations were performed using dialysis bag. Phosphate buffer, pH 7.4 was 
employed as dissolution medium. The in vitro salbutamol sulphate release evaluations 
were carried out for a period of 24 hours. These niosomes loaded with salbutamol 
sulphate displayed retarded release of salbutamol sulphate for 24 hours. Span 60 was 
observed as the most satisfactory surfactant among others, which released 78.40 % of 
salbutamol sulphate within 24 hours. The vesicle-size distribution analyses were 
performed by the optical microscopy. Most of these niosomes loaded with salbutamol 
sulphate were found spherical in shape. The thermal stability analyses were performed 
at 4°, 25° and 50° for one month. The niosomal product was lyophilized. The tissue 
distribution analyses were performed on the rabbits and the maximum concentration 
was measured in their lungs. 
Manconi et al., (2002)112 have prepared tretinoin loaded niosomes from the 
polyoxy ethylene (4) lauryl ether, sorbitan esters and a mixture of octyl/decyl poly 
glucosides, in the presence of cholesterol and dicetyl phosphate. Liposomes prepared 
from non-hydrogenated and hydrogenated phosphatidyl choline were prepared as 
comparison references to analyze the formulated tretinoin loaded niosomes. An 
investigation was planned to analyze the influence of vesicle-compositions and the 
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preparation method on the vesicle structure (MLV, LUV, or SUV), vesicle size 
distribution, drug entrapment efficiency and in-vitro release of incorporated tretinoin 
from these niosomes. Results obtained demonstrated that in the presence of 
cholesterol, all the amphiphiles employed were found capable to form stable vesicular 
dispersions with or without tretinoin. The vesicle sizes were found dependent on the 
preparation technique, the bilayer composition and the drug-load. The multilamellar 
(MLV) vesicles were observed as larger than the extruded (LUV) and the sonicated 
(SUV) vesicles; while the tretinoin-loaded vesicles were found generally smaller than 
the empty ones. The tretinoin entrapment efficiencies were always observed as very 
high particularly for the multilamellar (91–99 %) and extruded (88–98 %) vesicles. 
The in vitro tretinoin release from the formulated vesicular formulations was 
evaluated using the vertical Franz-diffusion cells. The in vitro tretinoin release rates 
through the Silastic membrane from liposomal and niosomal tretinoin dispersion were 
found faster than from a solution containing tretinoin. The in vitro tretinoin release 
data demonstrated that the tretinoin delivery through the niosomal formulations was 
found mainly affected by the vesicular structures and that tretinoin delivery was also 
observed increased from the MLVs to the LUVs to the SUVs. 
 
In an investigation, Himanshu et al., (2007)113 have designed and evaluated 
verapamil hydrochloride loaded niosomes. The verapamil hydrochloride loaded 
niosomes were prepared by thin film hydration technique using Span 40 and Span 60 
as non-ionic surfactants and cholesterol as lipids, in different ratios. The polymer to 
drug ratios was varied and the formulation variables were optimized to attain such 
verapamil hydrochloride release kinetics with a view to attain release in a controlled 
manner, improve bioavailability and decreased dosing frequency. Among these non-
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ionic surfactants, Span 60 showed an ecstatic result with high verapamil 
hydrochloride entrapment efficiency and in vitro verapamil hydrochloride release. 
Jain and Vyas (1995)114 have formulated niosomes containing rifampicin (an 
anti-tubercular agent) us Span as non-ionic surfactant and cholesterol in a ratio of 50 : 
50 mole fraction. The rifampicin-entrapped niosomal vesicles were characterized for 
their vesicle-shapes, sizes, drug entrapment efficiencies and in vitro release rates. The 
rifampicin-entrapped niosomes showing maximum rifampicin entrapment and 
minimum rifampicin release rate were chosen for the in vivo studies. The cumulative 
percent doses of rifampicin were recovered in the thoracic lymph following the 
intravenous as well as intraperitoneal administrations of rifampicin-entrapped 
niosomes and free rifampicin solution were compared. The results of this study 
displayed that the effective compartmentalization of rifampicin occurred in lymphatic 
system following the intraperitoneal administration of rifampicin-entrapped niosomes. 
Thus, rifampicin-entrapped niosomes could be employed for the tuberculosis 
treatment. 
 
Mullaicharam and Murthy (2004)115 also developed and optimized rifampicin 
(a first-line anti-tuberculosis drug) loaded niosomes. The formulation procedure along 
with the rifampicin entrapment efficiency of these niosomes was optimized using 
factorial design. The influences of changes of various formulation variables such as 
volume of solvents, volume of hydrating medium, hydration-time and sonication time 
were analyzed. The prepared rifampicin loaded niosomes were characterized for 
vesicle size, vesicle shape and lamellarity. The stability of these prepared rifampicin 
loaded niosomes was measured in terms of retention of the drug (rifampicin) at the 
ambient temperature (25-35°C) as well as refrigerated temperature (5°C) for 60 days. 
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The developed rifampicin loaded niosomes can be practical in the treatment of 
pulmonary tuberculosis. 
 
Rangasamy et al., (2008)116 have formulated acyclovir encapsulated niosomes 
through hand shaking technique and ether injection technique using various ratios 
(1:1, 1:2 and 1:3) of cholesterol (lipid) to Span 80 (Non-ionic surfactant). The vesicle 
size range was measured as 0.5-5 μm in the case of acyclovir encapsulated niosomes 
prepared by hand shaking technique and 0.5-2.5 μm in the case of acyclovir 
encapsulated niosomes prepared by ether injection technique. The acyclovir 
encapsulation efficiency was found increases, when the concentration of Span 80 was 
increased during preparation. In-vivo acyclovir release study of acyclovir 
encapsulated niosomes indicated that 76.64 % acyclovir release was measured for the 
niosomal formulation prepared with cholesterol to Span 80 ratio, 1:1. These niosomes 
indicated an extended acyclovir releasing period of 1 day. 
 
Ahuja et al., (2008)117 have formulated and evaluated lansoprazole (widely 
used as antiulcer agents and antacid) loaded niosomes. They have formulated these 
lansoprazole loaded niosomes through a modified reverse phase evaporation 
technique using Span 60 as non-ionic surfactant and cholesterol in a molar ratio of 
1:1. They dissolved Span 60 and cholesterol within a mixture of diethyl ether. 
Aqueous phase (5 ml) containing lasoprazole was added the above said mixture and 
the resulting 2 phases was homogenized using a homogenizer for 3 minutes at 4-5°C 
and 800 rpm. The formed clear gel was homogenized using a homogenizer once again 
for 2 minutes with the addition of phosphate buffer saline. The prepared suspension 
was heated using a water-bath for 10 minutes at 60°C.  
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In a study, Terzano et al., (2005)91 havedeveloped polysorbate 20-based 
niosomes containing beclomethasone dipropionate for the pulmonary delivery. They 
have formulated these niosomal formulations for the patients suffering from chronic 
obstructive pulmonary disease (COPD). They also have reported that these niosomes 
containing beclomethasone dipropionate presented targeted and sustained delivery of 
encapsulated beclomethasone dipropionate. Along with this, these niosomes exhibited 
enhanced mucus permeation and improved therapeutic effect. These niosomal vesicles 
exhibit an increased permeation rate of beclomethasone dipropionate through the 
model mucosal-barrier and therefore, presenting an enhanced targeting of 
beclomethasone dipropionate in the treatment of COPD. 
 
Pardakhty et al., (2006)118 have studied the encapsulation of insulin within the 
niosomes prepared polyoxy ethylene alkyl ethers (Brij 35, Brij 58 and Brij 92) by the 
film hydration technique. They have found that both Brij 35 and Brij 58 were unable 
to form niosomes without cholesterol owing to comparatively larger polar-head 
groups with reference to their alkyl chains. The vesicle sizes of these niosomes were 
depended on the cholesterol content as well as the incorporation of charges or the 
hydrophilicity of surfactants used in the preparation of niosomes. The encapsulation 
of insulin within the bilayer structure of niosomes guarded it against the proteolytic 
activity of α-chymotrypsin, pepsin and trypsin in vitro. The maximum protection 
activity against the proteolytic activity of α-chymotrypsin, pepsin and trypsin in vitro 
was observed when Brij 92 to cholesterol was employed in a molar ratio of 7:3. These 
niosomes containing insulin exhibited only 26.30 ± 3.98 % of encapsulated insulin 
was found to be released during 24 hours in the simulated intestinal fluid. The drug 
release kinetics for most of the niosomal formulations were best described by the 
Baker-Lonsdale equation indicating the diffusion-based drug delivery mechanism. 
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These results of this investigation indicated that niosomes of insulin can be developed 
for sustained releasing delivery of peptides and proteins such as insulin through oral 
route. 
 
Fang et al., (2001)119 have evaluated the skin permeation and partitioning of 
an antibacterial agent of fluoroquinolone group, enoxacin within liposomes and 
niosomes. They assessed the effectiveness of these vesicle formulations of enoxacin 
after the topical application. The in vitro percutaneous enoxacin absorption through 
the nude mouse skin was estimated using Franz-diffusion cells. The effects of these 
enoxacin loaded liposomes and niosomes on the physicochemical properties and 
stabilities were evaluated. The improved enoxacin delivery across the nude mouse 
skin from these enoxacin loaded liposomes and niosomes was observed after choosing 
the appropriate vesicular formulations. The optimized formulation of enoxacin was 
found able to reserve a larger amount of enoxacin in the nude mouse skin. A 
significant correlation between the skin permeation and the cumulative amount of 
enoxacin in the nude mouse skin was seen. Both the effects of permeation enhancer as 
well as the direct vesicle fusions with the stratum corneum were found to contribute to 
the skin permeation of enoxacin across nude mouse skin. These enoxacin loaded 
niosomes have revealed a higher stability after 48 hours of incubation as compared to 
enoxacin loaded liposomes. The addition of cholesterol enhanced the stability of 
enoxacin loaded liposomes consistent with the results from the enoxacin 
encapsulation and the turbidity. However, the addition of negative charges decreased 
the stability of the enoxacin loaded niosomes. The capability of the liposomes and 
niosomes to modulate the drug delivery without any significant toxicity, which 
indicated that these two vesicles (enoxacin loaded liposomes and niosomes) as useful 
for topical delivery. 
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Jin et al., (2013)120 have developed novel niosomal formulations for the oral 
delivery of Ginkgo biloba extract. They formulated these niosomes containing Ginkgo 
biloba extract through the film dispersion homogenization technique. The formulated 
niosomes containing Ginkgo biloba extract was spray-dried or freeze dried to enhance 
the stability of the niosomal formulations. These niosomes were characterized for 
their vesicle morphologies, vesicle sizes, zeta potentials, entrapment efficiencies, 
angle of reposes and thermal stability. The vesicle sizes of optimized niosomes 
containing Ginkgo biloba extract, prepared using Span 80, Tween 80 and cholesterol 
was measured about 141 nm. A significant difference (p< 0.05) was observed in the 
drug entrapment efficiency between the spray-drying (77.50 %) and the freeze-drying 
(50.10 %). The stability evaluation of the optimized niosomes containing Ginkgo 
biloba extract revealed that there was absence of any significant changes in the drug 
entrapment efficiency for these niosomes at 4°C as well as at 25°C after 3 months 
period. The in vitro release analyses suggested that these optimized niosomes 
containing Ginkgo biloba extract were able to prolong the release of Ginkgo biloba 
extract in the phosphate buffer solution (pH 6.8) over 48 hours. The in vivo evaluation 
of these optimized niosomes containing Ginkgo biloba extract demonstrated in rats 
that the Ginkgo biloba flavonoid glycoside content in the lung, heart, kidney, brain 
and blood of rats treated with the niosomes was found greater than that in the rats 
treated with the oral Ginkgo biloba extract tablet (p< 0.01). Any trace of the Ginkgo 
biloba flavonoid glycoside content was detected in the brain tissue of rats treated with 
the oral Ginkgo biloba tablets. However, the Ginkgo biloba flavonoid glycoside 
content was detected in the brain tissue of rats, when rats are treated with the 
optimized niosomes containing Ginkgo biloba extract. Thus, these niosomes 
containing Ginkgo biloba extract had shown a promise for the oral delivery of Ginkgo 
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biloba extract to the brain with enhanced oral bioavailability and to substitute the 
conventional Ginkgo biloba extract tablets. 
Azeem et al., (2008)121 have formulated and evaluate the niosomal vesicles 
containing frusemide in order to enhance transdermal permeation of frusemide. The 
formulation development of these niosomes containing frusemide was performed to 
analyze the process variables on the preparation and properties of these niosomal 
formulations. The process variables investigated such as type of Spans, Span to 
cholesterol ratio, cholesterol to dicetyl phosphate ratio, concentration of frusemide, 
solvent type, hydration media and hydration time were found to affect the preparation 
and properties of these niosomal vesicles containing frusemide. The maximum 
frusemide entrapment efficiency of 77.73 ± 2.36 % was observed with the niosomes 
formulated from Span 60 ∶ cholesterol ∶ dicetyl phosphate (47.5 ∶ 47.5 ∶ 5) and 
chloroform : methanol (4 ∶ 1) as the solvent system at the 1 hour of hydration time. 
The stability of the niosomes containing frusemide in terms of drug holding ability 
was evaluated for 30 days on storage. A direct correlation was seen between the 
percentage leaching of frusemide out of the niosomal vesicles and temperature. The 
higher transdermal flux of frusemide was attained with the frusemide niosomal gel 
(9.20 ± 0.50 μg/cm2/hour) as compared to the conventional frusemide gel (6.40 ± 
0.30 μg/cm2/hour). 
 
Pillai et al., (1999)122 have incorporated indomethacin within niosomes. In this 
investigation, the effect of indomethacin encapsulated niosomal formulations on the 
platelet functions like the inhibition of aggregation and ATP release induced through 
a range of agonists such as adenosine diphosphate (ADP), epinephrine, arachidonic 
acid, and ristocetine were investigated. The feasibility of these indomethacin 
encapsulated niosomal formulations based carrier-mediated drug delivery to the 
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platelets were also explored by this investigation. These indomethacin encapsulated 
niosomes were of MLV, which were prepared from Tween 60 through the lipid 
hydration technique. The freshly prepared human platelet rich plasma was employed 
for the aggregation/inhibition analyses. The extent of aggregation/inhibition was 
measured as an alteration in the light transmission, which was measured through the 
Chronolog Aggregometer. The percentage inhibition of the aggregation induced 
through the agonist ADP, ranged from 28.21 ± 0.28 % at the 2.0 μM level to 92.60 ± 
1.20 % at 12.7 μM of the encapsulated indomethacin; while the same concentrations 
of the indomethacin found to inhibit the aggregation only to the extent of 13.75 ± 0.13 
% and 36.82 ± 0.57 %, respectively. 100 % of aggregation inhibition induced by the 
arachidonic acid was attained by the action of indomethacin encapsulated niosomes; 
while the inhibition by the free indomethacin was found 41.90 % at the equimolar 
concentrations. The ATP release study demonstrated that the 100 % inhibition was 
attained by 8 μM of the encapsulated indomethacin; while the inhibition by the free 
indomethacin was 40.00 ±1.82 %. Thus, at the equimolar doses, the indomethacin 
encapsulated niosomal formulation demonstrated a more proficient activity in 
inhibiting the platelet aggregation than the free indomethacin, probably because of the 
greater quantity of the indomethacin reaching the specific-site of inhibition within the 
interior of the platelets as well as performing directly on the cyclooxygenase (COX) 
system to avert the formation of thromboxane. 
 
Carter et al., (1989)67 have reported that the multiple dosing with sodium 
stibogluconate-loaded niosomal formulations was found to be effectual against the 
parasite causing leishmaniasis. They have also investigated the characteristics and 
capability of sodium stibogluconate-loaded niosomal formulations to clear parasites 
from the spleen, liver and bone marrow in the Leishmania donovani infected BALB/c 
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mice. These sodium stibogluconate-loaded niosomal formulations were found to be 
effectual against the Leishmania donovani in the spleen, liver and bone marrow as 
compared to the simple solution of sodium stibogluconate. Therefore, these sodium 
stibogluconate-loaded niosomal formulations can be employed in the treatment of 
visceral leishmaniasis.   
 
Jadon et al., (2009)43 have investigated the formulation of griseofulvin loaded 
niosomes for the use in oral administration. They have observed an enhanced oral 
bioavailability of griseofulvin through the oral administration of griseofulvin loaded 
niosomes. An in vitro–in vivo correlation demonstrated that niosomes were the 
efficient way to enhance the oral bioavailability as well as sustained delivery of 
griseofulvin through the oral administration.  
 
In an investigation, Sharma et al., (2009)87 have formulated Span 60-based 
niosomal formulations containing fluconazole (an antifungal drug) for oral use. They 
have found the formulated Span 60-based niosomal formulations containing 
fluconazole contained an encapsulation efficiency of greater than 91 %. These 
niosomal formulations demonstrated sustained drug release pattern by the zero-order 
followed by first-order kinetics.  
 
Pavala Rani et al., (2010) 88 have developed niosomes loaded with rifampicin 
and gatifloxacin to investigate the effectiveness of the developed formulations against 
tuberculosis. They have observed that the orally administered niosomes loaded with 
rifampicin and gatifloxacin were found effective against the tuberculosis causing 
bacteria, Mycobacterium tuberculii for a prolonged period. It was also seen that these 
niosomes exerts better results than the conventional dosage forms due to the reduced 
dosing as well as greater patient compliances.  
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Raja Naresh et al. (1994)58 have reported the anti-inflammatory activity of 
niosome encapsulated diclofenac sodium in the arthritic rats. They have formulated 
these niosomes using Tween 85 and cholesterol. They have also found that the 
niosomal formulation prepared through employing a 1 : 1 combination of Tween 85 
and cholesterol exhibited an improved consistent in the anti-inflammatory activity for 
more than 72 hours after the administration of single-dose. 
 
Florence and Cable, (1993) 89have reported the development of 59Fe-
deferroxamine trioxyethylene cholesterol niosomal vesicles containing doxorubicin 
for the use in intravenous administration. They observed that the distribution of such 
niosomal vesicles was depended upon the vesicle-size as apparent from the result 
indicating the greater distribution in liver as well as spleen. The results indicated that 
the encapsulation of doxorubicin within the niosomes decreases the cardiac toxicity 
upon intravenous administration. 
 
Aggarwal et al., (2007)95 have prepared and evaluated bioadhesive coated 
niosomal formulations containing acetazolamide using Span 60, dicetyl phosphate or 
cholesterol stearylamine. These bioadhesive coated niosomal formulations containing 
acetazolamide demonstrated more affinity for the reduction of intra-ocular pressure as 
compared to the marketed formulation of acetazolamide, Dorzolamide.  
 
In another investigation, the same group (Aggarwal and Kaur, 2005)96 have 
formulated chitosan coated niosomal formulations containing timolol maleate (0.25 
%). The chitosan coated niosomal formulations containing timolol maleate (0.25 %) 
displayed more effectiveness for the reduction of intra-ocular pressure intraocular 
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pressure as compared to the marketed formulation of timolol maleate (0.25 %) with 
lesser chances of cardiovascular side-effects. 
 
Blazek-Walsh et al., (2001)61have reported the formulation of niosomes from 
maltodextrin-based proniosomes. This affords a rapid reconstitution of niosomes with 
the minimal residual carrier. The slurry of maltodextrin and surfactants was dried to 
form a free-flowing dry powder, which could be rehydrated through the addition of 
warm water. 
Yoshidaet al., (1992)76 have investigated the oral delivery of 9-
desglycinamide and 8-arginine vasopressin encapsulated in the niosomes in the in 
vitro intestinal-loop model. They have reported that the stability of these encapsulated 
peptides found increased significantly. 
 
Rogerson et al., (1987)75 have developed adriamycin-loaded niosomes. The 
efficiency of entrapment of aqueous solutions of adriamycin was found actually 
dependant on neither the niosomal vesicle composition nor the method of preparation 
and evidence of a degree of surfactant/adriamycin association. The light induced 
adriamycin degradation was found decreased through the encapsulation of adriamycin 
within the niosomes. The efflux of encapsulated adriamycin was found reduced 
through the incorporation of cholesterol into the these niosomal vesicles to that 
reported for the liposome preparations.  
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4. MATERIALS AND METHODS 
4.1. Preformulation Studies 
Preformulation is defined as the stage of research and development process 
where physical, and chemical characteristics of a new drug entity are characterized 
alone and when combined with excipients in order to develop stable, safe and 
effective dosage form. 
A thorough understanding of physicochemical properties may eventually 
provide a rationale for formulation design or carry, the need for molecular 
modification or purely confirms that there are no significant hindrances to the 
development of a substance. Therefore, preformulation studies were performed on the 
obtained sample of drug for solubility analysis, identification and compatibility 
studies. 
4.1. 1. Solubility analysis 
Preformulation solubility analysis was done, which include the selection of a 
suitable solvent to dissolve 5-Fluorouracil (5-FU) and Leucovorin (LV) as well as 
various excipients.  
4.1. 2. Compatibility studies 
Compatibility of drug and lipids which are used to prepare niosomes was 
established by infrared absorption spectra and DSC analysis.  
4.1. 3. FTIR Spectral analysis 
FTIR spectral analysis of pure drug and excipients was carried out and 
observation was made whether changes in the chemical constitution of drug after 
combining it with the excipients occurred. The samples were crushed with KBr to get 
pellets by applying pressure on 600 Kg/cm2 and scanned with the IR instrument 
(Shimadzu, 8400 Series, Tokyo, Japan) from 400-4000cm-1. 
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Fig 4.1. Schematic representation of compatibility studies 
Infra Red spectroscopy is one of the most powerful analytical techniques to 
recognize functional groups of a drug. 
 
4.1. 4. DIFFERENTIAL SCANNING COLORIMETRY (DSC) 
In Differential Scanning Colorimetry, the samples were heated from 25°C to 
100°C at a constant temperature increment of 10° C/min and purged with nitrogen gas 
at 40 ml/min. 
 Calibration curve 
The calibration curve for 5-Fluorouracil and Leucovorin (LV) was prepared by 
using phosphate buffer (pH 7.4). 
 Phosphate buffer pH 7.4 - Phosphate buffer was prepared by placing 25ml of 
0.2M potassium dihydrogen orthophosphate solution and 19.55ml of 0.2N sodium 
hydroxide solution in a 100ml volumetric flask and volume was made up to the 
mark with distilled water.  
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 Primary stock solution for 5-Fluorouracil and Leucovorin (LV)with 
phosphate buffer (pH 7.4) 
Accurately weighed 100mg of 5-Fluorouracil and Leucovorin (LV) was 
dissolved in 10ml of ethanol in a 100 ml of volumetric flask and volume was made up 
to the mark with pH 7.4 buffer to get a concentration of 1000µg/ml. 
 
 Secondary stock solution for phosphate buffer (pH 7.4) 
From primary stock solutions of phosphate  buffer  10ml was pipetted out in a 
100ml of volumetric flask and volume was made up to the mark with pH 7.4 buffer to 
obtain a concentration of 100µg/ml. 
 
From secondary stock solutions 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 and 1.0ml 
were pipetted out and diluted to 10ml with respect buffers to get a concentration range 
from 5µg/ml to 50µg/ml. The samples were analyzed spectrometrically at wavelength 
of 266 nm for 5-FU and 288 nm for LV. 
 
The calibration curve was plotted with the absorbance Vs concentration 
(µg/ml) and r2 and slope were calculated.  
 
4.2. Preparation of Niosomes 
Niosomes were prepared by a thin film hydration method using a surfactant 
mixture consisting of (span 40 and 60, tween 60 and 80) and cholesterol, at various 
ratios, at different specified ratios as given in Table. Surfactant and cholesterol was 
dissolved in 8 ml of diethyl ether and the drugs were dissolved in 2 ml of ethanol. 
Then the mixture was poured to a round bottom flask, and the solvent was evaporated 
under reduced pressure at a temperature 20-25º, using a rotary flash evaporator until a 
thin film of lipid layer was formed. The formed film was hydrated with 10 ml of 
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phosphate buffer saline pH 7.4. The hydration was continued for 1 h, while the flask 
was continued to rotate at 55-65°. The niosomes which were hydrated were sonicated 
for 20 min using a bath sonicator to obtain niosomal dispersion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. 2: Flow Chart for Preparation of Niosomes 
ORGANIC SOLVENT WAS ADDED TO THE ABOVE 
A  THIN LAYER OF FILM WAS FORMED IN A 
ROUND BOTTOM FLASK. 
THE DRUGS SOLUTION WERE ADDED TO THE 
THIN FLIM 
THE NIOSOMES WAS FORMED AND 
CHARECTERIZED 
WEIGHED QUANTITY OF CHOLESTEROL + 
SURFACTANT WAS TAKEN 
75 
 
Table 4.1: Formulation composition of Niosomes 
Type of 
formulation 
F1 F2 F3 F4 F5 F6 F7 F8 
Drug  10 10 10 10 10 10 10 10 
Cholesterol 10 20 10 20 10 20 10 20 
Span 40 10 10 - - - - - - 
Span 60 
- - 10 10 - - - - 
Tween 40 
- - - - 10 10 - - 
Tween 60 
- - - - - - 10 10 
Drug :cholesterol:  
SA 
1:1:1 1:2:1 1:1:1 1:2:1 1:1:1 1:2:1 1:1:1 1:2:1 
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4.3. Evaluation of Niosomes 
4.3.1. Entrapment efficiency for the Niosomes 
The niosomal dispersion is a homogeneous milky white suspension which is 
centrifuged at 12000 rpm for 15 min and entrapment efficiency of niosomes were 
evaluated by measuring the ultraviolet absorption of the supernatant. The 
corresponding calibration curves were made by testing the supernatant of blank 
niosomes. Each sample was measured in triplicate. 5-FU was measured at 266 nm 
where an intense characteristic peak was displayed while LV showed a characteristic 
peak at 288 nm. The percentage of the entrapment of the drug can be obtained for the 
niosomal formulations.  
4.3.2. Particle Size Analysis (PSA) 
The size division of the niosomes was determined using the particle size 
analyzer (Beckman Coulter, Delsa nano C, Brea, USA) prepared with a dry accessory 
system. Sample was diluted with water and temperature maintained at 25°C. 
 
4.3.3.Zeta Potential Analysis 
 
The zeta potential was measured using the appropriate instrument (Beckman 
Coulter Delsa Nano C, Brea, USA). The sample was made to dilute with distilled 
water and tranferred in the cuvettes and temperature maintained at 25°C. 
 
Zeta potential is the potential difference between the continuous phase and the 
stationary layer of the liquid attached to the particle dispersed. Stability of colloidal 
dispersions (dispersed systems, multi particulate, multi charge systems) can be 
predicted by Zeta potential value. 
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Zeta potential indicates the degree of repulsion between adjacent, similarly 
charged particles (likely charged particles) in dispersion. A high Zeta potential value 
will indicate stability for molecules and particles that are small enough (i.e. the 
solution or dispersion will resist aggregation/ do not flocculate). 
 
Colloids having higher Zeta potential are made to stabilize electrically while 
colloids with Low Zeta potential tends to coagulate or flocculate. 
 
Table 4.2: Zeta Potential Range 
Zeta Potential (mV) Stability behaviour of colloid 
From 0 to ±5 range Rapid coagulation or Flocculation 
From ±10 to ±30 range Insufficient instability 
From ±30 to ±40 range Medium stability 
From ±40 to ±60 range Good stability 
More than ±61 range Excellent stability 
 
 
4.3.4. Morphological analysis of niosomes 
Transmission electron microscopy (TEM) was used in the morphological 
analysis of niosomes. Samples were prepared by placing one drop of freshly prepared 
nano-suspension on a copper grid with carbon coated film support and the excess 
fluid was removed by using filter paper. Samples were viewed directly with TEM 
(JEM-100, JEOL, Tokyo, Japan) once they were made to dry under room temperature 
without any further staining. 
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The Scanning Electron Microcopy (SEM) is used to identify the particle size 
and the surface morphology of the nioosomes. For niosomes, the drop of the sample is 
placed on the covered glass slide and then dried by applying vacuum, later it was 
coated with gold to a thickness of 100Ǻ using VEGAS TESCAN Vacuum evaporator 
and the image was captured for the niosomal formulation. 
 
Vesicle dispersions were characterized by photo microscopy for vesicle 
formation and morphology. The size and shape of vesicles in niosomes formulations 
were observed by optical microscopy using a calibrated eyepiece micrometer, and 
photographs were taken at × 400 magnifications with a digital camera (Olympus, 8.1 
megapixel, Japan). 
 
4.3.5. In-vitro release studies for the niosomes 
In vitro release of 5-FU and LV niosomes was conducted by a dialysis 
membrane having a pore size of 2.4 mm (LA-395-5Mt Himedia Pvt. Ltd, Mumbai, 
India) with 75 ml of pH 7.4 phosphate buffer at 37°C. Briefly in a 100 ml beaker 
75ml of pH 7.4 phosphate buffer was placed.  2 ml of niosomal formulation was 
transferred into a dialysis bag and made to dip into the buffer solution.  The dialysis 
membrane was activated earlier using by soaking in 1% w/v NaOH over night. The 
flask was placed on a magnetic stirrer. Stirring was continued to maintain at 250 rpm 
and temperature of the buffer was maintained at 37°C. Sampling was done by 
withdrawing 1 ml of aliquots from a beaker. Immediately 1 ml of new buffer was 
added to keep the sink condition. Samples were analyzed after sufficiently diluting 
with buffer by using a UV-Visible Spectrophotometer (UV/VIS-Double beam 
Spectrophotometer, V-530, Jasco, Tokyo, Japan) at a wavelength of 266 nm for 5-FU 
and 288 nm for LV. 
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Figure 4.3: In vitro release study of niosomes 
4.3.6. In vitro release Kinetic study 
 The release data obtained were fixed into various mathematical models like 
zero order, First Order, Higuchi and Korsmeyer-Peppas to know which mathematical 
model was best fitting the obtained release profile. 
In order to analyze the release mechanism, several release models were 
experiencing such as 
Zero order Qt = Q0+K0t (1) 
Where, Qt is the amount of drug released at time t,  
K0 is the apparent dissolution rate constant or zero order release constant and  
Q0 is the initial concentration of the drug in the solution resulting from a burst 
effect; in this case the drug release runs at a constant rate. 
It describes the systems where the drug release rate is autonomous of its 
concentration of the dissolved substance. 
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A graph was plotted against time taken on x-axis and the cumulative 
percentage of drug release on y-axis and it yields a straight line. 
Application: This relationship can be used to describe the drug dissolution of various 
types of modified release  dosage forms, as in the case of some transdermal systems, 
as well as matrix particles with low soluble drugs in coated forms, osmotic systems, 
etc. 
The release of the drug that obeys first order kinetics may be given by the equation: 
dc/ dt = -Kc   
Where K is first order rate constant expressed in units of time-1. 
Equation can be expressed as: 
log C = log C0 - Kt / 2.303  
Where C0 is the initial concentration of drug, k is the first order reaction rate 
constant, and t is the time taken. The data obtained are plotted as log cumulative % of 
the remaining drug against time, which will give a straight line with a slope of -
K/2.303. 
Application: This relationship can be used to explain the drug dissolution in 
pharmaceutical dosage forms such as those containing water-soluble drugs in 
permeable matrices. 
The Higuchi release equation is 
Q = KHt1/2   
Where  
Q is the cumulative amount of drug release at time “t” 
KH is Higuchi constant 
T is time in hours 
The Higuchi equation suggests that drug release by diffusion. 
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A graph is plotted between the square root of time taken on x-axis and the 
cumulative percentage of drug release on y-axis and it gives a straight line. 
Application: This relationship can be used to illustrate the drug dissolution from 
several types of modified release pharmaceutical dosage forms, as in the case of some 
transdermal systems and matrix particles with water soluble drugs. 
The korsmeyer-peppas equation was given as 
F = (Mt/M) = Kmtn    
Where 
F is fraction of drug released at time‘t’ 
Mt is amount of drug release at time‘t’ 
M is total amount of drug in dosage form 
Km is kinetic constant 
n is diffusion or release exponent 
t is time in hours 
n is estimated from linear regression of log (Mt/M)  versus log t 
If n = 0.45 it indicates fickian diffusion 
0.45<n<0.89 it indicates anomalous diffusion or non-fickian diffusion 
Anomalous diffusion or non-fiction diffusion refers to a combination of both 
diffusion and erosion controlled rate rules. 
A graph was plotted between the log time release on x-axis and the log 
cumulative percentage of drug release on y-axis and it gives a straight line. 
Interpretation of drug release mechanism is given in following Table 4.3. 
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Table 4.3 Interpretation of Drug Release Mechanism 
Release exponent (n) Drug release mechanism Rate as a function of time 
0.5 Fickian diffusion t -0..5 
0.5 < n <1 Anomalous transport t n-1 
1 Case-II transport Zero order release 
> 1 Super case II transport t n -1 
 
4.4. Sterility Test for Niosomes 
After sterilization of 5-FU and LV loaded niosomes, the formulations were 
subjected to sterility test. The test for sterility is intended for detecting the presence of 
viable forms of bacteria, fungi and yeast in preparations. The tests were carried out 
under aseptic conditions designed to avoid accidental contamination of the product 
during the test.  
Culture Media  
A. For aerobic Bacteria and Fungi: Fluid thioglycollate medium: 
This medium can be used for the detection of aerobic bacteria and fungi. 
Preparation of fluid thioglycollate medium Trypticase 15g, L-cystine 0.5 g, Dextrose 
5g, Yeast extract 5g, Sodium chloride 2.5 g Sodium Thioglycollate 0.5 g, Reazurin 
0.001 g, Agar 0.75 g .The above ingredients were dissolved completely in 1000ml of 
distilled water and the medium was boiled for 10 minutes. The pH was adjusted to 7.2 
± 0.2. Media was distributed into 4 ½ size test tubes and sterilized by autoclaving at a 
pressure of 15 lbs/in 2 and at a temperature of 121°C for 15 minutes. Autoclaved 
medium was kept in room temperature.  
For Anaerobic Bacteria Chopped meat (CM) medium: This medium can be 
used for the detection of anaerobic bacteria.  
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Preparation of chopped meat medium  
Lean ground beef 500 g, Distilled water 1000 ml, Sodium hydroxide (In 
Solution) 25 ml b. Trypticase 30 g, Yeast extract 5 g, Dipotassim hydrogen phosphate 
5 g L-cystine 0.5 g, Hemin (1% solution) 0.5 g, Vitamin K (1% alcoholic solution) 0.1 
ml Procedure 1. 500g meat was mixed with 1000ml distilled water and 25ml sodium 
hydroxide.It was heated to boiling while stirring. After mixture has cooled,it was 
refrigerated overnight at 4°C. Mixture was filtered through two layers of gauze. Meat 
particles were retained and liquid was filtered. Enough distilled water was added to 
filtrate to give final volume of 1000ml. All ingredients were added into above two 
liquids except L-cystine. It was heated until ingredients dissolved completely, cooled 
to less than 50°C and L-cystine was added and mixed to dissolve it completely.The 
pH of broth was adjusted to 7.4. Meat particles were washed several times with 
distilled water to remove excess sodium hydroxide and spreaded thinly on clean towel 
to partially dry. About 0.5g meat particles was dispensed with small scoop into 
15X90mm screw cap tubes. 7ml enriched broth filtrate was added to each tube. The 
tubes were autoclaved at 1210°C for 15 minutes. Tubes were cooled and with caps 
loosened, they were passed into anaerobic glove box to cover the surface of the media 
with white petroleum jelly, so that atmosphere of approximately 85% nitrogen (N2), 
10% hydrogen (H2) 5%carbon dioxide (CO2) replaces air in tubes. After caps are 
tightened securely, tubes were removed from glove box. Chopped meat (CM) medium 
tubes were stored in refrigerator at 4°C at ambient temperature. 
 
Procedure 
The niosomal formulation (F4) was added to the fluid thioglycollate medium 
and incubated at 20-25°C for not less than seven days. Chopped meat medium is 
incubated for not less than fifteen days. At intervals during the incubation period, the 
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media were examined visually for microbial growth. In order to support the above 
performed test, a positive control and negative control tests were also carried out. 
Positive control test was carried out in order to confirm that the media and the 
environment provided for incubation were suitable for the growth of micro organisms. 
α - haemolytic Streptococci were inoculated into the fluid thioglycollate medium and 
Clostridium tetani was inoculated into the chopped meat medium and the growth 
promotion was observed.  
 
4.5. Stability Study of Niosomes  
 
Stability studies for the optimized niosomes (F4) were carried out at 
refrigeration temperature, room temperature and elevated temperature (4 ± 2°C, 25 ± 
2°C/ 60 % RH ± 5 % RH and 37 ± 2°C/ 65 % RH ± 5 % RH) for a period of three 
months. Samples from each batch were withdrawn at definite time intervals and 
evaluated using following parameters like appearance, size, assay, and dissolution.  
 
4.6. Preclinical Anti Colon Cancer Evaluation of Niosomes 
4.6.1. Chemicals: 
 The 1, 2-dimethyl hydrazine (DMH) was obtained from Sigma Chemical Company, 
Mumbai, India and all other chemicals and reagents used were of analytical grade. 
 
4.6.2. Animals 
Male Sprague-Dawley rats (300-400gm body weight) were procured from 
KMCH college of Pharmacy, Coimbatore, Tamilnadu, India.  All the animals were 
kept at room temperature of 22°C under 12 hr light/12 hr dark cycle in the animal 
house. Animals were fed with commercial pellet diet and water ad libitum freely 
throughout the study. All animal procedures were performed in accordance with the 
recommendation of CPCSEA the proper care and use of laboratory animals the 
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proposal of the present study was approved by IAEC of KMCH college of Pharmacy, 
Coimbatore, Tamilnadu, India 
 
4.6.3. Preparation of DMH solution 
DMH was dissolved in 1 mm EDTA just prior to use and the pH was adjusted 
to 6.5 with 1 mm sodium bicarbonate to ensure the stability of the chemical. 
 
4.6.4. Induction of Colon Cancer 
Animals were given a weekly subcutaneous (s.c.) injection of DMH in the 
groin area at a dose of 20 mg/kg body weight for 15 weeks. 
 
4.6.5. Study design 
The animals were divided into five groups of six animals each as follows, 
 
Group I: Control, received 1 ml of Normal saline. p.o everyday for 15weeks 
Group II: Received DMH (20mg/kg body weight once in a week for 15 weeks, s.c)  
Group III: Received DMH (20mg/kg body weight once in a week for 15 weeks,  
  s.c) + 5 fluorouracil (20mg/kg) i.p 
Group IV: Received DMH (20mg/kg body weight once in a week for 15 weeks,  
  s.c) + 5-FU and Leucovorin market formulation.  
Group V: Received DMH (20mg/kg body weight once in a week for 15 weeks,  
  s.c) + 5-FU and Leucovorin Niosomes formulation. 
4.6.6. Blood Collection 
After end of treatment period, the animals were anaesthetized with ketamine 
2mg/kg (i.p route), blood was collected by Retro orbital puncture , with EDTA and 7 
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without EDTA for the enumeration of blood cell (i.e. RBC, WBC,),estimation of 
Hemoglobin and for estimation of various biochemical parameters respectively. 
Separation of Serum 
For estimating the biochemical parameters such as SGOT, SGPT, ALP and 
total protein the serum was separated from blood by centrifuging at 10,000 rpm for 10 
minutes. The separated serum were collected and used for the parameter estimation.  
Separation of Plasma 
For the estimation of tumour markers such as Alpha-feto-protein (AFP), 
Carcinoembroyonic antigen (CEA), the blood was collected with EDTA, and 
centrifuged at 10,000 rpm for 5 min and the separated plasma was used for the 
parameter estimation. 
4.6.7. Estimation of Haematological Parameters123 
 
4.6.7.1. Estimation of RBC 
 
Procedure 
 
The RBC pipette was filled with blood up to the mark 0.5, immediately RBC 
diluting fluid (Hayem’s fluid) was filled up to the mark 101. Pipette was rolled 
between the palms to ensure thorough mixing of blood with diluting fluid and kept 
aside for a while. The counting chamber was placed and the RBC squares were 
focused under low power first, when markings were identified then turn to high 
power. The first 3-4 drops of blood mixture was discarded and it was mixed once 
again, the counting chamber was charged with the mixed blood. After charging mount 
the slide, allow the fluid to settle then using a 45X lens the RBC 
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4.6.7.2. Estimation of WBC 
Procedure 
The WBC pipette was filled with blood up to the mark 0.5, immediately RBC 
diluting fluid (Hayem’s fluid) was filled up to the mark 11.Pipette was rolled between 
the palms to ensure thorough mixing of blood with diluting fluid and kept aside for a 
while. The counting chamber was placed and the WBC squares were focused under 
low power first, when markings were identified then turn to high power .The first 3-4 
drops of blood mixture was discarded and it was mixed once again, the counting 
chamber was charged with the mixed blood. After charging mount the slide, allow the 
fluid to settle then using a 10X lens the WBC were counted uniformly in corner 
squares. The number of cells was expressed as 10[9] Cmm. 
4.6.7.3. Estimation of Haemoglobin 
Procedure 
The heamoglobinometer tube was filled with N/ 10 HCl up to the marking 10, 
to this 20μl of blood was added with the help of pipette. The superficial ac1d was 
sucked and it rinsed repeatedly till all the blood in the pipette washed out in mud. The 
contents in the tube were mixed by stirring, and allowed to stand for 10 minutes. A 
clear brown colour solution was formed due to the formation of acid hematin. Then 
distilled water was added drop by drop to dilute. The colour of diluted fluid was 
compared with the standard; dilution was continued until the colour of the flu1d 
exactly matches the standard. The lower meniscus of the fluid was noted and reading 
was noted directly 31 ~ from the graduated tube g/ percentage of haemoglobin. 
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4.6.7.4. Estimation of Serum glutamate oxalo acetate transaminase (SGOT) 
The enzyme catalyzes the reaction, 
 
 
The enzyme activity was assayed by the method of Reitman and Frankel 124 
Reagents: 
 Substrate:1.33 g of L-aspartic acid and 15 mg of 2-oxo glutaric acid were 
dissolved in 20.5 ml of buffer and 1 N sodium hydroxide to adjust the pH to 
7.4 and made up to 100 ml with the phosphate buffer. 
 0.1N Sodium hydroxide 
 2, 4-dinitro phenyl hydrazine (DNPH) (0.2% in 1 N HCl). 
 Standard pyruvate solution: 11 mg of sodium pyruvate was dissolved in 100 
ml of phosphate buffer. This contains 1 μmole of pyruvate/ml 
Procedure: 
            1 ml of buffered substrate was incubated at 37°C for 10 minutes. Then 0.2 ml 
of serum /tissue homogenate was added in the test tubes and incubated at 37°C for 30 
minutes. The reaction was arrested by adding 1 ml of DNPH reagent and tubes were 
kept at room temperature for 20 minutes. Then 10 ml of 0.4N sodium hydroxide 
solution was added. A set of pyruvic acid was also treated in a similar manner for the 
standard. The colour developed was read at 520 nm against the reagent blank. The 
activity of the enzyme was expressed as IU/L / μmoles of pyruvate liberated/min/mg 
protein. 
  
      L-aspartate + 2-oxoglutarate → oxaloacetate + L-gluatamate 
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4.6.7.5. Estimation of Serum glutamate pyruvate transaminase (SGPT) 
This enzyme catalyzes the reaction, 
 
 
The enzyme activity was assayed by the method of Reitman and Frankel 124 
Reagents: 
 Phosphate buffer: 0.1 M; pH 7.4. 
 Substrate: 1.78 g of DL-alanine and 30 mg of 2-oxo glutaric acid 
weredissolved in 20 ml of buffer. About 0.5 ml of 1 N sodium hydroxide was 
added and made up to 100 ml with buffer. 
 0.1N Sodium hydroxide. 
 2, 4-dinitro phenyl hydrazine (DNPH): 0.2% in 1 N HCl. 
 Standard pyruvate solution: 11 mg of sodium pyruvate was dissolved in 100 
ml of phosphate buffer. This contained 1 μmole of pyruvate/ml. 
Procedure: 
            1 ml of buffered substrate was incubated at 37°C for 10 minutes. Then 0.2ml 
of serum/tissue homogenate was added in the test tubes and incubated at37°C for 30 
minutes. The reaction was arrested by adding 1 ml of DNPH reagent and tubes were 
kept at room temperature for 20 minutes. Then 10 ml of0.4N sodium hydroxide 
solution was added. A set of pyruvic acid was also treated in a similar manner for the 
standard. The colour developed was read at 520 nm against the reagent blank. The 
activity of the enzyme was expressed as IU/L / μmoles of pyruvate liberated/min/mg 
protein. 
  
      L-alanine + 2-oxoglutarate → oxaloacetate + L-gluatamate 
90 
 
4.6.7.6. Estimation of Lipid parameters  
Extraction of serum lipids 
           Serum lipids were extracted according to the method of Folch et al125. 
Reagents 
 Alcohol  and ether  as a mixture (3: 1, v/v) 
 Chloroform-methanol mixture (1 : I , v/v) 
Procedure 
            1ml of serum sample was extracted with 3: l v/v alcohol ether mixture into 
15ml test tubes and kept at 65°C in a water bath for 2 hours. Cooled and centrifuged 
for 30 mins. Then another 6 ml of 3: l alcohol-ether mixture was added to the residue 
and heated for 2hrs at 65°C.Centrifuged and decanted the supernatant to the same tube 
containing previously decanted filtrate. Then 6 ml of 1: 1 chloroform methanol 
rnixture was added to the residue and heated at- 65°C for 1 hr. Centrifuged and 
decanted the supernatant to the same tube containing the filtrate previously decanted. 
The total volume was made to 25ml with chloroform methanol mixture. This was 
used for the estimation of total cholesterol, phospholipids (PL) and triglycerides (TG). 
4.6.7.6.1. Estimation of Cholesterol 
 
            Total cholesterol was estimated by the method of Zlatkis et al126. 
 
Reagents 
 Ferric chloride (0.05 per cent solution of FeC13.6H2O in acetic acid). 
 H2S04 
 Stock cholesterol standard, 100 mg in 100 ml acetic acid. 
 Working standard. The stock standard was diluted 1 to 25 with ferric chloride-
acetic acid reagent. 
 Acetone-ethanol reagent (1 : 1) 
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Procedure 
          0.l ml of serum was added to 10 ml of the ferric chloride acetic-acid reagent in 
a stoppered centrifuge tube. Mixed and allowed to stand for 10- 15 min for the 
proteins to flocculate. Then 5 ml of the clear supernatant fluid was transferred to a 
stoppered centrifuge tube after centrifugation. For standard, 0.1 ml of physiological 
saline was mixed with 10 ml of the cholesterol standard and 5 ml was transferred to a 
second stoppered centrifuge tube. As blank 5 ml. of the ferric chloride -acetic acid 
reagent was taken. 3 ml. of H2S04 was added to all three tubes stoppered and mixed. 
Allowed to stand for 20 to 30 min. The unknown and standard were read against the 
blank at 560 nm in a spectrophotometer. The values were expressed as mg/dl. 
 
4. 6.7.6.2. Estimation of Triglycerides 
Triglycerides were measured by the method of Foster and Dunn 127.  
Reagents 
 Alumina (neutral-chromatography  grade) -Wash  the  alumina  with  water  
until  all  the  fine  particles  are  removed.  Dry it in  an  oven at  100 – 110 ºC  
overnight,  cool  and  store  in  a  desicator.  Stable for six months. 
 Saponification reagent – 5 g of KOH was dissolved in 60 ml distilled water 
and to this 40 ml Isopropanol was added. 
 Sodium metaperiodate reagent - 77 g of anhydrous ammonium acetate was 
dissolved in 700 ml distilled water and to this 60 ml glacial acetic acid and 
650 mg of sodium metaperiodate were added. The contents were mixed and 
made up to 1000ml distilled water.  
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 Acetyl acetone reagent – To the 0.75 ml of acetyl acetone 20 ml of 
isopropanol was added and the contents were mixed and to this Add 80 ml of 
distilled was added. 
 Stock standard solution -4 mg/ml of triolein.  
 
Procedure: 
0.1ml of serum was taken and to this     0.6 ml    of saponification reagent was 
added and incubated at 60 - 70º C for 15 minutes.  The mixture was allowed to cool 
and to this 1 ml    of    sodium    metaperiodate    solution    was added and mixed well 
followed by 0.5 ml acetyl acetone reagent and mixed. The final contents were   
incubated at 50 º C for 30 minutes.  After cooling the color was read at 405 nm in a 
spectrophotometer.   The estimated triglyceride was expressed as mg/dl.     
4.6.7.7. Analysis of Tumor Markers 
4.6.7.7.1. Estimation of Carcinoembryonic antigen (CEA) 
CEA is a cell-surface 200-kd glycoprotein.  Elevated plasma  levels  are  
related  to  the  stage  and  extent  of  the  disease,   extent  of  the differentiation  in  
the  tumour,  area  of  metastasis.  CEA is also found in normal tissue. 
The  microtiter  plate  provided  in  this  kit  has  been  pre-coated  with  a 
monoclonal  antibody  specific  to  CEAThen the samples  were added  to the  suitable   
microtiter  plate  wells  with  a  biotin-conjugated  polyclonal antibody preparation 
specific for CEA. Next, Avidin conjugated to Horseradish Peroxidase was placed to 
all the microplate wells and incubated. After that a TMB substrate solution was placed 
to all wells.  Only those wells that contain CEA, biotin-conjugated   antibody   and   
enzyme-conjugated   Avidin may show a change in colour. The reaction between 
substrate and enzyme was terminated by the addition of a sulphuric   acid   solution       
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and     the     color change is measured spectrophotometrically at a wavelength of 
450nm.  Then  the amount of  CEA  in  the  samples  was  assessed  by  comparing  
the  O.D.  of the samples to the standard curve. 
Assay procedure 
 Wells for diluted standard, blank and sample were determined.  Seven wells 
for standard and 1 well for blank were prepared. 100 μl each of dilutions of  
standard,  blank  and  samples  was  added  into  the  appropriate  wells.  
Covered with the plate sealer and incubate for 2 hours at 37 °C. 
 The liquid was removed from each well. 
 100 μl of detection reagent A working solution was added to each well and 
incubated for 1 hour at 37 °C after covering it with the Plate sealer. 
 The  solution  was  aspirated    and  washed  with  400  μl  of  1x  wash  
solution  to  each well  using a squirt bottle,  multichannel pipette,  manifold 
dispenser or   auto washer,  and  let  it  sit  for  1~2  minutes.  The  remaining  
liquid  was removed  from  all  wells  completely  by  snapping  the  plate  
onto  absorbent paper.  Repeated for three times.  After the last wash, 
remaining wash buffer was removed by aspirating or decanting. Plate was 
inverted and bloted with absorbent paper. 
 100  μl  of  detection  reagent  B working  solution  was  added  to  each  well.  
Incubated for 30 minutes at 37 °C after covering it with the plate sealer. 
 The aspiration/wash process was repeated for five times as in step 4. 
 90 μl of substrate solution was added to each well. Covered with a new plate 
sealer and incubated for 15 -25 minutes at 37 °C. It was protected from light. 
The liquid turned blue by the ad dition of substrate solution. 
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 50 μl of stock solution was added to each well. The liquid turned yellow by 
the addition of stock solution.  The liquid was mixed by tapping the side of the 
plate.  If  color  change  does  not  appeared  uniform,  the  plate  was  gently  
taped to ensure thorough mixing. 
 The drop of water was removed and fingerprinted on the bottom of the plate 
and it was confirmed there was no bubble on the surface of the liquid. 
Then,the  microplate  reader  was  run  and  measurement  was  conducted  at 
450  nm immediately. 
Calculation  
 
 The standard curve was plotted by using the average absorbance for all 
standards on the x axis against the concentration on the y-axis and the best fit 
curve was drawn through the points on the graph. The data was linearized by 
plotting the log of the CEA concentrations versus the log of the O.D. and the 
best fit line was determined by regression analysis. 
 
Detection range 
 0.156-10 ng/ml. The standard curve concentrations used for the ELISA’s were 
10 ng/ml, 5 ng/ml, 2.5ng/ml, 1.25ng/ml, 0.625ng/ml, 0.312ng/ml, 0.156 ng/ml 
 
4.6.7.7.2. Estimation of Alfa- Fetoprotein (AFP) 
 
AFP is a glycoprotein with a molecular weight of between 65,000 and 70,000 
daltons including 4% of carbohydrate. During fetal development, AFP maintains high 
levels in the serum and drops to lesser levels throughout the rest of life. AFP values 
are higher in the malignant diseases of colon, hepatocellular, testicular 
nonseminomatous origin, and occasionally of other entodermal origin. AFP 
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measurement is widely accepted as tumor marker and for monitoring the therapeutic 
effectiveness of colon cancer and nonseminomatous testicular cancer. 
Principle 
The  microtiter  plate  present along with   this  kit  was already  coated  with  
an  antibody which is  specific   to   AFP.   Standards   or   samples   are   then   added   
to   the appropriate microtiter plate wells with a biotin-conjugated preparation which 
is specific   for   AFP.   Then, Avidin   conjugated   to   Horseradish Peroxidase (HRP) 
is added to each microplate well and incubated. Then a TMB substrate solution is 
added to each well.  Specific wells that contain AFP, biotin-conjugated   antibody, 
conjugated enzyme Avidin   will   exhibit   a change in color. The enzyme-substrate 
reaction is terminated by the addition of a solution of sulphuric acid and   the change 
in colour was determined spectrophotometrically at a wavelength of 450 nm±2 nm. 
Then the amount of AFP in the samples was assessed by comparing the O.D. of the 
samples to the standard curve. 
 
Sample collection and storage 
 Serum–  A serum separator tube was used  and samples  were allowed  to clot  
for  two  hours  at  room  temperature  or  overnight  at  4°C before  
centrifugation   for   20   minutes   at   approximately   1000x g. Freshly 
prepared serum was assayed immediately  or store samples in aliquot at -20 or 
-80°Cfor later use.  
 Plasma –Plasma was collected using   EDTA   or   heparin   as   an 
anticoagulant. Samples were centrifuge for 15 minutes at 1000x g at 2 –8 °C 
within 30 minutes of collection. Serum was removed and assayed immediately 
or store samples in aliquot at -20 or -80°C for later use. 
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Reagent preparation 
 All kit components and samples were kept atroom temperature (18-25 °C) 
before use. 
 Standard : Standard was reconstituted with 1  ml of standard diluent, kept for 
10   minutes   at   room   temperature,   shaked gently   (not   to   foam).   The  
concentration  of  the  standard  in  the  stock  solution  is  80  ng/ml.  stock  
solutiondiluted to  20  ng/ml and  the  diluted  standard  serves  as the  high  
standard  (20 ng/ml). Diluted standard was used to produce a dilution series. 
Each tube was thoroughly mixed before the next transfer. Seven points  of  
diluted  standard such as 20 ng/ml, 10 ng/ml, 5 ng/ml, 2.5 ng/ml, 1.25 ng/ml, 
0.625 ng/ml, 0.312 ng/ml were  setup,  and  the  last EP  tubes  with standard 
diluent  is  the  blank  as  0 ng/ml 
 Assay Diluent A and Assay Diluent B: 6mlof assay diluent A or  B were 
diluted,  concentrated with  6ml  of  deionized  or  distilled  water  to  prepared  
12 ml of assay diluents A or B.  
 Detection Reagent A and Detection Reagent B: The stock detection A and B 
were centrifuged before use. The  working  concentration  with  working  
assay diluent A or B were diluted, respectively (1:100) 
 Wash Solution:600 ml of wash solution was prepared as per instruction in the 
protocol 
 TMB  substrate: The  needed  dose  of  the  solution  was  aspirated  with  
sterilized tips and the residual solution  was not dumped  into the vial again. 
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Assay procedure 
 
 W ells for diluted standard, blank and sample were determined. Seven wells 
for standard and 1 well for blank were prepared. 100 μl each of dilutions of 
standard, blank and samples was added into the appropriate wells. Covered 
with the plate sealer and incubate for 2 hours at 37 °C. 
 The liquid was removed from each well. 
 100 μl of detection reagent A working solution was added to each well and 
incubatedfor 1 hour at 37 °C after covering it with the Plate sealer. 
 The  solution was  aspirated    and  washed  with  400  μl  of  1xwash  solution  
to  each well  using a squirt bottle,  multi-channel pipette,  manifold dispenser 
or auto washer,  and  let  it  sit  for  1~2  minutes.  The  remaining  liquid was 
removed from  all  wells  completely  by  snapping  the  plate  onto  absorbent 
paper. Repeated for3 times. After the last wash, remaining wash buffer was 
removed by aspirating or decanting.  Plate was inverted and bloted with 
absorbent paper. 
 100 μl of detection reagent B working solution was added to each well. 
Incubatedfor 30 minutes at 37°C after covering it with the plate sealer. 
 The aspiration/wash process was repeated for five times as in step 4. 
 90 μl of substrate solution was added to each well. Covered with a new plate 
sealer and incubated for 15 -25 minutes at 37°C. It was protected from light. 
The liquid turned blue by the addition of substrate solution. 
 50 μl of stock solution was added to each well. The liquid turned yellow by 
the addition of stock solution.  The liquid was mixed by tapping the side of the 
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plate.  If color change does not appeared uniform, the plate was gently taped to 
ensure thorough mixing. 
 The drop of water was removed and fingerprinted on the bottom of the plate 
and it was confirmed there was no bubble on the surface of the liquid. Then, 
the microplate reader was run and measurement was conducted at 450nm 
immediately. 
 
Calculation  
 The standard curve was constructed by plotting the mean absorbance for each 
standard on the x-axis against the concentration on the y-axis and the best fit 
curve was drawn through the points on the graph. The data was linearized by 
plotting  the  log  of  the  AFP  concentrations  versus  the  log  of  the  O.D.  
and  the best fit line  was determined by regression analysis 
 
Detection range 
 0.312-20 ng/ml. The standard curve concentrations used for the ELISA’s 
were20 ng/ml, 10 ng/ml, 5 ng/ml, 2.5 ng/ml, 1.25 ng/ml, 0.625 ng/ml, 0.312 
ng/ml. 
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4.6.7.8. Evaluation of Enzymic Hepatic Antioxidants 
4.6.7.8. 1.Estimation Superoxide dismutase (SOD) 
         This enzyme catalyzes the dismutation of superoxide anion (O2-.) to hydrogen 
peroxide and molecular oxygen in the following manner 
 
 
The enzyme activity was assayed by the method of Misra and Fridovich, 128. 
Reagents 
  0.1 M Carbonate-bicarbonate buffer; pH 10.2. 
 0.6 mM EDTA solution 
 1.8 mM Epinephrine (prepared in situ) 
  Absolute ethanol. 
  Chloroform 
Procedure 
        0.1 ml of tissue homogenate was added to the tubes containing 0.75 ml ethanol 
and 0.15 ml chloroform (cooled with ice) and then it was centrifuged. To the 0.5 ml of 
supernatant liquid, added 0.5 ml of 0.6 mM EDTA solution and 1 ml of 0.1 M 
carbonate-bicarbonate (pH 10.2) buffer. Then the reaction was proceeded by adding 
of 0.5 ml of 1.8 mM epinephrine (freshly prepared) and the increase in absorbance at 
480 nm was measured.One unit of the SOD activity was the amount of protein 
required to give 50% inhibition of epinephrine autoxidation. 
  
H2O + 2O2-. + 2H+ → 2H2O2 + O2 
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4.6.7.8. 2.Estimation of Catalase (CAT, E.C. 1.11.1.6) 
                This enzyme catalyzes conversion of hydrogen peroxide into water and 
molecular oxygen. 
 
  
The enzyme activity was assayed by the method of Sinha,129. 
 
Reagents 
 Dichromate-acetic acid reagent: 5% potassium dichromate in water was mixed 
with glacial acetic acid in the ratio of 1:3 (v/v). 
 0.01 M Phosphate buffer; pH 7.0. 
 0.2M Hydrogen peroxide 
Procedure 
             0.1 ml of the tissue homogenate was added to the reaction mixture containing 
1ml of 0.01 M phosphate buffer (pH 7.0) pre-warmed to 37°C, 0.4 ml of distilled 
water and the mixture was incubated at 37°C. The reaction was initiated by the 
addition of 0.5 ml of 0.2 M hydrogen peroxide and the reaction mixture was incubated 
at 37°C for one minute. The reaction was terminated by the addition of 2 ml of 
dichromate-acetic acid reagent after 15, 30, 45, and 60 seconds. Standard hydrogen 
peroxide in the range of 4-20 μmoles were taken and treated in the same manner. All 
the tubes were heated in a boiling water bath for 10 minutes, cooled and the green 
colour that developed was read at 590 nm against blank containing all components 
except the enzyme. Catalase activity was expressed in terms of μmoles of H2O2 
consumed/min/mg protein. 
  
2H2O2 → 2H2O + O2 
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4.6.7.8. 3.Estimation of Glutathione peroxidase (GPx) 
This enzyme catalyzes the reduction of H2O2 using glutathione as substrate. 
 
  
The enzyme activity was assayed by the method of Rotruck et al.130. 
Reagents 
 0.32 M Sodium phosphate buffer; pH 7.0. 
 0.8 mM EDTA 
 10 mM Sodium azide. 
 4mM reduced glutathione. 
 2.5 mM Hydrogen peroxide. 
 10%Trichloro acetic acid (TCA). 
 0.3M Disodium hydrogen phosphate. 
 0.04% 5,5' - dithiobis (2-nitro benzoic acid) (DTNB); 40 mg of DTNB in1% 
sodium citrate. 
 10 mM Standard reduced glutathione. 
Procedure 
             The assay mixture containing 0.5 ml sodium phosphate buffer, 0.1 ml of 
10mM sodium azide, 0.2 ml of 4 mM reduced glutathione, 0.1 ml of 2.5 mM H2O2, 
and 0.5 ml of 1:10 tissue homogenate was taken and the total volume was made up to 
2.0 ml with distilled water. The tubes were incubated at 37 8C for 3 min and the 
reaction was terminated by the addition of 0.5 ml of 10% TCA. To determine the 
residual glutathione content, the supernatant was removed after centrifugation, and to 
this 4.0 ml disodium hydrogen phosphate (0.3 M) solution and 1 ml DTNB reagent 
were added. The colour that developed was read at 412 nm against a reagent blank 
containing containing only phosphate solution and DTNB reagent using a 
spectrophotometer Aliquot portions of the standard were treated similarly. The 
enzyme activity is expressed in terms of μg of GSH utilized/min/mg protein. 
2GSH + H2O2 → GSSG + 2H2O 
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4.6.7.8. 4.Estimation of Glutathione-S-transferase (GST) 
                 This detoxifying enzyme catalyzes the conjugation of xenobiotics/ 
electrophiles (E) with the reduced glutathione (GSH), which acts as an electrophile. 
 
 
The enzyme activity was assayed by the method of Habig et al.131 
Reagents 
 0.3 M Phosphate buffer; pH 6.5. 
 30 mM 1-chloro-2, 4-dinitrobenzene (CDNB) in 95% ethanol. 
 30 mM reduced glutathione. 
 Double distilled water 
Procedure 
             The reaction mixture contained 1.0 ml of 0.3 M phosphate buffer, 0.1 ml of 
30 mM CDNB in 95% ethanol and 1.7 ml of distilled water. After completing the pre-
incubation of the reaction mixture at 37°C for 5 mins, the reaction was started by the 
addition of 0.1 ml of tissue homogenate and 0.1 ml of 30 mM glutathione as substrate. 
Then, the total reaction mixture (3 ml) was mixed well and the absorbance was read at 
340 nm for 3 min at an interval of 30 sec. Reaction mixture without the enzyme was 
used as the blank solution. The activity of GST is expressed as μmoles of GSH-
CDNB conjugate formed/min/mg protein. 
  
E + GSH → EH + GSSG 
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4.6.7.8. 5.Estimation of reduced glutathione (GSH) 
             The total reduced glutathione was determined according to the method of 
Ellman, 132. The assay procedure is based on the oxidation of Ellman´s reagent [5, 5΄- 
dithio bis (2- nitrobenzoic acid)] (DTNB) by SH groups of glutathione to form 2-
nitro-S-mercaptobenzoic acid per mole of glutathione. The product is measured 
spectrophotometically at 412 nm. 
 
Reagents 
 0.2 M Phosphate buffer; pH 8.0. 
 0.6 mM DTNB reagent. 
 5%TCA  
Procedure 
0.1 ml of tissue homogenate was made to precipitate using 5% TCA. Then the 
contents were mixed well for complete precipitation of proteins and centrifuged. To 
0.1 ml of supernatant, 2 ml of 0.6 mM DTNB reagent and 0.2 M phosphate buffer (pH 
8.0) were added to make up to a final volume of 4 ml. The absorbance was read at 412 
nm against a blank containing TCA instead of sample. A series of standards were also 
treated in the same manner to determine the amount of glutathione. The amount of 
glutathione was expressed as nmoles/g tissue. 
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4.6.7.9. Measurement of Lipid peroxidation  
Estimation of Lipid Peroxidation (LPO) 
            Lipid peroxidation (LPO) was assayed by the method of Ohkawa et al.133 in 
which the malondialdehyde (MDA) released served as the index of LPO. The extent 
of LPO in the hepatic tissue was assayed by measuring one of the end products of this 
process, the thiobarbituric acid-reactive substances (TBARS). As 99% TBARS is 
malondialdehyde (MDA), thus this assay is based on the reaction of 1 molecule of 
MDA with 2 molecules of TBARS at low pH (2- 3) and at a temperature of 95°C for 
60 min. The resultant pink chromogen can be detected spectrophotometrically at 532 
nm. 
Reagents 
 Standard: 1, 1, 3, 3-tetra ethoxypropane (TEP). 
 8.1% Sodium dodecyl sulphate (SDS) 
 20%Acetic acid 
 0.8%Thiobarbituric acid (TBA)  
 15:1 v/v n-butanol: pyridine mixture 
Procedure 
To 0.2 ml of tissue homogenate, following were added - 0.2 ml of 8.1% SDS, 1.5 ml 
of 20% acetic acid (pH 3.5) and 1.5 ml of 0.8% TBA. Then the mixture was made up 
to 4 ml with water and heated in a water bath at 95.8ºC for 60 min using glass ball as 
a condenser. After cooling, 1 ml of water and 5 ml of n-butanol: pyridine (15:1 v/v) 
mixture were added and shaken vigorously. After centrifugation at 4000 rpm for 10 
min, the organic layer was taken and its absorbance was observed at 532 nm. The 
concentration of lipid peroxides was denoted as nmoles of MDA formed per mg of 
protein. 
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4.6.7.10. Histopathological Studies  
           Hematoxylin, a basic bye is oxidized to hematein with a mordant, a metallic 
ion such as the salts of aluminium. The positively charged aluminium-hematein 
complex combines with the negatively charged phosphate groups of the nucleic acids 
(DNA and RNA) forming blue/purple colour, which is characteristic of hematoxylin 
stains. Eosin is an acidic dye, which is consideredto have a selective affinity for the 
basic parts of the cell, i.e., the cytoplasm. Thus, the hematoxylin and eosin (H & E) 
stain is used to demonstrate different structures of the tissue. 
             The various steps involved in the preparation of tissues for histological 
studies are as follows: 
 Fixation 
 In order to avoid tissue by the lysosomal enzymes and to preserve its 
physicaland chemical structure, a bit of tissue from all the organs was cut and placed 
in bouin’s fluid immediately once it is  removed from the animal body. The tissues 
were fixed in bouin’s fluid for about 24 hours. The tissues were then taken and 
washed in glass distilled water for a day to remove excess of picric acid. 
 Dehydration 
 The tissues were kept in the following solutions for an hour each; 30%, 50%, 
70% and 100% alcohol. Inadequately dehydrated tissues cannot be successfully 
infiltered using paraffin. Also too much of dehydration resultswhich would be 
difficult for sectioning. So, careful precautions shoule be followed whilw performing 
the dehydration process. 
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 Clearing 
            Dealcoholization or replacement of alcohol from the tissues with a clearing 
agent is called as clearing. Xylene was used as the clearing agent for a period of one 
to two hours and two or three times. Because the clearing agent is miscible with both 
dehydration and embedding agents, it permits paraffin to infilterate the tissues. So, the 
clearing was performed next after dehydration to allow tissue spaces to be filled with 
paraffin. The tissues were kept in the clearing agent till they become transparent and 
impregnated with xylene. 
 Impregnation 
 In this process the clearing agent xylene was placed by paraffin wax. The 
tissues were taken out of xylene and were kept in paraffin embedding bath which was 
molten. It comprises of of metal pots which is filled with molten wax maintained. The 
tissues were given three changes in the molten wax at half an hour intervals. 
 
 Embedding 
 The paraffin wax which is used for embedding shall be fresh and heated to the 
optimum melting point at about 56–58oC. A clear glass plate was smeared with 
glycerine. L-shaped mould was placed on it to from a rectangular cavity. The molten 
paraffin wax was discarded and the entrapped air bubbles were withdrawn by using a 
hot needle. Then the tissue was placed in the paraffin and oriented with the surface to 
be sectioned. Then the tissue was pressed slowly on the glass plate so that it settles 
uniformly with a metal pressing rod and allowed the wax to settle and solidity room 
temperature. The paraffin was kept in cold water for cooling 
 Section Cutting 
 Section cutting was done using a rotating microtome. The excess of paraffin 
around the tissue was removed by trimming, leaving ½ cm around the tissue.  The 
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block was then fixed to the warm holder. Extra support was given by some additional 
wax, which was applied on the sides of the block. Before sectioning, all set screws 
used for holding the object holder and knife were carefully tightened by using hands 
to avoid vibration. To make uniform sections, the microtome knife was placed to the 
appropriate angle in the knife holder so that the cutting edge alone is coming in 
contact with the paraffin block. The tissue was cut in the thickness range of about 
7µm. 
 Flattening and Mounting of Sections 
 The procedure was carried out using tissue flotation warm water bath. The 
sections were made to fall on a warm water bath after they were detached from the 
knife using a hair brush. Clean slides which are free from dust were coated with egg 
albumin over the whole surface. Required sections were made to spread on clean slide 
and maintained at room temperature. 
Staining of Tissue Sections 
The sections were stained as follows; deparaffinization with xylene two timeseach for 
five minutes 
Dehydration through descending grades of ethyl alcohol 
 100% alcohol  - 2 mins 
 90% alcohol - 1min 
 50% alcohol - 1 min 
Staining with Ehrlich’s Haemaoxylin was done for 15-20 minutes. Then the sectioned 
tissues were thoroughly washed in tap water for 10 minutes. Rinsed with distilled 
water and stained with Eosin. Dehydration again with ascending grades of alcohol. 
 70% alcohol - 2 minute 
 90% alcohol - 2 minute 
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 100%alcohol - 1 minute 
Finally the tissues were cleared with xylene two times, each for about 3 minutes 
interval. 
 
 Mounting 
                        On the stained slide, DPX mountant was applied uniformly and 
microglass cover slides were spread. The slides were observed in Nikon microscope 
and microphotographs were taken. 
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5. RESULTS AND ANALYSIS 
5.1. Preformulation Studies 
5.1.2. Organoleptic Characteristics 
The color, odor, and appearance of the drug were characterized and recorded 
using descriptive terminology; the results were shown in the Table 5.1 
Table 5.1: Organoleptic Charecteristics of 5-Fluorouracil and Leucovorin 
Properties 5-Fluorouracil Leucovorin 
Odour Odourless Odourless 
Colour White to off-white Pale White 
Form Crystalline Crystalline 
 
5.1.3. Melting point 
The melting point of the 5-Fluorouracil and Leucovorin was reported in Table 5. 2. 
Table 5.2: Melting point of 5-Fluorouracil and Leucovorin 
Sample Reported Observed 
5-Fluorouracil 282-2830C 287.150C   
Leucovorin 240-2500C 241.020C 
 
5.1.4. Solubility analysis 
The available literature on solubility profile of 5-Fluorouracil and Leucovorin 
indicated that the drug is soluble in water, alcohol and methanol and insoluble in 
chloroform, ether and benzene. 
 
5-Fluorouracil and Leucovorin was found to be soluble in water, alcohol and 
methanol and insoluble in chloroform, ether and benzene. 
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5.1.5. Calibration curve 
Table 5.3:  Observations for Standard graph of 5-Fluorouracil in pH 7.4 at       
266nm 
Concentration 
(µg/ml) 
Absorbance (266nm) in 
pH 7.4 
10 0.206 
20 0.394 
30 0.586 
40 0.766 
50 0.913 
 
 
Fig 5.1:Calibration curve of 5-Fluorouracil in pH 7.4 at 266nm 
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Table 5.4:  Observations for Standard graph of Leucovorin in pH 7.4 at 288 nm 
Concentration 
(µg/ml) 
Absorbance (288nm) 
in pH 7.4 
10 0.109 
20 0.323 
30 0.475 
40 0.697 
50 0.86 
 
 
 Fig 5.2: Calibration curve of Leucovorin in pH 7.4 at 288nm 
 
The data are plotted and the graph is shown in the Figure 5. 1 &5.2. The r 2 
value was obtained by using the linear curve and it was found to be nearly to 1.The 
slope the curve (5-FU and LV ) was found 0.0184 and 0.0172 respectively. 
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5.1.6. FT-IR Spectral Analysis 
The development of a successful formulation depends only on a suitable 
selection of excipients. Hence the physical state of the drug 5-Fluorouracil and 
leucovorin and the combination of drug and cholesterol and surfactant used for 
niosomes preparation were studied by FTIR (Fourier transform infrared spectroscopy) 
to know the drug – excipients compatibility. The physicochemical compatibility of the 
drugs and the excipients was obtained by FTIR studies with the interpretation values 
of the FTIR were mentioned in Fig No (5.3A, 5.3.B and 5.3.C). 
 
 
Fig 5.3.A: FTIR spectrum of 5-fluorouracil 
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Fig 5.3.B:  FTIR spectrum of Leucovorin 
 
 
Fig 5.3.C: FTIR spectrum of 5-FU + LV Niosomes 
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5.2. Optimization of Niosomes 
The optimization of the niosomes was made by altering the cholesterol ratio 
and evaluating the niosomes by using in vitro drug release (Table 5.5).  
 
Table 5.5: Optimization of niosomal formulation compositions 
Type of 
formulation F1 F2 F3 F4 F5 F6 F7 F8 
Drug  10 10 10 10 10 10 10 10 
Cholesterol 10 20 10 20 10 20 10 20 
Span 40 10 10 - - - - - - 
Span 60 
- - 10 10 - - - - 
Tween 40 
- - - - 10 10 - - 
Tween 60 
- - - - - - 10 10 
Drug 
:Cholesterol:  
SA 
1:1:1 1:2:1 1:1:1 1:2:1 1:1:1 1:2:1 1:1:1 1:2:1 
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5.3. Evaluation of Niosomes 
5.3.1. Particle Size Analysis 
 The particle size of the niosomes was analyzed by using the particle size 
analyzer (Malvern) and it is shown in the Figure 5.4.The particles of the drug loaded 
niosomes are in the size of 0.1 to 1 µ range. More number of the particles is in the 
0.1μ to 0.8 μ approximately and then larger particle size distribution is also seen. 
 
 
 
 
 
 
 
Figure 5.4: Particle size analysis of 5-FU + LV Niosomes 
5.3.2. Optical   Microscopy  
The formulated niosomes were viewed through optical microscope (Fig 5.5) 
Fig 5.5: Optical microscopy images of 5-FU + LV Niosomes 
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5.3.3. Morphological studies: 
High-Resolution Transmission Electron Microscopy helps to find the internal 
morphology of the sample. For this the sample is diluted and it is placed on the TEM 
grid, approximately two or three drops is sufficient. Then it is air dried until the water 
molecule is removed from it. Further it is taken for the analysis. The images of the 5-
FU and LV loaded niosomes are shown in the Figure 5.6.  The TEM image shows the 
discrete formation of the structure and the internal morphology.  
 
Fig 5.6: TEM image of 5-FU + LV Niosomes 
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5.3.4. Scanning Electron Microscopy 
 
Niosomes were characterized by SEM (JEOL). Niosomes containing 5-FU + LV was 
taken in a cover glass and transferred on a specimen stub. Dried samples were coated 
using a platinum alloy upto a thickness of 100 Ǻ by a sputter coater. After coating, 
scanning was done to examine the shape and size (Fig 5.7). 
 
 
Fig5.7: SEM image of 5-FU + LV Niosomes 
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5.3.5.Differential scanning Colorimetry 
 
The drugs 5-Fluorouracil, Leucovorin, cholesterol, span 40, span 60, span 80 
and mixture of drug and excipients were subjected to DSC studies for testing the 
compatibility of the drug with the excipients used in the formulation (Fig 5.8). 
 
 
Fig 5.8: DSC studies of 5-FU + LV niosomes 
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5.3.6. Zeta Potential 
The surface charge of 5-Fluorouracil and leucovorin niosomes was measured 
using Zetapotentiometer. The zeta potential graph was shown in Figure 5.9.  
 
 
 
 
 
Figure 5.9.: Zeta potential of Niosomes 
5.3.7. Drug entrapment efficiency: 
The Entrapment Efficiency of the formulations was calculated and Tabulated 
in the Table 5.6.  The entrapment efficiency of drug containing span 60 was found to 
be 72.21% which showed maximum percent drug entrapment where as those 
containing span 40, span 60, tween 40, tween 60 were found to encapsulate 66.35, 
72.21, 50.44, and 52.24. These results indicates that span 60 is the more suitable 
surfactant along with higher concentration of cholesterol for enhancing maximum 
entrapment for the drugs 5-Fluorouracil and leucovorin. 
Table 5.6: Entrapment Efficiency of the 5-FU + LV niosome formulations 
Formulations Code 5-FU Entrapment (%) LV Entrapment (%) 
F1 62.44 63.28 
F2 66.35 65.02 
F3 68.30 64.86 
F4 72.21 69.45 
F5 47.05 54.76 
F6 50.44 57.92 
F7 50.92 59.55 
F8 52.24 60.27 
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5.3.8. In Vitro Drug Release 
The formulated niosomes were subjected to in vitro drug release. The amount 
of 5-Fluorouracil and leucovorin diffused was estimated spectrophotometrically at 
266 nm and 288 nm respectively and the results were shown in Table 5.7 &5.8.  
Niosomes containing 5-Fluorouracil prepared with span 60 showed 99.65 % of 
drug release upto 12 hours (Figure 5.10). 5-Fluorouracil release from the formulation 
containing span 40, Tween 40 and Tween 60 was observed almost 100% drug release 
within 10 hours. These results showed that niosomal formulation containing 5-
Fluorouracil prepared with span 60 has sustained release upto 12 hours. Leucovorin 
release profile from niosomal formulation was shown in Figure 5.11. Niosomes 
containing leucovorin prepared with span 60 showed 99.91 % of drug release upto 12 
hours. Leucovorin release from the formulation containing span 40, Tween 40 and 
Tween 60 was observed almost 100% drug release within 10 hours. These results 
showed that niosomal formulation containing leucovorin prepared with span 60 has 
sustained release upto 12 hours. 
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Table 5.7: In-vitro release study of the 5-FU niosomes 
 
Table 5.8:In-vitro release study of the 5-FU + LV Niosomes 
 
Time in 
Hours 
% Drug Released 
F1 F2 F3 F4 F5 F6 F7 F8 
1 25.12 20.78 23.43 19.23 28.34 23.02 24.72 21.66 
2 42.04 39.02 40.12 30.22 40.22 33.22 35.15 32.17 
4 51.06 48.9 52.22 46.89 61.27 48.82 49.42 50.92 
6 69.35 70.33 68.79 65.88 72.52 67.94 70.21 66.25 
8 90.23 83.45 88.16 79.43 84.67 82.64 82.56 81.92 
10 99.34 95.74 95.34 89.58 99.96 99.52 98.9 95.99 
12 99.9 99.13 100.02 99.65 100 99.99 100 100 
Time in 
Hours 
% Drug Released 
F1 F2 F3 F4 F5 F6 F7 F8 
1 38.96 36.72 35.07 30.01 40.04 39.02 39.27 38.12 
2 50.22 50.38 48.39 45.22 52.78 51.35 50.55 49.55 
4 65.15 62.12 62.07 59.12 66.9 66.17 65.22 62.49 
6 79.6 76.2 72.98 70.36 84.56 72.56 79.21 78.01 
8 92.1 90.08 90.14 85.43 95.9 88.54 90.56 88.32 
10 99.34 98.94 99 93.12 99 98.18 99.82 100 
12 99.9 100 100 99.91 99.98 99 100 100 
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Fig5.10: In-vitro release study of the 5 – FU from Niosomes 
 
 
 Fig5.11. In-vitro release study of the 5-FU + LV Niosomes 
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5.3.9. In vitro release kinetics: 
In vitro release kinetics data was sown in Table 5.9. The results shown that 
formulation F4, Span 60 with cholesterol follows zero-order kinetics. Calculation of 
Higuchi’s correlation coefficient confirms that drug release was proportional to the 
square root of time indicating that drug release from niosomes was diffusion 
controlled (Figure 5.12 and 5.12.A). The n value from the Korsmeyer-Peppas model 
for release 5-FU from niosomal formulation was 0.67 which confirms the Non 
Fickian type diffusion, whereas release LV from niosomal formulations follow an 
Fickian diffusion mechanism (n  >  0.47). 
Table 5.9: In vitro release kinetics of 5-FU + LV niosomes 
Formulation 
code 
Higuchi 
R2 
Korsmeyer-
Peppas Zero order First order 
Release 
mechanism 
R2 N R2 K0 (%mg/h) R
2
 
K1  
(h-1) 
F4 (5- FU) 0.996 0.998 0.67 0.969 8.01 0.770 0.161 Non 
Fickian 
F4 (LV) 0.996 0.995 0.47 0.907 7.44 0.745 0.194 Fickian 
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Figure 5.12 In vitro release kinetics of 5-FU + LV niosomes (F4) 
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Figure 5.12 .A: In vitro release kinetics of 5-FU + LV niosomes (F4) 
 
 
 
 
 
y = 28.313x + 3.0212
R² = 0.9955
0
20
40
60
80
100
120
0 1 2 3 4
HIGUCHI KINETICS
Series3
Linear (Series3)
y = 0.4775x + 1.4893
R² = 0.9953
0
0.5
1
1.5
2
2.5
0 0.2 0.4 0.6 0.8 1 1.2
Korsmeyer-Peppas
CP AG1
Linear (CP AG1)
y = 7.4369x + 20.423
R² = 0.9073
0
20
40
60
80
100
120
0 5 10 15
ZERO ORDER
Series1
Linear (Series1)
y = -0.1941x + 2.2461
R² = 0.7456
-1.5
-1
-0.5
0
0.5
1
1.5
2
2.5
0 5 10 15
FIRST ORDER
Series3
Linear (Series3)
126 
 
5.4. Preclinical evaluation of Niosomes 
5.4.1. Effect of 5-FU + LV niosomes (F4) against 1, 2 Dimethyl hydrazine (DMH) 
induced colon cancer 
5.4.1.1. Effect of 5-FU + LV niosomes (F4) on Hematological parameters on 
DMH induced colon cancer 
In this study, haematological parameters were significantly altered in the 
DMH treated as a carcinogenesis and altered immune function. The level of RBC and 
haemoglobin were significantly (p<0.05) reduced in DMH groups, whilst the WBC 
level was significantly (p<0.05) increased as that of the control rats. Meanwhile, 
treatment with 5-FU+ LV niosomes significantly (p<0.05) restored the altered blood 
parameters level to normalcy (Table 5.10 and Fig 5.13).      
Table 5.10: Effect of 5-FU + LV niosomes (F4) onHematological parameters on 
DMH induced colon cancer 
 
Units: RBC: millions/μl of blood; WBC: thousands/μl of blood; Hb: g/dl. The values 
are expressed as mean ±S.E.M, n=6. The statistical analysis was carried out using one 
way ANOVA followed by Dunnet’s multiple comparison test. The comparison were 
made between a- Control vs DMH; b - DMH vs DMH+5-FU; c- DMH vs DMH + (5-
FU +LV) Market formulation; d- DMH vs DMH + (5-FU +LV) Niosomes. * denotes 
statistically significant p< 0.05. 
 
Groups RBC WBC Hb 
Control 7.53 ± 0.17 
 
2.53±0.11  
 
14.48±0.26  
 
DMH 3.21± 0.14a* 8.42±0.16 a* 
 
8.97±0.16 a* 
DMH+5-FU 4.40±0.13 b* 
 
5.64±0.17 b* 11.23± 0.21 b* 
DMH + (5-FU +LV) 
Market formulation 
5.87±0.16c* 4.32±0.12 c* 12.24±0.23 c* 
DMH + (5-FU +LV) 
Niosomes 
6.40±0.18 d* 3.15±0.09 d* 13.89±0.18 d* 
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Fig 5.13: Effect of 5-FU + LV niosomes (F4) on Hematological parameters on 
DMH induced colon cancer 
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5.4.1.2. Effect of 5-FU + LV niosomes (F4) on antioxidants and MDA level in 
DMH induced colon cancer 
The present result show that, the colonic tissue level of the LPO (Table 5.11& 
Fig 5.13) increased significantly (p<0.05) and GSH (Table 5.11 and Fig 5.14), SOD, 
CAT, GPx and GST level (Table 5.12 and Fig 5.15) were decreased significantly 
(p<0.05) in DMH alone group compared with normal control group. Whilst, treatment 
with 5-FU+ LV niosomes significantly (p<0.05) decreased the level of MDA in 
colonic tissue of DMH treated rats, as well as significantly (p<0.05) increased the 
level of the antioxidants defense enzymatic system of SOD, CAT, GPx and GSH 
level. 
Table 5.11: Effect of 5-FU + LV niosomes on GSH and MDA level in DMH 
induced colon cancer 
 
 
 
 
 
 
 
 
 
GSH: Reduced Glutathione (nmole/mg of tissue) ; MDA: Malondialdehyde 
(nmole/mg of tissue). The values are expressed as mean ±S.E.M, n=6. The statistical 
analysis was performed by one way ANOVA and Dunnet’s multiple comparison test. 
The comparison were made between a- Control vs DMH; b - DMH vs DMH+5-FU; c- 
DMH vs DMH + (5-FU +LV) Market formulation; d- DMH vs DMH + (5-FU +LV) 
Niosomes. * denotes statistically significant p< 0.05. 
Groups GSH  MDA 
Control 4.98±0.54 1.4±0.12 
            DMH 1.52±0.15 a* 4.24±0.35 a* 
DMH+5-FU 2.67±0.21 b* 3.47±0.26 b* 
DMH + (5-FU +LV) 
Market formulation 
3.12±0.29 c* 2.42±0.18 c* 
DMH + (5-FU +LV) 
Niosomes 
3.92±0.42 d* 1.86±0.16 d* 
129 
 
 
 
 
Fig 5.14: Effect of 5-FU + LV niosomes on GSH and MDA level in DMH induced 
colon cancer 
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Table 5.12: Effect of 5-FU + LV niosomes on colon antioxidant enzymes in DMH 
induced colon cancer 
 
SOD: Superoxide dismutase (U/mg protein); CAT: Catalase (nmoles of H2O2 
utilized/min/mg/protein); GPx: Glutathione peroxidase (nmoles of GSH 
utilized/min/mg protein); GST: Glutathione -S- Transferase (nmoles of CDNB 
conjugate formed/min/mg/protein).The values are expressed as mean ±S.E.M, n=6. 
The statistical analysis was performed by one way ANOVA and Dunnet’s multiple 
comparison test. The comparison were made between a- Control vs DMH; b - DMH 
vs DMH+5-FU; c- DMH vs DMH + (5-FU +LV) Market formulation; d- DMH vs 
DMH + (5-FU +LV) Niosomes. * denotes statistically significant p< 0.05. 
 
Fig 5.15: Effect of 5-FU + LV niosomes on colon antioxidant enzymes in DMH 
induced colon cancer 
Groups SOD CAT GPx GST 
Control 7.84±0.75 7.14±0.68 2.34±0.05 0.75±0.006 
            DMH 2.89±0.29 a* 2.63±0.25 a* 0.57±0.01 a* 0.25±0.003 a* 
DMH+5-FU 4.87±0.35 b* 4.32±0.29 b* 1.6±0.03 b* 0.48±0.002 b* 
DMH + (5-FU 
+LV) Market 
formulation 
5.92±0.37 c* 5.75±0.42 c* 1.98±0.03 c* 0.65±0.005 c* 
DMH + (5-FU 
+LV) Niosomes 
7.12±0.67 d* 6.87±0.54 d* 2.12±0.04 d* 0.71±0.006 d* 
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5.4.1.3. Effect of 5-FU + LV niosomes (F4) on serum lipid profiles in DMH 
induced colon cancer 
In this study, serum level of cholesterol and triglycerides were significantly 
(p<0.05) elevated in DMH induced group may be due to higher cholesterogenesis 
induced by DMH. Whilst, treatment with 5-FU+ LV niosomes in DMH induced rats 
significantly (p<0.05) reduced the serum level of total cholesterol and triglycerides 
(Table 5.13 and Fig 5.16).  
Table 5.13: Effect of 5-FU + LV niosomes on serum lipid profiles in DMH 
induced colon cancer 
 
 
 
 
 
 
 
 
 
 
 
The values are expressed as mean ±S.E.M, n=6. The statistical analysis was 
performed by one way ANOVA and Dunnet’s multiple comparison test. The 
comparison were made between a- Control vs DMH; b - DMH vs DMH+5-FU; c- 
DMH vs DMH + (5-FU +LV) Market formulation; d- DMH vs DMH + (5-FU +LV) 
Niosomes. * denotes statistically significant p< 0.05. 
 
 
 
 
Groups Total Cholesterol 
(mg/dl) 
Triglycerides 
(mg/dl)  
 
Control 
 
76.94±2.46 122.6±3.33  
 
DMH 
 
171.4±7.65 a* 
 
 
164.4±2.68 a* 
 
 
DMH+5-FU  110.7±2.05 b* 
147.1±3.7 b* 
 
DMH + (5-FU +LV) 
Market formulation 90.44±2.47 c* 138.28±1.88
 c*
 
DMH + (5-FU +LV) 
Niosomes 
 
81.17±1.08 d* 
 
125.5±5.23 d* 
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Fig 5.16: Effect of 5-FU + LV niosomes on serum lipid profiles in DMH induced 
colon cancer 
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5.4.1.4. Effect of 5-FU + LV niosomes (F4) on serum hepatic markers enzyme in 
DMH induced colon cancer 
In this study, DMH intoxicated rats displayed significantly (p<0.05) elevated 
level of hepatic marker enzymes (SGOT, SGPT and ALP) in serum and treatment 
with 5-FU+ LV niosomes significantly (p<0.05) decreased the hepatic markers 
enzyme level and restores the hepatocellular membrane damage elicited by DMH 
(Table 5.14 and Fig 5.17). 
Table 5.14: Effect of 5-FU + LV niosomes (F4) on serum hepatic markers 
enzyme in DMH induced colon cancer 
 
The values are expressed as mean ±S.E.M, n=6. The statistical analysis was carried 
out using one way ANOVA followed by Dunnet’s multiple comparison test. The 
comparison were made between a- Control vs DMH; b - DMH vs DMH+5-FU; c- 
DMH vs DMH + (5-FU +LV) Market formulation; d- DMH vs DMH + (5-FU +LV) 
Niosomes. * denotes statistically significant p< 0.05. 
 
 
 
 
 
 
Groups SGOT (IU/L) SGPT (IU/L) ALP (IU/L) 
Control 56.87±3.23 66.45±3.76 144.34±7.98 
DMH 132.65±5.76 a* 124.32±6.84 a* 304.65±9.65 a* 
DMH+5-FU 98.76±4.25 b* 92.12±3.25 b* 197.65±6.87 b* 
DMH + (5-FU +LV) 
Market formulation 86.87±5.65
 c*
 79.67±4.82 c* 175.42±4.56 c* 
DMH + (5-FU +LV) 
Niosomes 62.76±3.29
 d*
 64.65±3.98 d* 153.89±5.25 d* 
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Figg 5.17: Effect of 5-FU + LV niosomes (F4) on serum hepatic markers enzyme 
in DMH induced colon cancer 
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5.4.1.5. Effect of 5-FU + LV niosomes (F4) on tumour markers in DMH induced 
colon cancer 
In this study, serum level of CEA and AFP were significantly (p<0.05) 
elevated and 5-FU+ LV niosomes treatment significantly (p<0.05)   reduced the level 
of tumor markers (CEA and AFP) to normalcy (Table 5.15 and Fig 5.18). 
Table 5.15: Effect of 5-FU + LV niosomes (F4) on tumour markers in DMH 
induced colon cancer 
 
 
 
 
 
 
 
CEA: Carcinoembryonic Antigen; AFP-Alpha-Feto-Protein. The values are expressed 
as mean ±S.E.M, n=6. The statistical analysis was carried out using one way ANOVA 
followed by Dunnet’s multiple comparison test. The comparison were made between 
a- Control vs DMH; b - DMH vs DMH+5-FU; c- DMH vs DMH + (5-FU +LV) 
Market formulation; d- DMH vs DMH + (5-FU +LV) Niosomes. * denotes 
statistically significant p< 0.05. 
 
Fig 5.18: Effect of 5-FU + LV niosomes (F4) on tumour markers in DMH 
induced colon cancer 
Groups CEA (ng/dl) AFP (ng/dl) 
Control 0.21±0.02 0.45±0.01 
 
DMH 
1.24±0.07 a* 1.62±0.05 a* 
DMH+5-FU 0.56± 0.06 b* 0.89±0.04 b* 
DMH + (5-FU +LV) 
Market formulation 
0.45±0.03 c* 0.72±0.03 c* 
DMH + (5-FU +LV) 
Niosomes 
0.29±0.05 d* 0.55±0.04 d* 
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5.4.1.6. Effect of 5-FU + LV niosomes on colon histology in DMH induced colon 
cancer 
The histopathological analysis revealed the thickened mucosa with densely 
packed inflammatory cell infiltration and a higher degree of hyperplasia in DMH 
intoxicated rats and treatment with 5-FU+ LV niosomes showed normal appearing 
glands with normal mucosa of colon (Fig5.19). 
Fig 5.19: Effect of 5-FU + LV niosomes on colon histology in DMH induced colon 
cancer 
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6. DISCUSSION 
6.1. Preformulation Studies 
Preformulation study is the primary step in the rational development of dosage 
forms of a new drug entity. It is the investigation of physical and chemical properties 
of a drug substance alone and when combined with excipients. The overall objective 
of preformulation testing is to provide information related to the formulation in 
developing stable and bioavailable dosage forms that can be mass-produced.  The 
type of information needed will depend on the dosage form to be developed. 
The first step in any formulation design activity is careful consideration of the 
Preformulation data. It is important that the formulation have a complete 
physicochemical profile of the active ingredients available prior to initiating 
formulation development activity.  
 
6.1.2. FT-IR Spectral Analysis 
 Based on the results,  intense characteristic peaks at 3160, 1727, 1662, 1426, 
1247, 811.7 and 547cm−1 are detected due to the vibration of imide stretch (amide II 
and amide III) and aromatic ring in the structure of 5-FU . In the case of the FTIR 
spectra of LV, some absorption bands are observed at 1609, 1324, 1190, and 763cm−1 
corresponding to the vibration of NH stretch, aromatic ring, C-O, C–H groups. The 
characteristic peaks of 5-Fluorouracil and leucovorin appeared in spectra without any 
remarkable change position in that of prepared niosomes. The results revealed that no 
chemical interaction between drugs and excipients. 
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6.2. Optimization of Niosomes 
The optimization of the niosomes was made by altering the cholesterol ratio 
and evaluating the niosomes by using in vitro drug release. The uniformity of the 
particle size and the formation of the particles are considerably noted. Following 
which the sonication process was carried out. The larger the cholesterol content the 
formation of the flakes in the solution takes place and the formation of the thin film in 
the round bottom flask is increasing timely. Optimum amount is by taking the equal 
proportion of the cholesterol and the surfactant (Span 40, Span 60, Tween 40 and 
Tween 60) gives a better formulation. 
From composition of all the formulations,  the best formulation is obtained 
from the  as we increase the cholesterol concentration and keeping the surfactant 
concentration constant the formation of the niosomes is uniform and the visibility of 
the cholesterol flakes in the formulation is nil. But the time taken for the organic 
solvents to get evaporated is increasing. The film which is formed on the round 
bottom flask is kept overnight for the complete removal and drying of the organic 
solvents from the film. The best formulation is taken from the further evaluation.  
Large volume of organic solution of lipids is most easily dried in a rotary 
evaporator fitted with a coil which is cool and a thermostatically controlled water 
bath. Rapid evaporation of solvent is carried out by gentle warming (20° - 40°C) 
under reduced pressure (400 - 700 mmHg). Rapid rotation of the solvent containing 
flask increases the surface area for evaporation. In case, where sufficient vacuum is 
not attainable or if the concentration of lipids is particularly high, it may be difficult to 
remove the last traces of chloroform from the lipid. Therefore, it is recommended as a 
matter of routine that after rotary evaporation some further means is provided so that 
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the residue is completely dried. Attachment of the flask to the manifold of lyophilizer 
and overnight exposure to high vacuum is a good method. 
Increasing the sonication time resulted into reduction in percent drug 
entrapment the decrease drug entrapment is due to leakage of the drug during 
sonication. Cholesterol provides endurance against mechanical strain during 
sonication and centrifugation. Sonication brings about size reduction by breaking 
large niosomes to smaller ones and in doing so, leakage of small quantities of drug 
from the niosomes occur. Hence the sonication time was made to optimize for 15 
minutes, and further size reduction by increasing the time of sonication was not 
attempted. 
6.3. Evaluation of Niosomes 
6.3.1. Particle Size Analysis 
The particles of the drug loaded niosomes are in the size of 0.1 to 1 µ range. 
More number of the particles is in the 0.1μ to 0.8 μ approximately and then larger 
particle size distribution is also seen. 
6.3.2. Optical   Microscopy  
The microscopic methods include the use of Bright field, phase contrast 
microscope and fluorescent microscope and are useful in evaluating the vesicle size of 
large vesicles (>1µm) particularly the upper end of the size distribution for 
miltilamellar vesicles. Vesicular dispersion appropriately diluted are wet mounted on 
a haemocytometer and photographed by using phase contrast microscope. Then the 
negatives can be observed  on a piece of calibrated paper using a photographic 
enlarger at X 1250  diameters of approximately 500 vesicles are determined and 
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hence this method is tedious and coupled with the limitation of resolution, hence 
electron microscopic methods with greater resolutions are  preferred. 
6.3.3. Morphological studies 
The TEM image shows the discrete formation of the structure and the internal 
morphology. The mean size of the niosome increased with progressive increase in the 
HLB value because surface free energy decreases on increasing hydrophobicity of 
surfactant. Surfactants with longer alkyl chains generally give larger vesicles. These 
result reasonable with that of higher entrapment efficiencies with span 60 niosomes. 
6.3.4. Zeta Potential 
Niosomes has a Negative Zeta Potential which indicates that it has excellent 
stability due weak electrostatic repulsive force exists in the niosomal bilayer. The 
niosome formulations have more tendencies to be in suspended condition/ dispersed 
condition for longer duration. Particles with zeta potential close to zero are less able 
to be phagocytosed than charged particles 
6.3.5. Drug entrapment efficiency: 
The quantity of the drug entrapped in the niosomes is very essential to know 
before analysing the behaviours of the drug entrapped in physical or biological 
system. The process and formulation variables like cholesterol was altered and 
optimized to obtain the niosomes with maximum drug entrapment. 5-Fluorouracil and 
leucovorin entrapped niosomes were subjected to percentage drug entrapment. 
With increase in the cholesterol concentration more number of niosomes per 
ml of the niosomal dispersion was formed, though the optimum concentration 
resulting into an increased percent drug entrapment. The solvent mixture composition 
used was chloroform / methanol, is an attempt to enhance percent drug entrapment. 
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The solvent mixture composition was optimized to 1:1 (5ml v/v). The presence of 
large volume of hydration medium helps in faster and efficient hydration of the 
niosomes. Therefore, the volume of the hydration medium was optimized to 10ml. 
Incorporation of cholesterol into niosomes at ratios up to 1:2 increased the 
encapsulation efficiency of drugs. Inclusion of cholesterol increases the viscosity of 
the formulation indicating more rigidity of the bilayer membrane. Moreover, drug 
partitioning will occur rapidly in highly ordered systems containing both surfactant 
and cholesterol. The ability of the lamellar surfactant phase to accommodate drug, 
depends upon the structure of the surfactant phase. The entrapment efficiency of Span 
60 was higher than Span 40. The higher entrapment may be due to the solid nature, 
hydrophobicity, and high-phase transition temperature of the surfactant. 
6.3.6. In Vitro Drug Release 
The slower release of 5-Fluorouracil and leucovorin from the lipid layer may 
be due to slow partitioning and diffusion of 5-Fluorouracil and leucovorin from the 
lipid layer to the surrounding aqueous layer. Increasing cholesterol markedly reduces 
the efflux of the drug. Inclusion of cholesterol fills the pores in vesicular bilayers and 
abolishes the gel-liquid phase transition of liposomal and niosomal systems resulting 
in niosomes that are less leaky. This confirms that cholesterol in the formulation acts 
as a membrane stabilizing agent that helps to sustain drug release.  Differences in the 
in vitro release profiles may be due to vesicle size, lamellarity, and membrane fluidity 
as a function of chain length of surfactant and cholesterol content. In vitro release data 
of niosomal formulation containing 5-Fluorouracil and leucovorin prepared with span 
60 was selected for kinetics study analysis. 
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6.4. Preclinical evaluation of Niosomes 
6.4.1. Effect of 5-FU + LV niosomes (F4) against 1, 2 Dimethyl hydrazine (DMH) 
induced colon cancer 
Colon carcinogenesis multistage process which involves initial, secondary, 
and progression phases. Hence, the multistage sequence of events has many phases 
for prevention and intervention. Chronic inflammation is a well-recognized risk factor 
for development of human cancer. DMH is a chemical carcinogen known to cause 
colon cancer with a reproducible experimental in vivo system for studying “sporadic” 
(nonfamilial) forms of colon carcinoma. Metabolism of DMH leads to the formation 
of AOM, MAM, and methyl diazonium ions which involves alkylation of colonic 
mucosal DNA. The primary metabolite of DMH, namely AOM, w is responsible for 
the methylation at the O-6 position of guanine, occurs within 6 to 12  h of DMH 
injection134. 
6.4.2. Effect of 5-FU + LV niosomes (F4) on antioxidants and MDA level in DMH 
induced colon cancer. 
Studies suggest that rapid cell proliferation involved in colon cell. Hence, 
cancer cell have certain characteristics that promote proliferation and tend to faster 
cell proliferation135. DMH itself can generate H2O2 in the presence of copper ions. In 
the presence of metal ions such as Fe2+ and Cu2+, H2O2 can react with O2 to convert it 
into the more reactive OH radical. If sufficient amounts of CAT or GPx are not 
available to decompose H2O2, the generated OH radicals are capable of attacking 
DNA basement. GSH an important non-protein thiol in conjunction with GPx and 
GST plays a significant role in protecting cells against cytotoxic and carcinogenic 
chemicals by scavenging reactive oxygen species136. The present study, correlates 
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with the decline in circulatory antioxidants such as SOD, CAT, GPx and GSH. This 
may be due to their overusage to scavenge the products of lipid peroxidation and 
sequestration by tumor cells. GPx uses H2O2 to catalyse the oxidation of GSH to 
GSSG, thereby nullifying the deleterious effects of H2O2137. Diminished GPx activity 
indicates cellular accumulation of the lipid hydroperoxides, which can potentially turn 
on a chain reaction, wherein more polyunsaturated fatty acid become targets for 
further peroxidative tissue injury. In the present study, GPx level was reduced in 
colonic tissue, which could be due to the elevated levels of hydroperoxides. However, 
5-FU + LV niosomes treatment effectively reduced the lipid peroxidation and 
improved the antioxidant status. 
6.4.3. Effect of 5-FU + LV niosomes (F4) on serum lipid profiles in DMH induced 
colon cancer 
Previous studies  elicits that xenobiotic like DMH causes an increase in 
nonspecific microsomal enzyme activities like liver microsomal HMG-CoA reductase 
which is involved in the synthesis of  cholesterol. Also, DMH induce liver damage 
and consequently results in loss of feedback control of cholesterol synthesis in liver, 
thereby increasing the concentration of bile acids and cholesterol in the bowel and 
serum 138,139. In our study, serum level of cholesterol and triglycerides were 
significantly elevated in DMH induced group may be due to higher cholesterogenesis 
induced by DMH. Whilst, treatment with 5-FU+ LV niosomes in DMH induced rats 
markedly reduced the serum level of total cholesterol and triglycerides. 
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6.4.4. Effect of 5-FU + LV niosomes (F4) on serum hepatic markers enzyme in 
DMH induced colon cancer 
The hepatic cell membrane damage releases the enzymes SGOT, SGPT, ALP 
into circulation, which can be measured in serum. High levels of SGOT indicate liver 
damage. SGPT catalyses the conversion of alanine to pyruvate and glutamate, and is 
released in a similar manner. Hence, SGPT is highly specific to the liver, and 
therefore a better parameter for detecting liver injury. Previous studies indicate the 
heaptotoxicity role of DMH during the event of colon cancer 140. In this study, DMH 
intoxicated rats displayed markedly elevated the level of hepatic marker enzymes 
(SGOT, SGPT and ALP) in serum and treatment with 5-FU+ LV niosomes effectively 
decreased the hepatic markers enzyme level and restores the hepatocellular membrane 
damage elicited by DMH. 
6.4.5. Effect of 5-FU + LV niosomes (F4) on tumour markers in DMH induced 
colon cancer 
CEA is the best marker in colorectal cancer patients and also most thoroughly 
characterized tumour-associated antigens, in both biochemical and clinical aspects141. 
AFP is rarely reported until now in colorectal cancer compared to other cancers but it 
can also be an indicative of colorectal cancer142.  In this study, serum level of CEA 
and AFP were significantly elevated and 5-FU+ LV niosomes treatment effectively 
reduced the level of tumor markers (CEA and AFP) to normalcy. 
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6.4.6. Effect of 5-FU + LV niosomes (F4) on colon histology in DMH induced 
colon cancer 
Histopathological observations of the tissue sections of different experimental 
group of animals showed that the administration of 5-FU+LV niosmes inhibited the 
histological changes induced by DMH in rats and effectively preserved colonic 
epithelium from carcinogenic effect of DMH.  
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7. SUMMARY AND CONCLUSION 
Niosomal formulations containing 5- Fluorouracil and leucovorin were 
successfully prepared with different surfactants like Span 40, Span 60, Tween 40, and 
Tween 60 by thin film hydration technique. The evaluation parameters revealed that 
5-Fluorouracil and leucovorin niosomes shows reduced particle size distribution with 
better entrapment efficiency. Niosomes has negative surface charges which indicate 
excellent stability. In vitro release of 5-Fluorouracil and Leucovorin from niosomes 
was carried out. Formulation F4 was shown better sustained release among other 
formulations. In vitro release kinetics study was done for formulation F4 to find out 
the release mechanism. The release of 5-FU from niosomal formulation follow Non 
Fickian type diffusion, whereas release LV from niosomal formulations follows 
Fickian diffusion mechanism. The result suggests that niosomal formulation can 
provide consistent and prolonged release of the entrapped drug molecules. Niosomal 
delivery system can provide sustained action of the entrapped drug and reduce the 
side effects associated with frequent administration of the drug and potentiate the 
therapeutic effects of the drug. 
Further, preclinical evaluation of prepared 5-FU+ LV niosomes displayed 
efficient anticancer potential in DMH induced colon cancer by restoration of altered 
biochemical levels. Furthermore,  5-FU+ LV niosomes displayed marked anticancer 
efficacy as that of the 5-FU+ LV market formulation and 5-FU alone 
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8. IMPACT OF THE STUDY 
 
Attempt has been made  to  incorporate 5-Fluorouracil and Leucovorin   
niosomes  in  blend of surfactants    to  provide  sustained  release of  the entrapped 
drug for  colon  delivery  system.  The niosomes designed and prepared in the   
current study elicits reduced particle size distribution with marked entrapment 
efficiency. Further, the prepared niosomes displayed better sustained release as that of 
the marketed formulation containing 5-FU+LV and 5-FU alone.  
The highlights of the study, was the marked anti-colon cancer activity exhibited by 
the 5-FU+LV niosomes in a preclinical model as that of the market formulation 5-
FU+LV and 5-FU alone.  
Further trials   could   be   attempted     in   future   on   these 5-FU+LV niosomes, 
 The  anti  colon cancer  activity  of  5-FU+LV niosomes  could  be tested  in  
cell  lines.  
 Attempt towards further preclinical studies for 5-FU+LV niosomes could be 
carried out based on the pharmacokinetic evaluation. 
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INTRODUCTION 
In recent years, niosomes as a drug carrier has been 
received much attention in pharmaceutical 
academia and industrial research. Generally 
niosomes have a bilayer structure and are formed by 
self-association of nonionic surfactants and 
cholesterol in an aqueous phase1. It has many 
advantages like biodegradable, biocompatible, and 
nonimmunogenic, long shelf life, exhibit high 
stability and achieves the delivery of drug at target 
ABSTRACT 
In the present study, niosomes co-loaded with 5-Fluorouracil and Leucovorin was prepared and evaluated for 
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drug entrapment. Microscopic observation confirmed that all particles were uniform in size and shape. The 
entrapment efficiency was optimized using different concentration of cholesterol and non-ionic surfactants. The 
in vitro release studies of drug from niosomes exhibited a prolonged drug release as observed over a period of 12 
h. The negative values of zeta potential indicated that the 5-Fluorouracil and Leucovorin loaded niosomes were 
stabilized by electrostatic repulsive forces. Results from stability study have shown that the drug leakage from 
the vesicles was least at 4°C followed by 25°C and 37°C. The mechanism of release of 5-FU and LV was found 
Non-Fickian and Fickian diffusion respectively. Niosomes can be formulated by optimised process parameters to 
enhance 5-FU and LV entrapment efficiency and sustainability of release. These improvements in 5-Fluorouracil 
and Leucovorin niosomal formulation may be useful in developing a more effective combination for cancer 
therapy. 
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site in a controlled and/or sustained manner. Also 
niosomes may alleviate the disadvantages 
associated with liposomes such as chemical 
instability, variable purity of phospholipids and 
high cost2. Encapsulation of a large number of 
drugs with a wide range of solubility in niosomes 
using various types of nonionic surfactants has been 
extensively studied3.  
Combination therapy with drugs of different 
therapeutic effects shows an improving efficacy in 
the treatment of various diseases. Particularly, 
cancer treatment requires simultaneous 
administration of different combination of drugs 
due to the molecular complexity of cancer 
diseases4,5. Niosomes show potential in combination 
of drug delivery and targeting combine transdermal 
and tumor targeting ability in cancer therapy6,7. 5-
Fluorouracil (5-FU) has been in clinical use as an 
anticancer drug for more than 30 years. Although 5-
FU has a broad spectrum of anticancer activity 
including common solid tumors present in the 
gastrointestinal system. But only a minority of 
patients treated with 5-FU experience an objective 
response to therapy8. Leucovorin is an active 
metabolite of folic acid and an essential coenzyme 
for nucleic acid synthesis. Leucovorin may 
significantly increase both the clinical efficacy and 
the clinical toxicity of 5-FU in cancer patients. 
From literature we found that 5-Flurouracil in 
combination with leucovorin is well acknowledged 
in the treatment of cancer9-11. But only a few 
approaches consider the developing new drug 
delivery systems co-loaded with 5-FU and 
Leucovorin has been investigated.  
The purpose of this study was to evaluate the 
process parameters that critically affect the 
formulation of niosomes with respect to entrapment 
and release of 5-FU and Leucovorin. There is little 
information in the literature on optimizing the 
different processing variables that are important in 
the formulation of 5-FU and Leucovorin niosomes 
for development of an improved drug delivery 
system. In this investigation, we optimized 
concentration of cholesterol and non ionic 
surfactants (Span 40, Span 60, Tween 40 and 
Tween 60) used in the niosomal formulations. The 
niosomes was characterized such as entrapment 
efficiency, particle size analysis, surface 
morphology (SEM and TEM) and zeta potential.   
Measurements of in vitro drug release of 5-FU and 
leucovorin were done to assess the effectiveness of 
the drug delivery system.  
 
MATERIAL AND METHODS 
Drugs and Chemicals 
5-Fluorouracil and Leucovorin was procured from 
Sigma Aldrich, India. Cholesterol, polyoxyethylene 
sorbitan monopalmitate (Tween 40), 
polyoxyethylene sorbitan monostearate (Tween 60), 
sorbitan monopalmitate (Span 40), sorbitan 
monostearate (Span 60) and dicetyl phosphate 
(DCP) were procured from Merck, India. All 
materials used in the study were of analytical grade. 
FTIR Spectral analysis 
FTIR spectral analysis of pure drug and excipients 
was carried out and observation was done to 
analyze any changes in the chemical nature of the 
drug after combining it with the excipients 
occurred. The drug samples were mixed with KBR 
and the pressure (600 Kg/cm2) were applied to   get 
pellets and scanned with the IR instrument 
(Shimadzu, 8400 Series, Tokyo, Japan) from 400-
4000cm-1. 
Differential Scanning Colorimetry (DSC) 
In differential Scanning Colorimetry, the samples 
were heated from 25°C to 100°C at a constant 
temperature increment of 10° C/min and purged 
with nitrogen gas at 40 ml/min. 
Preparation of the niosomes 
Niosomes were prepared by a thin film hydration 
technique using a mixture of surfactants 
encompassing (span 40, span 60, tween 60 and 
tween 40) and cholesterol, at different specified 
ratios as given in Table No.1. Surfactant and 
cholesterol was dissolved in 8 ml of diethyl ether 
and the drugs were dissolved in 2 ml of ethanol. 
The mixture was then transferred to a round bottom 
flask, and the solvent was evaporated under reduced 
pressure at a temperature 20-25º, using a rotary 
flash evaporator until the formation of a thin lipid 
film. The resultant film was made wet with 10 ml of 
phosphate buffer saline pH 7.4. The hydration was 
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continued for 1 h, while the flask was kept rotating 
at 55-65°. The hydrated niosomes were sonicated 
for 20 min using a bath sonicator to obtain niosomal 
dispersion. 
Entrapment efficiency for the Niosomes 
The niosomal dispersion is a homogeneous milky 
white suspension which is centrifuged at 12000 rpm 
for 15 min and entrapment efficiency of niosomes 
were evaluated by measuring the UV absorption of 
the supernatant. The corresponding calibration 
curves were made by testing the supernatant of 
blank niosomes. Each sample was measured in 
triplicate. 5-FU was measured at 266nm and elicited 
an intense characteristic peak whilst LV displayed a 
characteristic peak at 288 nm. The percentage of the 
entrapment of the drug can be obtained for the 
niosomal formulations.  
Particle Size Analysis (PSA) 
The size division of the niosomes was analyzed 
using the Beckman particle size analyzer (Beckman 
Coulter, Delsa nano C, Brea, USA) prepared with a 
dry accessory system. Samples were mixed with 
water and maintained at a temperature of 25°C. 
Zeta Potential Analysis 
The zeta potential was measured using a Beckman 
Coulter (Beckman Coulter Delsa Nano C, Brea, 
USA). The sample was diluted with double distilled 
water and transferred to cuvettes and maintained at 
a temperature of 25°C. 
 
MORPHOLOGICAL ANALYSIS OF 
NIOSOMES 
Optical microscopy 
Characterizations of vesicle dispersions were done 
by photo microscopy for vesicle formation and 
morphology. The size and shape of vesicles in 
niosomes formulations were observed by optical 
microscopy using a calibrated eyepiece micrometer, 
and images were captured at resolution of 400 X 
with a digital camera (Olympus, 8.1 megapixel, 
Japan). 
Transmission electron microscopy (TEM) 
Transmission electron microscopy (TEM) was used 
in the morphological analysis of niosomes. Samples 
were processed by spreading a drop of freshly 
prepared nano-suspension onto copper grid with 
carbon film support and excess solution was cleared 
using a filter paper. Samples were allowed to dry at 
room temperature and observed directly with TEM 
(JEM-100, JEOL, Tokyo, Japan) without further 
staining. 
Scanning Electron Microscopy (SEM) 
The SEM is used to identify the particle size and the 
surface morphology of the niosomes. For niosomes, 
the drop of the sample is placed on the covered 
glass slide and then dried by applying vacuum, later 
it was coated with gold to a thickness of 100A using 
VEGAS TESCAN Vacuum evaporator and the 
image was captured for the niosomal formulation. 
In-vitro release studies for the niosomes 
In vitro release of 5-FU and leucovorin niosomes 
was conducted by a dialysis membrane having a 
pore size of 2.4 mm (LA-395-5Mt Himedia Pvt. 
Ltd, Mumbai, India) with 75 ml of pH 7.4 
phosphate buffer at 37°C. Briefly in a 100 ml 
beaker 75ml of pH 7.4 phosphate buffer was taken. 
A 2 ml of formulation was taken into a dialysis bag 
and immersed into the buffer solution. The dialysis 
membrane was activated earlier using by soaking in 
1% w/v NaOH over night. Then the flask was 
placed on   a magnetic stirrer. The stirring was done 
at 250 rpm and the temperature of the buffer was 
maintained at 37°C. Sampling was done by 
withdrawing 1 ml of aliquots from a beaker. 
Immediately 1 ml of new buffer was added to keep 
the sink condition. Samples were analyzed after 
sufficiently diluting with buffer by using a UV-
Visible Spectrophotometer (UV/VIS-Double beam 
Spectrophotometer, V-530, Jasco, Tokyo, Japan) at 
a wavelength of 266 nm for 5-FU and 288 nm for 
LV [15]. 
In vitro release kinetics study  
The release data obtained via the above procedure 
was derived using Ritger and Peppas model to 
devise its release mechanism. The initial 60% 
cumulative release data were used to estimate the 
diffusion exponent ‘n’ by using following equation.  
nKtM / tM =∞  
Where tM  is the amount of drug released at time t, 
M ∞  the nominal total amount of drug released, K 
the kinetic constant, and n the diffusion exponent 
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that is used to characterize the release mechanism. 
For spheres, a value of n ≤ 0.43 indicates Fickian 
release and ‘n’ value between 0.43 and 0.85 is an 
indication of non-Fickian release (both diffusion-
controlled and swelling-controlled drug release). An 
‘n’ value ≥0.85 indicates case-II transport that 
involves polymer dissolution and polymeric chain 
enlargement or relaxation. 
Stability studies  
Stability studies for the optimized niosomes (F4) 
were carried out at refrigeration temperature, room 
temperature and elevated temperature (4 ± 2°C, 25 
± 2°C/ 60 % RH ± 5 % RH and 37 ± 2°C/ 65 % RH 
± 5 % RH) for a period of three months. At definite 
time intervals, the samples from each batch were 
taken and evaluated using following parameters like 
appearance, size, assay, and dissolution.  
 
RESULTS AND DISCUSSION 
FT-IR spectral analysis 
The development of a successful formulation 
depends only on a suitable selection of excipients. 
Hence the physical state of the drug 5-Flurouracil 
and leucovorin and the combination of drug and 
chloestrol and surfactant used for niosomes 
preparation were studied by FTIR to study the drug 
and excipients compatibility. The physicochemical 
compatibility of the drugs and the excipients was 
obtained by FTIR studies with the interpretation 
values of the FTIR were mentioned in Figure No.1. 
The spectra were recorded for pure drugs, 
surfactants, cholesterol and optimized formulations 
using FTIR spectrophotometer. The spectra of pure 
5-FU, LV and niosomes loaded with 5-FU and LV 
was shown the intense characteristic peaks at 3160, 
1727, 1662, 1426, 1247, 811.7 and 547cm−1 are 
detected due to the vibration of imide stretch (amide 
II and amide III) and aromatic ring in the structure 
of 5-FU . In the case of the FTIR spectra of LV, 
some absorption bands are observed at 1609, 1324, 
1190, and 763cm−1 corresponding to the vibration 
of NH stretch, aromatic ring, C O, C–H groups. The 
characteristic peaks of 5-Fluorouracil and 
leucovorin appeared in spectra without any 
remarkable change position in that of prepared 
niosomes. The results revealed that no chemical 
interaction between drugs and excipients. 
Optimization of niosomes 
The optimization of the niosomes was made by 
altering the cholesterol ratio and evaluating the 
niosomes by using in vitro drug release. The 
uniformity of the particle size and the formation of 
the particles are considerably noted. Following 
which the sonication process was carried out. The 
larger the cholesterol content the formation of the 
flakes in the solution takes place and the formation 
of the thin film in the round bottom flask is 
increasing timely. Optimum amount is by taking the 
equal proportion of the cholesterol and the 
surfactant (Span 40, Span 60, Tween 40 and Tween 
60) gives a better formulation. 
From composition of all the formulations (Table 
No.1),  the best formulation is obtained from the  as 
we increase the cholesterol concentration and 
keeping the surfactant concentration constant the 
formation of the niosomes is uniform and the 
visibility of the cholesterol flakes in the formulation 
is nil. But the time taken for the organic solvents to 
get evaporated is increasing. The film which is 
formed on the round bottom flask is kept overnight 
for the complete removal and drying of the organic 
solvents from the film. The best formulation is 
taken from the further evaluation.  
Large volume of organic solution of lipids is most 
easily dried in a rotary evaporator fitted with a 
cooling coil and a thermostatically controlled water 
bath. Rapid evaporation of solvent is carried out by 
gentle warming (20° - 40°C) under reduced pressure 
(400 - 700 mmHg). Rapid rotation of the solvent 
containing flask increases the surface area for 
evaporation. In case, where sufficient vacuum is not 
attainable or if the concentration of lipids is 
particularly high, it may be difficult to remove the 
last traces of chloroform from the lipid. Therefore, 
it is recommended as a matter of routine that after 
rotary evaporation some further means is employed 
to bring the residue to complete dryness. 
Attachment of the flask to the manifold of 
lyophilizer and overnight exposure to high vacuum 
is a good method. 
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Increasing the sonication time resulted into 
reduction in percent drug entrapment the decrease 
drug entrapment is due to leakage of the drug 
during sonication. Cholesterol provides endurance 
against mechanical strain during sonication and 
centrifugation. Sonication brings about size 
reduction by breaking large niosomes to smaller 
ones and in doing so, leakage of small quantities of 
drug from the niosomes occur. Hence the sonication 
time was optimized to 15 minutes, and further 
reduction in the size by increasing sonication time 
was not attempted.  
Particle Size Analysis 
The particle size of the niosomes was analyzed by 
using the particle size analyzer (Malvern) and it is 
shown in the Figure No.2. The particles of the drug 
loaded niosomes are in the size of 0.1 to 1 µ range. 
More number of the particles was in the 0.1μ to 0.8 
μ approximately and also found some larger particle 
size distribution. 
Optical   microscopy  
The formulated niosomes were viewed through 
optical microscope and image was shown in Figure 
No.3. The microscopic methods include the use of 
Bright field, phase contrast microscope and 
fluorescent microscope and are useful in evaluating 
the vesicle size of large vesicles (>1µm) particularly 
the upper end of the size distribution for 
miltilamellar vesicles. Vesicular dispersion 
appropriately diluted is wet mounted on a 
haemocytometer and photographed with a phase 
contrast microscope. The negatives then can be 
projected on a piece of calibrated paper using a 
photographic enlarger at X 1250 (Vyas and Katar, 
1991), diameters of approximately 500 vesicles are 
measured and thus this method is tedious and 
coupled with the limitation of resolution, hence 
electron microscopic methods with greater 
resolutions are  preferred. 
Morphological studies 
The TEM and SEM images of the 5-FU and LV 
loaded niosomes are shown in the Figure No. 4 and 
5.  The images are shown the discrete formation of 
the structure and the internal morphology. The 
mean size of the niosome increased with 
progressive increase in the HLB value because 
surface free energy decreases on increasing 
hydrophobicity of surfactant12. Surfactants with 
longer alkyl chains generally give larger vesicles. 
These result reasonable with that of higher 
entrapment efficiencies with span 60 niosomes. 
Differential scanning Colorimetry 
The drugs 5-Flurouracil, Leucovorin, cholesterol, 
span 40, span 60, span 80 and mixture of drug and 
excipients were subjected to DSC studies for testing 
the compatibility of the drug with the excipients 
used in the formulation. DSC thermo gram was 
shown in Figure 6. The results clearly indicates that 
there is no interaction between drug and excipients. 
The surface charge of 5-Fluorouracil and leucovorin 
niosomes was measured using Zeta potentiometer. 
The zeta potential graph was shown in Figure No.7. 
Zeta value of niosomes was found to be – 10 mV. 
Niosomes has a Negative Zeta Potential which 
indicates that it has excellent stability due weak 
electrostatic repulsive force exists in the niosomal 
bilayer. The noisome formulations have more 
tendencies to be in suspended condition/ dispersed 
condition for longer duration13. Particles with zeta 
potential close to zero are less able to be 
phagocytosed than charged particles. 
Drug entrapment efficiency 
The quantity of the drug entrapped in the niosomes 
is very essential to know before studying the 
behaviours of this entrapped drug in physical or 
biological system. The process and formulation 
variables like cholesterol was altered and optimized 
to obtain the niosomes with maximum drug 
entrapment. 5-Fluorouracil and leucovorin 
entrapped niosomes were subjected to percentage 
drug entrapment. The entrapment efficiency of drug 
containing span 60 was found to be 72.21% which 
showed maximum percent drug entrapment where 
as those containing span 40, span 60, tween 40, 
tween 60 were found to encapsulate 66.35, 72.21, 
50.44, and 52.24. This result indicates that span 60 
is the more suitable surfactant along with higher 
concentration of cholesterol for enhancing 
maximum entrapment for the drugs 5-Fluorouracil 
and leucovorin. 
With increase in the cholesterol concentration more 
number of niosomes per ml of the niosomal 
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dispersion was formed, though the optimum 
concentration resulting into an increased percent 
drug entrapment. The solvent mixture composition 
used was chloroform / methanol, is an attempt to 
enhance percent drug entrapment. The solvent 
mixture composition was optimized to 1:1 (5ml 
v/v). The presence of large volume of hydration 
medium helps in faster and efficient hydration of 
the niosomes. Therefore, the volume of the 
hydration medium was optimized to 10ml. The 
Entrapment Efficiency of the formulations was 
calculated and Tabulated in the Table No.2.  
Incorporation of cholesterol into niosomes at ratios 
up to 1:2 increased the encapsulation efficiency of 
drugs. Inclusion of cholesterol increases the 
viscosity of the formulation indicating more rigidity 
of the bilayer membrane. Moreover, drug 
partitioning will occur more easily in highly ordered 
systems of surfactant and cholesterol. The ability of 
the lamellar surfactant phase to accommodate drug, 
depends upon the structure of the surfactant phase. 
The entrapment efficiency of Span 60 was higher 
than Span 40. The higher entrapment may be due to 
the solid nature, hydrophobicity, and high-phase 
transition temperature of the surfactant12. 
In vitro drug release 
The formulated niosomes were subjected to in vitro 
drug release. The amount of 5-Fluorouracil and 
leucovorin diffused was estimated 
spectrophotometrically at nm 266 and 288 nm 
respectively14,15. The in vitro release profile of 
drugs was shown in Table No.3 and 4. Niosomes 
containing 5-Fluorouracil prepared with span 60 
showed 99.65 % of drug release up to 12 hours 
shown in Figure No.8. 5-Fluorouracil release from 
the formulation containing span 40, Tween 40 and 
Tween 60 was observed almost 100% drug release 
within 10 hours. These results showed that niosomal 
formulation containing 5-Fluorouracil prepared with 
span 60 has sustained release up to 12 hours. 
Leucovorin release profile from niosomal 
formulation was shown in Figure No.9. Niosomes 
containing leucovorin prepared with span 60 
showed 99.91 % of drug release up to 12 hours. 
Leucovorin release from the formulation containing 
span 40, Tween 40 and Tween 60 was observed 
almost 100% drug release within 10 hours. These 
results showed that niosomal formulation 
containing leucovorin prepared with span 60 has 
sustained release up to 12 hours.  
The slower release of 5-Fluorouracil and leucovorin 
from the lipid layer may be due to slow partitioning 
and diffusion of 5-Fluorouracil and leucovorin from 
the lipid layer to the surrounding aqueous layer. 
Increasing cholesterol markedly reduces the efflux 
of the drug. Inclusion of cholesterol fills the pores 
in vesicular bilayers and abolishes the gel-liquid 
phase transition of liposomal and niosomal systems 
resulting in niosomes that are less leaky. This 
confirms that cholesterol in the formulation acts as a 
membrane stabilizing agent that helps to sustain 
drug release.  Differences in the in vitro release 
profiles may be due to vesicle size, lamellarity, and 
membrane fluidity as a function of chain length of 
surfactant and cholesterol content. In vitro release 
data of niosomal formulation containing 5-
Fluorouracil and leucovorin prepared with span 60 
was selected for kinetics study analysis. 
In vitro release kinetics 
In vitro release kinetics data was sown in Table 
No.5. The results shown that formulation F4, Span 
60 with cholesterol follows zero-order kinetics. 
Calculation of Higuchi’s correlation coefficient 
confirms that drug release was proportional to the 
square root of time indicating that drug release from 
niosomes was diffusion controlled. The n value 
from the Korsmeyer-Peppas model for release 5-FU 
from niosomal formulation was 0.67 which 
confirms the Non Fickian type diffusion, whereas 
release LV from niosomal formulations follow an 
Fickian diffusion mechanism (n > 0.47). 
Stability study 
The stability study result indicates that stability 
studies for the optimized niosomes (F4) were 
carried out at refrigeration temperature, room 
temperature and elevated temperature (4 ± 2°C, 25 
± 2°C/ 60 % RH ± 5 % RH and 37 ± 2°C/ 65 % RH 
± 5 % RH) for a period of three months. Niosomes 
were evaluated for physical appearance, size, assay 
and dissolution studies. 5 – FU and LV loaded 
niosomes have not shown any significant change in 
storage condition 4°C ± 2°C. But drug leakage was 
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found in conditions 25 ± 2°C/ 60 % RH ± 5 % RH 
and 37 ± 2°C/ 65 % RH ± 5 % RH. This may be 
attributed to phase transition of surfactant and lipid 
causing vesicles leakage at higher temperature 
during storage13. Hence, it is concluded from the 
obtained data that the optimum storage condition 
for niosomes was found to be 4°C.  
 
 
Table No.1: Formulation composition of Niosomes 
S.No Type of formulation F1 F2 F3 F4 F5 F6 F7 F8 
1 Drug 10 10 10 10 10 10 10 10 
2 Cholesterol 10 20 10 20 10 20 10 20 
3 Span 40 10 10 - - - - - - 
4 Span 60 - - 10 10 - - - - 
5 Tween 40 - - - - 10 10 - - 
6 Tween 60 - - - - - - 10 10 
7 Drug :cholesterol:  SA 1:1:1 1:2:1 1:1:1 1:2:1 1:1:1 1:2:1 1:1:1 1:2:1 
Table No.2: Entrapment Efficiency of the Niosomal formulations 
S.No Formulations Code 5-FU (%) LV (%) 
1 F1 62.44 63.28 
2 F2 66.35 65.02 
3 F3 68.30 64.86 
4 F4 72.21 69.45 
5 F5 47.05 54.76 
6 F6 50.44 57.92 
7 F7 50.92 59.55 
8 F8 52.24 60.27 
Table No.3: In-vitro release study of the 5 – FU from Niosomes 
S.No Time(hr) % Drug Released F1 F2 F3 F4 F5 F6 F7 F8 
1 1 25.12 20.78 23.43 19.23 28.34 23.02 24.72 21.66 
2 2 42.04 39.02 40.12 30.22 40.22 33.22 35.15 32.17 
3 4 51.06 48.9 52.22 46.89 61.27 48.82 49.42 50.92 
4 6 69.35 70.33 68.79 65.88 72.52 67.94 70.21 66.25 
5 8 90.23 83.45 88.16 79.43 84.67 82.64 82.56 81.92 
6 10 99.34 95.74 95.34 89.58 99.96 99.52 98.9 95.99 
7 12 99.9 99.13 100.02 99.65 100 99.99 100 100 
Table No.4: In-vitro release study of the Leucovorin from Niosomes 
S.No 
 
Time (hr) 
% Drug Released 
F1 F2 F3 F4 F5 F6 F7 F8 
1 1 38.96 36.72 35.07 30.01 40.04 39.02 39.27 38.12 
2 2 50.22 50.38 48.39 45.22 52.78 51.35 50.55 49.55 
3 4 65.15 62.12 62.07 59.12 66.9 66.17 65.22 62.49 
4 6 79.6 76.2 72.98 70.36 84.56 72.56 79.21 78.01 
5 8 92.1 90.08 90.14 85.43 95.9 88.54 90.56 88.32 
6 10 99.34 98.94 99 93.12 99 98.18 99.82 100 
7 12 99.9 100 100 99.91 99.98 99 100 100 
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Table No.5: In vitro release kinetics of 5-FU and LV from niosomes 
S.No 
Formulation  
code 
Higuchi 
R2 
Korsmeyer-
Peppas Zero order First order Release 
mechanism R2 N R2 K0 (%mg/h) R
2
 
K1 
(h-1) 
1 F4 (5- FU) 0.996 0.998 0.67 0.969 8.01 0.770 0.161 Non Fickian 
2 F4 (LV) 0.996 0.995 0.47 0.907 7.44 0.745 0.194 Fickian 
 
A) FTIR spectrum of 5-fluorouracil 
 
B) FTIR spectrum of Leucovorin 
 
C) FTIR spectrum of Niosomes 
 
Figure No.1: FTIR spectrum 
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Figure No.2: Particle size analysis of niosomes 
 
 
 
 
    
      
 
 
 
 
Figure No.3: Optical microscopy images of Niosomes 
 
 
 
 
 
 
 
 
 
 
Figure No.4: TEM image of Niosomes 
  
 
 
 
     
 
 
 
 
 
 Figure No.5: SEM image of Niosomes 
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Figure No.6: DSC Studies of niosomes Zeta potential 
   
Figure No.7: Zeta potential of Niosomes 
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Figure No.8: In-vitro release study of the 5 – FU from Niosomes 
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Figure No.9: In-vitro release study of the Leucovorin from Niosomes 
 
CONCLUSION 
Niosomal formulations containing 5- Fluorouracil 
and leucovorin were successfully prepared with 
different surfactants like Span 40, Span 60, Tween 
40, and Tween 60 by thin film hydration technique. 
The evaluation parameters revealed that 5-
Fluorouracil and leucovorin niosomes shows 
reduced particle size distribution with better 
entrapment efficiency. Niosomes has negative 
surface charges which indicate excellent stability. In 
vitro release of 5-Flurouracil and Leucovorin from 
niosomes was carried out. Formulation F4 was 
shown better sustained release among other 
formulations. In vitro release kinetics study was 
done for formulation F4 to find out the release 
mechanism. The release of 5-FU from niosomal 
formulation follow Non Fickian type diffusion, 
whereas release LV from niosomal formulations 
follows Fickian diffusion mechanism. The result 
suggests that niosomal formulation can provide 
consistent and prolonged release of the entrapped 
drug molecules. Niosomal delivery system can 
provide sustained action of the entrapped drug and 
reduce the side effects associated with frequent 
administration of the drug and potentiate the 
therapeutic effects of the drug. 
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INTRODUCTION 
In recent years, niosomes as a drug carrier has been 
received much attention in pharmaceutical 
academia and industrial research. Generally 
niosomes have a bilayer structure and are formed by 
self-association of nonionic surfactants and 
cholesterol in an aqueous phase1. It has many 
advantages like biodegradable, biocompatible, and 
nonimmunogenic, long shelf life, exhibit high 
ABSTRACT 
In the present study, niosomes co-loaded with 5-Fluorouracil and Leucovorin was prepared and evaluated for 
in vivo anticancer efficacy in Dimethyl hydrazine (DMH) induced colon cancer. In the present study, colon 
cancer was induced by s.c injection of DMH (20 mg/kg b.wt) for 15 weeks. The animals were divided into five 
groups as follows control, DMH alone, DMH and 5-FU, DMH and 5-FU + LV market formulation and DMH 
and 5-FU + LV niosomes formulation and the treatment was carried out for 15 weeks. At the end of the study 
period the blood was withdrawn and serum was separated for haematological, biochemical analysis and tumor 
markers. Further, the colonic tissue was removed for the estimation of antioxidants and histopathological 
analysis. The results of the study displays that DMH intoxication elicits altered haematological parameters 
(RBC, WBC and Hb), elevated lipid peroxidation and decreased antioxidants level (SOD, CAT, GPX, GST 
and GSH), elevated lipid profiles (cholesterol and triglycerides), tumor markers (CEA and AFP) and altered 
colonic tissue histology. Mean while, treatment with 5-FU + LV niosomes significantly restored the altered 
biochemicals parameters in DMH induced colon cancer mediated by its anticancer efficacy. Further, 5-FU + 
LV niosomes showed marked efficacy as that of the 5-FU + LV market formulation and 5-FU-alone. 
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stability and achieves the delivery of drug at target 
site in a controlled and/or sustained manner. Also 
niosomes may alleviate the disadvantages 
associated with liposomes such as chemical 
instability, variable purity of phospholipids and 
high cost2. Encapsulation of a large number of 
drugs with a wide range of solubility in niosomes 
using various types of nonionic surfactants has been 
extensively studied3. 
Combination therapy with drugs of different 
therapeutic effects shows an improving efficacy in 
the treatment of various diseases. Particularly, 
cancer treatment requires simultaneous 
administration of different combination of drugs 
due to the molecular complexity of cancer 
diseases4,5. Niosomes show potential in combination 
of drug delivery and targeting combine transdermal 
and tumor targeting ability in cancer therapy6,7. 5-
Fluorouracil (5-FU) has been in clinical use as an 
anticancer drug for more than 30 years. Although 5-
FUhas a broad spectrum of anticancer activity 
including common solid tumors present in the 
gastrointestinal system. But only a minority of 
patients treated with 5-FU experience an objective 
response to therapy8. Leucovorin is an active 
metabolite of folic acid and an essential coenzyme 
for nucleic acid synthesis. Leucovorin may 
significantly increase both the clinical efficacy and 
the clinical toxicity of 5-FU in cancer patients. 
From literature we found that 5-Flurouracil in 
combination with leucovorin is well acknowledged 
in the treatment of cancer9-11. But only a few 
approaches consider the developing new drug 
delivery systems co-loaded with 5-FU and 
Leucovorin has been investigated.  
The purpose of this study was to prepare 5-FU and 
Leucovorin niosomes formulation and evaluate its 
anticancer efficacy in Dimethyl hydrazine (DMH) 
induced colon cancer in a animal model. 
 
MATERIAL AND METHODS 
Drugs and Chemicals 
5-Fluorouracil and Leucovorin was procured from 
Sigma Aldrich, India. Cholesterol, polyoxyethylene 
sorbitan monopalmitate (Tween 40), 
polyoxyethylene sorbitan monostearate (Tween 60), 
sorbitan monopalmitate (Span 40), sorbitan 
monostearate (Span 60) and dicetyl phosphate 
(DCP) were procured from Merck, India. All 
materials used in the study were of analytical grade. 
Preparation of 5-FU and Leucovorin Niosomes 
Niosomes were prepared by a thin film hydration 
technique using a mixture of surfactants 
encompassing (span 40, span 60, tween 60 and 
tween 40) and cholesterol, at different specified 
ratios as given in Table No.1. Surfactant and 
cholesterol was dissolved in 8 ml of diethyl ether 
and the drugs were dissolved in 2 ml of ethanol. 
The mixture was then transferred to a round bottom 
flask, and the solvent was evaporated under reduced 
pressure at a temperature 20-25º, using a rotary 
flash evaporator until the formation of a thin lipid 
film. The resultant film was made wet with 10 ml of 
phosphate buffer saline pH 7.4. The hydration was 
continued for 1 h, while the flask was kept rotating 
at 55-65°. The hydrated niosomes were sonicated 
for 20 min using a bath sonicator to obtain niosomal 
dispersion. 
Evaluation of 5-FU and Leucovorin Niosomes  
The evaluation of niosomes was carried in our 
laboratory as described in the previously published 
paper12. 
Preclinical anti colon cancer evaluation of 5-FU 
and Leucovorin Niosomes  
Chemicals 
The 1, 2-dimethyl hydrazine (DMH) was obtained 
from Sigma Aldrich, India and all other chemicals 
and reagents used were of analytical grade. 
Animals 
Male Sprague-Dawley rats (300-400gm body 
weight) were procured from KMCH college of 
Pharmacy, Coimbatore, Tamilnadu, India.  All the 
animals were kept at room temperature of 22°C 
under 12 hr light/12 hr dark cycle in the animal 
house. Animals were fed with commercial pellet 
diet and water ad libitum freely throughout the 
study. All animal procedures were performed in 
accordance with the recommendation of CPCSEA 
the proper care and use of laboratory animals the 
proposal of the present study was approved by 
IAEC of KMCH college of Pharmacy, Coimbatore, 
Tamilnadu, India. 
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Preparation of DMH solution 
DMH was dissolved in 1 mm EDTA just prior to 
use and the pH was adjusted to 6.5 with 1mm 
sodium bicarbonate to ensure the stability of the 
chemical. 
Induction of colon cancer 
Animals were given a weekly subcutaneous (s.c.) 
injection of DMH in the groin area at a dose of 20 
mg/kg body weight for 15 weeks. 
Study design 
The animals were divided into five groups of six 
animals each as follows, 
Group I - Control, received 1 ml of Normal saline. 
p.o everyday for 15weeks. 
 Group II - Received DMH (20mg/kg body weight 
once in a week for 15 weeks, s.c)  
Group III - Received DMH (20mg/kg body weight 
once in a week for 15 weeks, s.c) +5 fluorouracil 
(20mg/kg) i.p. 
Group IV - Received DMH (20mg/kg body weight 
once in a week for 15 weeks, s.c) +5-FU and 
Leucovorin market formulation. 
Group V - Received DMH (20mg/kg body weight 
once in a week for 15 weeks, s.c) +5-FU and 
Leucovorin Niosomes formulation. 
Blood Collection 
After end of treatment period, the animals were 
anaesthetized with ketamine 2mg/kg (i.proute), 
blood was collected by Retro orbital puncture, with 
EDTA and 7 without EDTA for the enumeration of 
blood cell (i.e. RBC, WBC,) estimation of 
Hemoglobin and for estimation of various 
biochemical parameters respectively. 
Separation of Serum 
For estimating the biochemical parameters such as 
SGOT, SGPT, ALP and total protein the serum was 
separated from blood by centrifuging at 10,000 rpm 
for 10 minutes. The separated serum were collected 
and used for the parameter estimation.  
Separation of Plasma 
For the estimation of tumour markers such as Alpha 
– feto - protein (AFP), Carcinoembroyonicantigen 
(CEA), the blood was collected with EDTA, and 
centrifuged at 10,000 rpm for 5 min and the 
separated plasma was used for the parameter 
estimation 
Estimation of Haematological parameters 
Total Leukocyte count (TLC), total erythrocyte 
count (TEC) and hemoglobin (Hb) content were 
determined by auto analyzer according to methods 
described by Dacie and Lewis13. 
Assay of serum hepatic markers 
The level of serum glutamate oxalo acetate 
transaminase (SGOT) and serum glutamic-pyruvic 
transaminase (SGPT) was determined by the 
method of Reitman and Frankael14. The level of 
alkaline phosphatase (ALP) was estimated by the 
method of Plummer15 and the protein was measured 
by the Lowry et al method16. 
Estimation of Lipid profiles 
The extraction of serum lipids was done according 
to the procedure of Folch et al17. The estimation of 
total cholesterol was carried out by the method of 
Zlatkis et al18 and triglycerides by the method of 
Foster and Dunn19. 
Analysis of Serum tumor markers 
The serum hepatic tumor markers - α-feto protein 
(AFP) and carcinoembryonic antigen (CEA) were 
measured using ELISA assay kits from USCN LIFE 
science and technology (Wuhan, China).  
Estimation of oxidative stress parameters 
The colonic tissue level of superoxide dismutase 
(SOD) was assayed by the method of Misra and 
Fridovich20. Catalase (CAT) level was estimated by 
the method described by Sinha21. Glutathione 
peroxidase (GPx) was assayed by the method of 
Rotruck et al22. Glutathione S-transferase (GST) 
was assayed by the method of Habig et al23. 
Reduced glutathione (GSH) was determined by the 
method of Ellman24. 
Estimation of Lipid peroxidation:  
The colonic tissue lipid peroxide level was 
determined as MDA by the method of Ohkawa et 
al25. The absorbance was measured photometrically 
at 532 nm and the concentrations were expressed as 
nmol malondialdehyde (MDA) min/mg/protein. 
Histopathology Studies 
The colon was fixed for 24 h in 10 % buffered 
formalin solution for histological study. Then a 2 × 
2 mm dissected tissue was then sectioned (5 μm 
thickness), embedded and stained with 
haematoxylin and eosin (H and E). 
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Statistical Analysis 
Values were expressed as mean ± SEM. The 
variation between groups was estimated by the one-
way ANOVA followed by Dunnet’s multiple 
comparison test using SPSS version 20.0 (SPSS Inc. 
Chicago, IL, USA). 
 
RESULTS AND DISCUSSION 
In our study, the formulation F4of 5-FU and 
Leucovorin noisome was found to satisfactory 
based upon the various parameters done for the 
evaluation of niosomes12.  
Colon carcinogenesis is a multistage process which 
involves initiation, promotion, and progression 
phases. Thus, the multistage sequence of events has 
many phases for prevention and intervention. Long 
term inflammation, is a hallmark risk factor for the 
progression of development of cancer in humans. 
DMH is a chemical carcinogen known to cause 
colon cancer with a reproducible preclinical in vivo 
system for evaluating “sporadic” (nonfamilial) 
forms of colon carcinoma26. Metabolism of DMH 
leads to the formation of AOM, MAM, and methyl 
diazonium ions which involves colonic mucosal 
DNA alkylation process. The metabolite, AOM, is a 
cardinal moiety involved in the methylation at the 
O-6 position of guanine, occurs within 6 to 12 h of 
DMH injection. 
In our study, haematological parameters were 
significantly altered in the DMH treated as a 
carcinogenesis and altered immune function. The 
level of RBC and haemoglobin were significantly 
(p<0.05) reduced in DMH groups, whilst the WBC 
level was significantly (p<0.05) increased as that of 
the control rats. Meanwhile, treatment with 5-FU+ 
LV niosomes significantly (p<0.05) restored the 
altered blood parameters level to normalcy (Table 
No.2). The present result show that, the colonic 
tissue level of the LPO (Table No.3) increased 
significantly (p<0.05) and GSH (Table No.2), SOD, 
CAT, GPx and GST level (Table No.4) were 
decreased significantly (p<0.05) in DMH alone 
group compared with normal control group. Suggest 
that rapid cell proliferation involved in colon cell. 
Hence, cancer cell have certain characteristics that 
promote proliferation and tend to faster cell 
proliferation27. DMH itself can generate H2O2 in the 
presence of copper ions. In the presence of metal 
ions such as Fe2+ and Cu2+, H2O2 can react with O2 
to convert it into the more reactive OH radical. If 
sufficient amounts of CAT or GPx are not available 
to decompose H2O2, the generated OH radicals are 
capable of attacking DNA basement. GSH an 
important non-protein thiol in conjunction with GPx 
and GST plays a significant role in protecting cells 
against cytotoxic and carcinogenic chemicals by 
scavenging reactive oxygen species28. The present 
study, correlates with the decline in circulatory 
antioxidants such as SOD, CAT, GPx and GSH, 
and. This may be due to their accelerated synthesis 
to inhibit the lipid peroxidation end products the 
products of lipid peroxidation as well as 
sequestration by tumor cells. GPx uses H2O2 to 
catalyse the oxidation of GSH to GSSG, thereby 
nullifying the deleterious effects of H2O229. 
Diminished GPx activity indicates cellular 
accumulation of the lipid hydro peroxides, which 
can potentially turn on a chain reaction, wherein 
more polyunsaturated fatty acid become targets for 
further per oxidative tissue injury. In the present 
study, GPx level was reduced in colonic tissue, 
which could be due to the elevated levels of hydro 
peroxides. Whilst, treatment with 5-FU+ LV 
niosomes significantly (p<0.05) decreased the level 
of MDA in colonic tissue of DMH treated rats, as 
well as significantly (p<0.05) increased the level of 
the antioxidants defense enzymatic system of SOD, 
CAT, GPx and GSH level. 
Previous studies elicits that xenobiotic like DMH 
causes an increase in nonspecific microsomal 
enzyme activities of hepatic microsomal HMG -Co 
A reductase which mediates the cholesterol 
synthesis process. DMH also provoke hepatic 
damage and consequently results in loss of feedback 
control of cholesterol synthesis in liver, thereby 
elevating the level of bile acids and cholesterol in 
the bowel and serum30,31. In our study, serum level 
of cholesterol and triglycerides were significantly 
(p<0.05) elevated in DMH induced group may be 
due to higher cholesterogenes is induced by DMH. 
Whilst, treatment with 5-FU+ LV niosomes in 
DMH induced rats significantly (p<0.05) reduced 
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the serum level of total cholesterol and triglycerides 
(Table No.5).  
The hepatic cell membrane damage releases the 
enzymes SGOT, SGPT, ALP into circulation, which 
can be measured in serum. High levels of SGOT 
indicate liver damage. SGPT catalyses the 
conversion of alanine to pyruvate and glutamate, 
and is released in a similar manner. Therefore, 
SGPT is more specific to the liver, and is thus a 
better parameter for detecting liver injury. Previous 
studies indicate the hepatotoxicity role of DMH 
during the event of colon cancer32. In our study, 
DMH intoxicated rats displayed significantly 
(p<0.05) elevated level of hepatic marker enzymes 
(SGOT, SGPT and ALP) in serum and treatment 
with 5-FU+ LV niosomes significantly (p<0.05) 
decreased the hepatic markers enzyme level and 
restores the hepato cellular membrane damage 
elicited by DMH (Table No.6). 
CEA is the best marker in colorectal cancer patients 
and also most thoroughly characterized tumour-
associated antigens, in both biochemical and 
clinical aspects33. AFP is rarely reported until now 
in colorectal cancer compared to other cancers but it 
can also be an indicative of colorectal cancer34. In 
our study, serum level of CEA and AFP were 
significantly (p<0.05) elevated and 5-FU+ LV 
niosomes treatment significantly (p<0.05)   reduced 
the level of tumor markers (CEA and AFP) to 
normalcy (Table No.7). 
Further, the histopathological analysis revealed the 
thick enedmucosa with densely packed 
inflammatory cell in filtration and a higher degree 
of hyperplasia in DMH intoxicated rats and 
treatment with 5-FU+ LV niosomes showed normal 
appearing glands with normal mucosa of colon 
(Figure No.1). 
Units 
RBC 
Millions /μl of blood; WBC: thousands/μl of blood; 
Hb: g/dl. The values are expressed as mean ±S.E.M, 
n=6. The statistical analysis was carried out using 
one way ANOVA followed by Dunnet’s multiple 
comparison test. The comparison were made 
between a- Control vs DMH; b - DMH vs DMH+5-
FU; c- DMH vs DMH + (5-FU +LV) Market 
formulation; d- DMH vs DMH + (5-FU +LV) 
Niosomes* denotes statistically significant p< 0.05. 
GSH 
Reduced Glutathione (nmole/mg of tissue); MDA: 
Malondialdehyde (nmole/mg of tissue). The values 
are expressed as mean ±S.E.M, n=6. The statistical 
analysis was carried out using one way ANOVA 
followed by Dunnet’s multiple comparison test. The 
comparison were made between a- Control vs 
DMH; b - DMH vs DMH+5-FU; c- DMH vs DMH 
+ (5-FU +LV) Market formulation; d- DMH vs 
DMH + (5-FU +LV) Niosomes* denotes 
statistically significant p< 0.05. 
SOD 
Superoxide dismutase (U/mg protein); CAT: 
Catalase (nmoles of H2O2 utilized/ min/ mg/ 
protein); GPx: Glutathione peroxidase (nmoles of 
GSH utilized/ min/ mg protein); GST: Glutathione -
S- Transferase (nmoles of CDNB conjugate formed/ 
min/ mg/ protein). The values are expressed as 
mean ± S.E.M, n=6. The statistical analysis was 
carried out using one way ANOVA followed by 
Dunnet’s multiple comparison test. The comparison 
were made between a- Control vs DMH; b - DMH 
vs DMH+5-FU; c- DMH vs DMH + (5-FU +LV) 
Market formulation; d- DMH vs DMH + (5-
FU+LV) Niosomes. *denotes statistically 
significant p< 0.05. 
The values are expressed as mean ±S.E.M, n=6. The 
statistical analysis was carried out using one way 
ANOVA followed by Dunnet’s multiple 
comparison test. The comparison were made 
between a- Control vs DMH; b - DMH vs DMH+5-
FU; c- DMH vs DMH + (5-FU +LV) Market 
formulation; d- DMH vs DMH + (5-FU +LV) 
Niosomes* denotes statistically significant p< 0.05. 
The values are expressed as mean ±S.E.M, n=6. The 
statistical analysis was carried out using one way 
ANOVA followed by Dunnet’s multiple 
comparison test. The comparison were made 
between a- Control vs DMH; b - DMH vs DMH+5-
FU; c- DMH vs DMH + (5-FU +LV) Market 
formulation; d- DMH vs DMH + (5-FU +LV) 
Niosomes* denotes statistically significant p< 0.05. 
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CEA 
Carcinoembryonic Antigen; AFP - Alpha – Feto -
Protein. The values are expressed as mean ±S.E.M, 
n=6. The statistical analysis was carried out using 
one way ANOVA followed by Dunnet’s multiple 
comparison test.  
The comparison were made between a- Control vs 
DMH; b - DMH vs DMH+5-FU; c- DMH vs DMH 
+ (5-FU +LV) Market formulation; d- DMH vs 
DMH + (5-FU +LV) Niosomes denotes statistically 
significant p< 0.05. 
 
 
Table No.1: Formulation composition of 5-FU and Leucovorin Niosomes 
S.No Type of formulation F1 F2 F3 F4 F5 F6 F7 F8 
1 Drug 10 10 10 10 10 10 10 10 
2 Cholesterol 10 20 10 20 10 20 10 20 
3 Span 40 10 10 - - - - - - 
4 Span 60 - - 10 10 - - - - 
5 Tween 40 - - - - 10 10 - - 
6 Tween 60 - - - - - - 10 10 
7 Drug: cholesterol: SA 1:1:1 1:2:1 1:1:1 1:2:1 1:1:1 1:2:1 1:1:1 1:2:1 
 
Table No.2: Effect of 5-FU + LV niosomes on Haematological parameters on DMH induced colon 
S.No Groups RBC WBC Hb 
1 Control 7.53±0.17 2.53±0.11 14.48±0.26 
2 DMH 3.21±0.14a* 8.42±0.16 a* 8.97±0.16 a* 
3 DMH+5-FU 4.40±0.13b* 5.64±0.17 b* 11.23± 0.21 b* 
4 DMH + (5-FU +LV) Market formulation 5.87±0.16c* 4.32±0.12 c* 12.24±0.23 c* 
5 DMH + (5-FU +LV) Niosomes 6.40±0.18d* 3.15±0.09 d* 13.89±0.18 d* 
 
Table No.3: Effect of 5-FU + LV niosomes on GSH and MDA level in DMH induced 
colon cancer 
S.No Groups GSH MDA 
1 Control 4.98±0.54 1.4±0.12 
2 DMH 1.52±0.15 a* 4.24±0.35 a* 
3 DMH+5-FU 2.67±0.21b* 3.47±0.26 b* 
4 DMH + (5-FU +LV) Market formulation 3.12±0.29c* 2.42±0.18 c* 
5 DMH + (5-FU +LV) Niosomes 3.92±0.42d* 1.86±0.16 d* 
 
Table No.4: Effect of 5-FU + LV niosomes on colon antioxidant enzymes in DMH induced 
S.No Groups SOD CAT GPx GST 
1 Control 7.84±0.75 7.14±0.68 2.34±0.05 0.75±0.006 
2 DMH 2.89±0.29 a* 2.63±0.25 a* 0.57±0.01 a* 0.25±0.003 a* 
3 DMH+5-FU 4.87±0.35 b* 4.32±0.29 b* 1.6±0.03 b* 0.48±0.002 b* 
4 DMH + (5-FU +LV)  Market formulation 5.92±0.37
 c*
 5.75±0.42 c* 1.98±0.03 c* 0.65±0.005 c* 
5 DMH + (5-FU +LV)  Niosomes 7.12±0.67
 d*
 6.87±0.54 d* 2.12±0.04 d* 0.71±0.06 d* 
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Table No.5: Effect of 5-FU + LV niosomes on serum lipid profiles in DMH induced colon cancer 
S.No Groups Total Cholesterol (mg/dl) 
Triglycerides 
(mg/dl) 
1 Control 76.94±2.46 122.6±3.33 
2 DMH 171.4±7.65 a* 164.4±2.68 a* 
3 DMH+5-FU 110.7±2.05 b* 147.1±3.7 b* 
4 DMH + (5-FU +LV) Market formulation 90.44±2.47 c* 138.28±1.88 c* 
5 DMH + (5-FU +LV) Niosomes 81.17±1.08d* 125.5±5.23d* 
 
Table No.6: Effect of 5-FU + LV niosomes on serum hepatic markers enzyme and total protein level in 
DMH induced colon cancer 
S.No Groups SGOT (IU/L) SGPT (IU/L) ALP (IU/L) Tot. Protein (mg/dl) 
1 Control 56.87±3.23 66.45±3.76 144.34±7.98 8.22±0.50 
2 DMH 132.65±5.76 a* 124.32±6.84 a* 304.65±9.65a* 5.21±0.31 a* 
3 DMH+5-FU 98.76±4.25 b* 92.12±3.25 b* 197.65±6.87b* 6.76±0.35b* 
4 DMH + (5-FU+LV)  Market formulation 86.87±5.65
 c*
 79.67±4.82 c* 175.42±4.56c* 7.02±0.25c* 
5 DMH + (5-FU 
+LV) Niosomes 62.76±3.29
 d*
 64.65±3.98 d* 153.89±5.25d* 8.02±0.50 d* 
 
Table No.7: Effect of 5-FU + LV niosomes on tumour markers in DMH induced colon cancer 
S.No Groups CEA (ng/dl) AFP (ng/dl) 
1 Control 0.21±0.002 0.45±0.01 
2 DMH 1.24±0.007 a* 1.62±0.05 a* 
3 DMH+5-FU 0.56± 0.006 b* 0.89±0.04 b* 
4 DMH + (5-FU +LV) Market formulation 0.45±0.003 c* 0.72±0.03 c* 
5 DMH + (5-FU +LV) Niosomes 0.29±0.005 d* 0.55±0.04 d* 
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Figure No.1: Effect of 5-FU + LV niosomes on colon histology in DMH induced colon cancer 
CONCLUSION  
Niosomal formulations containing 5- Fluorouracil 
and leucovorin were successfully prepared with 
different surfactants like Span 40, Span 60, Tween 
40, and Tween 60 by thin film hydration technique. 
Further, preclinical evaluation of prepared 5-FU+ 
LV niosomes displayed efficient anticancer 
potential in DMH induced colon cancer by 
restoration of altered biochemical levels. 
Furthermore, the in our study 5-FU+ LV niosomes 
displayed marked anticancer efficacy as that of the 
5-FU+ LV market formulation and 5-FU alone. 
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